Human CGRP Receptor Binding Protein
Isolated antibodies targeting the CGRP receptor components CRLR and RAMP1 provide a specific and potent solution to alleviate migraine and chronic pain by inhibiting CGRP-mediated responses, addressing the limitations of current therapies.
Patent Information
- Application Number
- JP2023101810
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2009-11-25
- Filing Date
- 2023-06-21
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2029-12-18
AI Technical Summary
Current treatments for conditions such as migraine and chronic pain associated with CGRP (calcitonin gene-related peptide) are limited in efficacy and specificity, with many patients not responding well to existing therapies targeting CGRP pathways.
Development of isolated antibodies and antigen-binding proteins that selectively inhibit the CGRP receptor (CGRP R), specifically binding to both CRLR and RAMP1 components, thereby modulating CGRP-mediated responses to alleviate symptoms.
These proteins effectively inhibit CGRP receptor activity, reducing vasodilation and neurogenic inflammation, providing potential relief for migraine and chronic pain symptoms with high specificity and potency.
Smart Images

Figure 0007584577000047 
Figure 0007584577000048 
Figure 0007584577000049
Abstract
Description
[Background technology]
[0001] This application contains a Sequence Listing that has been submitted via EFS-Web and is incorporated herein by reference in its entirety. The ASCII copy, created on December 14, 2009, is named A1472PCT.txt and is 312,447 bytes in size.
[0002] The calcitonin superfamily of peptides includes at least five known members: calcitonin, amylin, adrenomedullin, and two calcitonin gene-related peptides ("CGRPs"): CGRP1 (also known as ctCGRP or CGRP) and CGRP2 (also known as βCGRP). CGRP is a 37-amino acid vasoactive neuropeptide expressed in both the central and peripheral nervous systems and has been shown to be a potent vasodilator in the periphery, where CGRP-containing neurons are closely associated with blood vessels. CGRP-mediated vasodilators are also associated with neurogenic inflammation as part of a cascade of events leading to plasma extravasation and microvasculature dilation, as seen in migraine. Amylin also has specific binding sites in the CNS and is thought to regulate gastric emptying and play a role in carbohydrate metabolism. Adrenomedullin is a potent vasodilator. Adrenomedullin has specific receptors on astrocytes, and its messenger RNA is upregulated in CNS cells prone to ischemia (Zimmermann, et al., Identification of adrenomedullin receptors in cultured rat astrocytes and in neuroblastoma glioma hybrid cells (NG108-15), Brain Res., 724:238-245 (1996) (Non-Patent Document 1); Wang et al., Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage, Proc. Natl. Acad. Sci. USA, 92:11480-11484 (1995)).
[0003] Calcitonin is involved in the regulation of bone metabolism and is also active in the central nervous system (CNS). The biological activities of CGRP include modulation of the neuromuscular junction, regulation of antigen presentation within the immune system, regulation of vascular tone, and sensory neurotransmission (Poyner, DR, Calcitonin gene-related peptide: multiple actions, multiple receptors, Pharmacol. Ther., 56:23-51 (1992); Muff et al., Calcitonin, calcitonin gene-related peptide, adrenomedullin, and amylin homologous peptides, separate receptors and overlapping biological actions, Eur. J. Endocrinol., 133:17-20 (1995)). Three calcitonin receptor-stimulating peptides (CRSPs) have also been identified in many mammalian species, and CRSPs may form a new subfamily within the CGRP family (Katafuchi, T and Minamino, N, Structure and biological properties of three calcitonin receptor-stimulating peptides, novel members of the calcitonin gene-related peptide family, Peptides, 25(11):2039-2045 (2004)).
[0004] Calcitonin superfamily peptides act through seven transmembrane domain G protein-coupled receptors (GPCRs). The calcitonin receptor ("CT", "CTR", or "CT receptor") and CGRP receptor are type II ("family B") GPCRs; this family includes other GPCRs that recognize regulatory peptides, such as secretin, glucagon, and vasoactive intestinal polypeptide (VIP). The best-characterized splice variant of the human calcitonin receptor is the presence of 16 amino acids in the first intracellular loop (formerly known as CTR). II+ or CTR1, now CT(b) ) or absence (major splice variant, formerly known as CTR II or CTR2, now CT (a)The expression of amylin receptors varies depending on the type of bone involved (known as the skeletal calcitonin receptor isoforms) (Gorn et al., Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone: the first intracellular domain modulates ligand binding and signal transduction, J. Clin. Invest., 95:2680-2691 (1995); Hay et al., Amylin receptors: molecular composition and pharmacology, Biochem. Soc. Trans., 32:865-867 (2004); Poyner et al., 2002). The existence of at least two CGRP receptor subtypes has been suggested based on their differential agonist affinities and potencies in various in vivo and in vitro bioassays (Dennis et al., CGRP8-37, A calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery, J. Pharmacol. Exp. Ther., 254:123-128 (1990); Dennis et al., Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for multiplicity, J. Pharmacol. Exp. Ther., 251:718-725 (1989); Dumont et al., A potent and selective CGRP2 agonist, [Cys(Et)2,7]hCGRP: comparison in prototypical CGRP1 and CGRP2 in vitro). assays, Can. J. Physiol. Pharmacol., 75:671-676 (1997)).
[0005] The CGRP1 receptor subtype has been shown to be sensitive to the antagonist fragment CGRP(8-37) (Chiba et al., Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37), Am. J. Physiol., 256:E331-E335 (1989); Dennis et al., 1990; Mimeault et al., Comparative affinities and antagonistic potencies of various human calcitonin gene-related peptide fragments on calcitonin gene-related peptide receptors in the brain and periphery, J. Pharmacol. Exp. Ther., 258:1084-1090 (1991)). In contrast, the CGRP2 receptor is sensitive to linear human CGRP (hCGRP) analogs, in which the cysteine residues at positions 2 and 7 are modified (e.g., acetaminomethyl [Cys(ACM)]). 2,7 ] or ethylamide [Cys(Et) 2,7 ]), but the CGRP2 receptor was not sensitive to the fragment CGRP(8-37) (Dennis et al. (1989), Dennis et al. (1990), Dumont et al. (1997)).
[0006] The ligand specificity of calcitonin receptors and calcitonin-like receptors ("CLs," "CLRs," or "CRLRs") is determined by receptor activity-modifying proteins ( R Receptor A activity M odifying PCalcitonin receptor-like protein (RAMP) expression depends on the coexpression of a family of accessory proteins called calcitonin receptor-like proteins (CALPs). The RAMP family contains three polypeptides (RAMP1, RAMP2, and RAMP3) that act as receptor modulators, determining the ligand specificity of calcitonin family member receptors. RAMPs are type I transmembrane proteins that share approximately 30% amino acid sequence identity and a common predicted topology: a short cytoplasmic C-terminus, a single transmembrane domain, and a large extracellular N-terminus responsible for specificity (McLatchie et al., (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor, Nature, 393:333-339; Fraser et al., (1999) The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor, Molecular Pharmacology, 55:1054-1059).
[0007] In 1998, the CGRP1 receptor was identified as a heterodimer composed of a novel single-transmembrane domain accessory protein, receptor activity-modifying protein 1 (RAMP1), and CRLR (McLatchie et al., supra). Cross-linking experiments suggested that the CGRP receptor consists of a 1:1 stoichiometric arrangement of CRLR and RAMP1 (Hilairet et al., JBC 276, 42182-42190 (2001)). Recent studies using several methods, including BRET and BiFC, have revealed that the functional CGRP receptor complex may consist of an asymmetric homo-oligomer of CRLR and a monomer of RAMP1 (Heroux et al., JBC 282, 31610-31620 (2007)).
[0008] The purified CRLR N-terminal domain was 125 CRLR has been shown to specifically bind to I-CGRP (Chauhan et al., Biochemistry 44, 782 (2005)), confirming the critical direct interaction between CRLR and CGRP ligands. In particular, Leu24 and Leu34 of CRLR are thought to constitute the docking site for the C-terminal Phe37 of CGRP (Banerjee et al., BMC Pharmacol. 6, 9 (2006)). Furthermore, Koller et al. (FEBS Lett. 531, 464-468 (2002)) provided evidence that the N-terminal 18 amino acid residues of CRLR contribute to the selective interaction with CGRP or adrenomedullin, and Ittner et al. (Biochemistry 44, 5749-5754 (2005)) suggested that the N-terminal amino acid residues 23-60 of CRLR mediate its association with RAMP1.
[0009] Structure-function analysis of RAMP1 identified residues 91-103, which correlate with "helix 3" (Simms et al. Biophys. J. 91, 662-669 (2006)), as potentially important in the interaction with CRLR, and residues Trp74 and Phe92 as potentially interacting with CGRP ligands in relation to their binding to the CGRP-receptor complex. Ligand-binding studies using human / rat RAMP1 chimeras suggest that the binding site for certain small molecule inhibitors of CGRP (e.g., BIBN4096BS) is located within a region encompassing amino acids 66-102 of RAMP1 (Mallee et al. JBC 277, 14294-14298 (2002)).
[0010] CRLR shares 55% overall amino acid sequence identity with CTR, but the transmembrane domains are approximately 80% identical (McLatchie et al. (1998); Poyner et al., International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors, Pharmacol. Rev., 54:233-246 (2002)).
[0011] It has been shown that CRLR, when associated with RAMP1, forms a high-affinity receptor for CGRP, or, when associated with RAMP2 or RAMP3, selectively binds adrenomedullin (McLatchie et al. (1998); Sexton et al., Receptor activity modifying proteins, Cellular Signaling, 13:73-83 (2001); Conner et al., Interaction of calcitonin-gene-related peptide with its receptors, Biochemical Society Transactions 30(Part 4):451-454 (2002)). The glycosylation state of CRLR correlates with its pharmacokinetics. RAMPs 1, 2, and 3 transport CRLR to the plasma membrane with similar efficiency. However, RAMP1 presents CRLR as a terminally glycosylated mature glycoprotein and CGRP receptor, whereas RAMP2 and 3 present CRLR as an immature, core-glycosylated adrenomedullin receptor ("AM" or "AMR" or "AM receptor" (Fraser et al. (1999))). Radioligand binding (as a radioligand) 125Characterization of the CRLR / RAMP2 and CRLR / RAMP3 receptors in HEK293T cells by I-adrenomedullin), functional assays (cAMP measurement), or biochemical analysis (SDS-polyacrylamide gel electrophoresis) revealed that RAMP2 and 3 are indistinguishable, even though they share only 30% amino acid sequence identity (Fraser et al. 1999). However, differences were observed in the pharmacology of the CRLR expressed by RAMP2 and 3. Both CGRP and CGRP8-37, as well as adrenomedullin and the adrenomedullin-derived peptide AM22-52, are active in the RAMP3 heterodimer, indicating that this complex can act as both a CGRP and an AM receptor (Howitt et al., British Journal of Pharmacology, 140:477-486 (2003); Muff et al., Hypertens. Res., 26:S3-S8 (2003)). Coexpression of human CRLR with rat RAMP1 and vice versa suggested that the RAMP1 species determines the pharmacological characteristics of CRLR / RAMP1 for several small-molecule CGRP receptor antagonists tested (Mallee et al., Receptor Activity-Modifying Protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists, J. Biol. Chem., 277(16):14294-14298 (2002)). CRLR is not known to bind any endogenous ligands unless associated with a RAMP, and it is currently the only GPCR thought to behave in this manner (Conner et al., A key role for transmembrane prolines in calcitonin receptor-like agonist binding and signaling: implications for family B G-protein-coupled receptors, Molec. Pharmacol., 67(1):20-31 (2005)).
[0012] Calcitonin receptors (CTs) have also been shown to form heterodimeric complexes with RAMPs, known as amylin receptors ("AMYs," "AMYRs," or "AMY receptors"). Generally, the CT / RAMP1 receptor (referred to as "AMY1" or "AMY1") has high affinity for salmon calcitonin, amylin, and CGRP, and low affinity for mammalian calcitonin. A similar pattern is largely observed for the CT / RAMP2 receptor ("AMY2" or "AMY2") and the CT / RAMP3 receptor ("AMY3" or "AMY3"), although the affinity for CGRP is lower and may not be significant at physiologically relevant ligand concentrations. The exact receptor phenotype depends on the receptor cell type and the CTR splice variant (CT). (a) or CT (b)), especially for RAMP2-generated amylin. For example, it has been reported that pure populations of osteoclast-like cells expressed RAMP2, CTR, and CRLR, but not RAMP1 or RAMP3 (Hay et al. (2004); Christopoulos et al., Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product, Molecular Pharmacology, 56:235-242 (1999); Muff et al., An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3, Endocrinology, 140:2924-2927 (1999); Sexton et al. (2001); Leuthauser et al., Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition,Biochem.J.,351:347-351(2000),Tilakaratne et al.,Amylin receptor phenotypes derived from human calcitonin receptor / RAMP co-expression exhibit pharmacological differences dependent on receptor isoform and host cell environment,J.Pharmacol.Exp.Ther.,294:61-72(2000),Nakamura et al., Osteoclast-like cells express receptor activity modifying protein 2: application of laser capture microdissection, J. Molec. Endocrinol., 34:257-261 (2005)). .
[0013] Table 1 below summarizes the relationships of the receptor components described above.
[0014] [Table 1]
[0015] Therapeutic uses of CGRP antagonists have been proposed. Noda et al. described the use of CGRP or CGRP derivatives to inhibit platelet aggregation and for the treatment or prevention of arteriosclerosis or thrombosis (European Patent No. EP0385712 B1). Liu et al. disclosed therapeutic agents that modulate the activity of CTR, including mediator-coupled peptides such as calcitonin and human αCGRP (International Publication Nos. WO01 / 83526 A2 and US2002 / 0090646 A1). Smith et al. disclosed vasoactive CGRP peptide antagonists and their use in methods for inhibiting CGRP binding to CGRP receptors, and showed that such CGRP peptide antagonists inhibited CGRP binding to coronary artery membranes and relaxed capsaicin-treated porcine coronary arteries (U.S. Patent Nos. 6,268,474 B1 and 6,756,205 B2). Rist et al. disclosed peptide analogs with CGRP receptor antagonist activity and their use in drugs for the treatment and prevention of various diseases (German Patent No. DE 19732944 A1).
[0016] CGRP is a potent vasodilator that has been implicated in the pathology of all forms of vascular headache, including numerous vasomotor symptoms, such as migraine (with or without aura) and cluster headache. Durham, N. Engl. J. Med. 350:1073-1075, 2004. The pathophysiology of migraine involves activation of the trigeminal ganglion, where CGRP is located, and CGRP levels increase significantly during a migraine attack. This then promotes cranial vasodilation, neurogenic inflammation, and sensitization (Doods, H., Curr. Opin. Investig. Drugs, 2:1261-1268 (2001)). Furthermore, CGRP serum levels in the external jugular vein are elevated in patients with migraine. Goadsby et al., Ann. Neurol. 28:183-7, 1990. Intravenous administration of human ci-CGRP induces headache and migraine in patients with migraine without aura, supporting the notion that CGRP plays a causative role in migraine (Lassen et al, Cephalalgia 22:54-61, 2002).
[0017] Migraine is a complex, common neurological condition characterized by severe episodic headache attacks and associated symptoms, including nausea, vomiting, and sensitivity to light, sound, or movement. In some patients, headaches are preceded by or accompanied by aura. The headaches can be severe and, in certain patients, can be unilateral. Migraine attacks adversely affect daily life. In the United States and Western Europe, the overall prevalence of migraine sufferers is 11% of the population (6% of men and 15-18% of women). Furthermore, the median individual attack frequency is 1.5 attacks per month. While numerous treatments are available to alleviate or reduce symptoms, preventive therapy is recommended for patients experiencing more than three to four attacks per month. (Goadsby, et al. New Engl. J. Med. 346(4):257-275, 2002) Some migraine patients are treated with topiramate, an anticonvulsant that blocks voltage-gated sodium channels and certain glutamate receptors (AMPA-kainate), enhances GABA-A receptor activity, and blocks carbonic anhydrase. The relatively recent success of serotonin 5HT-IB / ID and / or 5HT-1a receptor agonists, such as sumatriptan, in some patients has led researchers to propose a serotonergic etiology for the disease. Unfortunately, while some patients respond well to this treatment, others are relatively resistant to its effects.
[0018] The possible involvement of CGRP in migraine has led to the development and testing of numerous compounds that inhibit CGRP release (e.g., sumatriptan), antagonize CGRP receptors (e.g., dipeptide derivative BIBN4096BS (Boehringer Ingelheim), CGRP(8-37)), or interact with one or more receptor-associated proteins, such as RAMP1. Brain, S. et al., Trends in Pharmacological Sciences 23:51-53, 2002. The alpha-2 adrenoceptor subtype and adenosine A1 receptors also regulate (inhibit) CGRP release and trigeminal nerve activation (Goadsby et al., Brain 125:1392-401, 2002). On the other hand, treatment with compounds that inhibit only neurogenic inflammatory activation (e.g., tachykinin NKI receptor antagonists) or only trigeminal activation (e.g., 5HT10 receptor agonists) appears to be relatively ineffective as acute treatments for migraine, leading some researchers to question whether inhibiting CGRP release is the basis for effective antimigraine therapy (Arulmani et al., Eur. J. Pharmacol. 500:315-330, 2004).
[0019] Although the exact pathophysiology of migraine is still poorly understood, the therapeutic use of CGRP antagonists and CGRP-targeting aptamers has been proposed for the treatment of migraine and other diseases (e.g., Olesen et al., Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine, New Engl. J. Med., 350:1104-1110 (2004); Perspective: CGRP-receptor antagonists—a fresh approach to migraine, New Engl. J. Med., 350:1075 (2004); Vater et al., Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX, Nuc. Acids Res., 31 (21 e130):1-7 (2003), International Publication No. WO 96 / 03993. Furthermore, a potent small molecule CGRP antagonist has been shown in a recent Phase 3 clinical trial to relieve moderate to severe migraine attacks, including migraine and migraine-related symptoms (Connor, et al. Efficacy and Safety of telcagepant (MK-0974), a Novel Oral CGRP Receptor Antagonist, for Acute Migraine Attacks. Poster, European Headache and Migraine Trust International Congress, London, England, September 2008).
[0020] CGRP may also be involved in chronic pain syndromes other than migraine. In rodents, intrathecally delivered CGRP induces severe pain, and CGRP levels are enhanced in multiple pain models. Furthermore, CGRP antagonists partially block pain sensation in rodents with acute pancreatitis (Wick, et al., (2006) Surgery, Volume 139, Issue 2, Pages 197-201). Taken together, these observations suggest that potent and selective CGRP receptor antagonists may be effective therapeutic agents for the treatment of chronic pain, including migraine. [Prior art documents] [Non-patent literature]
[0021] [Non-Patent Document 1] Zimmermann, et al., Identification of adrenomedullin receptors in cultured rat astrocytes and in neuroblastoma glioma hybrid cells (NG108-15), Brain Res., 724:238-245 (1996) Summary of the Invention [Means for solving the problem]
[0022] Described herein are isolated antibodies, antigen-binding fragments thereof, and other isolated antigen-binding proteins that bind to CGRP-R, particularly primate CGRP-R, e.g., human CGRP-R. Such isolated antigen-binding proteins can selectively inhibit CGRP-R (compared to primate AM1, AM2, CT, or amylin receptors) and can bind to both the CRLR and RAMP1 components of CGRP-R. CGRP-binding proteins have been shown to inhibit, interfere with, or regulate at least one biological response associated with CGRP-R, and are therefore useful for ameliorating the effects of CGRP-related diseases or disorders. Thus, binding of a given antigen-binding protein to CGRP-R can have one or more of the following activities: inhibiting, interfering with, or regulating CGRP-R, inhibiting vasodilation, reducing neurogenic inflammation, and alleviating, ameliorating, treating, preventing, or alleviating the symptoms of chronic pain or migraine.
[0023] In a typical aspect, the isolated antigen binding protein selectively inhibits the human CGRP receptor (compared to AM1, AM2, CT, or amylin receptors). In some embodiments, the isolated antigen binding protein selectively inhibits the human CGRP receptor with a selectivity ratio of 50 or greater, 75 or greater, 100 or greater, 150 or greater, 200 or greater, 250 or greater, 300 or greater, 400 or greater, 500 or greater, 750 or greater, or 1000 or greater. The degree of selective inhibition can be determined using any suitable method, for example, using a cAMP assay as described in the Examples herein. In some embodiments, the isolated antigen binding protein specifically binds to both human CRLR and human RAMP1, and does not specifically bind to human AM1, human AM2, or human amylin receptors (e.g., AMY1 or AMY2). For example, the isolated antigen binding protein has a K of 1 μM or less, 100 nM or less, 10 nM or less, or 5 nM or less. DIn some embodiments, the isolated antigen-binding protein has a K of 100 nM or less, 10 nM or less, or 5 nM or less, as determined using a FACS binding assay and analyzed using, for example, the method described in Rathanaswami, et al., Biochemical and Biophysical Research Communications 334 (2005) 1004-1013. D In some embodiments, the isolated antigen binding protein specifically binds to human CGRP-R. In some embodiments, the isolated antigen binding protein has a K of 100 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less in a CGRP-binding competition assay. In some embodiments, the isolated antigen binding protein is radiolabeled to membranes from cells expressing human CGRP-R. 125 In an I-CGRP binding competition assay, such as the assay described in Example 5 herein, the K is 100 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less.
[0024] In another exemplary embodiment, the isolated antigen binding protein competes for binding to human CGRP R, e.g., the extracellular portion of CGRP R, with a reference antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 158-170 and a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 137-153. In some embodiments, binding competition is assessed using a binning assay, e.g., using a Biacore assay as described in Example 7 herein. In some embodiments, the isolated antigen binding protein competes for binding to human CGRP R with a reference antibody comprising (i) a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 161, 163, 164, 166, and 168, and (ii) a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 140, 143, 146, 148, and 150. In certain embodiments, the reference antibody comprises (i) a heavy chain defined by a sequence selected from the group consisting of SEQ ID NOs: 32, 34, 35, 37, and 39, and (ii) a light chain defined by a sequence selected from the group consisting of SEQ ID NOs: 15, 18, 21, 23, and 25. In some particular embodiments, the reference antibody comprises a heavy chain and a light chain defined by one of the following sequence pairs: (i) SEQ ID NO: 32 and SEQ ID NO: 15, (ii) SEQ ID NO: 34 and SEQ ID NO: 18, (iii) SEQ ID NO: 35 and SEQ ID NO: 21, (iv) SEQ ID NO: 37 and SEQ ID NO: 23, and (v) SEQ ID NO: 39 and SEQ ID NO: 25. In one such embodiment, the reference antibody comprises a heavy chain comprising SEQ ID NO: 32 and a light chain comprising SEQ ID NO: 15. In another such embodiment, the reference antibody comprises a heavy chain comprising SEQ ID NO: 34 and a light chain comprising SEQ ID NO: 18. In another such embodiment, the reference antibody comprises a heavy chain comprising SEQ ID NO: 35 and a light chain comprising SEQ ID NO: 21. In another such embodiment, the reference antibody comprises a heavy chain comprising SEQ ID NO: 37 and a light chain comprising SEQ ID NO: 23. In another such embodiment, the reference antibody comprises a heavy chain comprising SEQ ID NO: 39 and a light chain comprising SEQ ID NO: 25.
[0025] In certain embodiments, the isolated antigen binding protein that competes for binding to human CGRP-R also selectively inhibits the human CGRP receptor with a selectivity of 100 or greater, 250 or greater, 500 or greater, 750 or greater, 1,000 or greater, 2,500 or greater, 5,000 or greater, or 10,000; such selectivity may be determined, for example, using a cAMP assay as described in the Examples herein. In related embodiments, the isolated antigen binding protein that competes for binding to human CGRP-R exhibits a K determined using a FACS binding assay and analyzed, for example, using the method described in Rathanaswami, et al., Biochemical and Biophysical Research Communications 334 (2005) 1004-1013. D In a related embodiment, the isolated antigen binding protein that competes for binding to human CGRP-R is capable of specifically binding to human CGRP-R at a binding affinity of 1 μM or less, 100 nM or less, 10 nM or less, or 5 nM or less. In a related embodiment, the isolated antigen binding protein that competes for binding to human CGRP-R is capable of binding to human CGRP-R in a CGRP binding competition assay, e.g., by radiolabeling membranes from cells expressing human CGRP-R. 125 In an I-CGRP binding competition assay, for example, the assay described in Example 5 herein, the K is 100 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less.
[0026] In any of the above-described embodiments, the isolated antigen-binding protein that competes for binding to human CGRP₃ may be, for example, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human (e.g., fully human) antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antigen-binding fragment thereof. Furthermore, the antibody fragment of the isolated antigen-binding protein that competes for binding to human CGRP₃ may be a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an Fv fragment, a bispecific antibody, or a single-chain antibody molecule, and may be, for example, a human monoclonal antibody, such as an IgG₁, IgG₂, IgG₃, or IgG₄ type antibody. In certain embodiments, the isolated antigen-binding protein that competes for binding to human CGRP₃ may be a neutralizing antigen-binding protein.
[0027] In certain exemplary embodiments, the described isolated antigen binding protein, e.g., isolated antibody or fragment thereof, comprises: (A) one or more heavy chain complementarity determining regions (CDRHs) selected from the group consisting of: (i) a CDRH1 having SEQ ID NO: 134; (ii) a CDRH2 having SEQ ID NO: 135; (iii) a CDRH3 having SEQ ID NO: 136; and optionally (iv) a CDRH of (i), (ii), and (iii) that comprises one or more amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or amino acid insertions, totaling no more than four amino acids; (B) (i) a CDRH selected from the group consisting of SEQ ID NOs: 107, 111, and 118; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 108, 112, and 119; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 109, 113, and 120; and optionally (iv) one or more light chain complementarity determining regions (CDRLs) selected from the group consisting of the CDRLs of (i), (ii), and (iii), which contain one or more, e.g., one, two, three, four, or more, amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or amino acid insertions, totaling no more than four amino acids; or (C) one or more heavy chain CDRHs of (A) and one or more light chain CDRLs of (B).
[0028] In some embodiments, the CDRH is further selected from the group consisting of: (i) a CDRH1 having SEQ ID NO: 131; (ii) a CDRH2 having SEQ ID NO: 132; (iii) a CDRH3 having SEQ ID NO: 133; and optionally (iv) a CDRH of (i), (ii), and (iii) that contains one or more, e.g., one, two, three, four, or more, amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or amino acid insertions, not exceeding three amino acids in total. In related embodiments, the CDRH is further selected from the group consisting of: (i) a CDRH1 selected from the group consisting of SEQ ID NOs: 76, 88, 100, 121, 125, and 128; (ii) a CDRH2 selected from the group consisting of SEQ ID NOs: 89, 101, 122, 124, 126, and 129; (iii) a CDRH3 selected from the group consisting of SEQ ID NOs: 78, 90, 102, 123, 127, and 130; and optionally (iv) a CDRH of (i), (ii), and (iii) that contains one or more, e.g., one, two, three, four, or more amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or amino acid insertions, not exceeding two amino acids in total. In other related embodiments, the CDRH is further selected from the group consisting of: (i) a CDRH1 selected from the group consisting of SEQ ID NOs: 73, 76, 79, 82, 85, 88, 92, 97, and 100; (ii) a CDRH2 selected from the group consisting of SEQ ID NOs: 74, 77, 80, 83, 86, 89, 91, 93, 95, 98, 101, and 129; (iii) a CDRH3 selected from the group consisting of SEQ ID NOs: 75, 78, 81, 84, 87, 90, 96, 99, 102, and 123; and optionally (iv) a CDRH of (i), (ii), and (iii) that contains one or more, e.g., one, two, three, four, or more amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or amino acid insertions, not exceeding two amino acids in total.
[0029] In some embodiments, the CDRLs are further selected from the group consisting of: (i) a CDRL1 selected from the group consisting of SEQ ID NOs: 107, 111, and 115; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 108, 112, and 116; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 109, 113, and 117; and optionally (iv) a CDRL of (i), (ii), and (iii) that comprises one or more, e.g., one, two, three, four, or more, amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. In some embodiments, the amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions collectively do not exceed a total of three amino acids per CDRL. In some embodiments, the amino acid substitutions, deletions, or insertions collectively do not exceed a total of two amino acids per CDRL. In related embodiments, the CDRL is further selected from the group consisting of: (i) a CDRL1 selected from the group consisting of SEQ ID NOs: 42, 45, 51, 57, 62, 69, 103, and 110; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 43, 52, 55, 58, 63, 70, 104, 108, and 114; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 44, 47, 53, 56, 59, 64, 105, and 106; and optionally (iv) a CDRL of (i), (ii), and (iii) that contains one or more, e.g., one, two, three, four, or more amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or amino acid insertions, not exceeding two amino acids in total. In further related embodiments, the CDRL is further selected from the group consisting of: (i) a CDRL1 selected from the group consisting of SEQ ID NOs: 42, 45, 48, 51, 54, 57, 62, 65, 66, and 69; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 43, 46, 49, 52, 55, 58, 61, 63, 67, and 70; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 44, 47, 50, 53, 56, 59, 64, 68, 71, and 72; and optionally (iv) CDRLs of (i), (ii), and (iii) that contain one or more, e.g., one, two, three, four or more amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.In one embodiment, the total number of amino acid substitutions, deletions, or insertions is no more than two amino acids per CDR. In another embodiment, the amino acid substitutions are conservative substitutions.
[0030] In another embodiment, the isolated antigen binding protein comprises at least one or two CDRHs of any of (A) above and (B) above. In yet another embodiment, the isolated antigen binding protein comprises (i) at least three CDRHs of any of (A) above, comprising CDRH1, CDRH2, and CDRH3, and (ii) at least three CDRLs of any of (B) above, wherein the three CDRLs comprise CDRL1, CDRL2, and CDRL3. In a further embodiment, the isolated antigen binding protein described above comprises a first amino acid sequence comprising at least one CDRH and a second amino acid sequence comprising at least one CDRL. In one embodiment, the first and second amino acid sequences are covalently linked to each other.
[0031] In another embodiment, the isolated antigen binding protein comprises CDRH1, CDRH2, and CDRH3. In one embodiment, CDRH1 comprises SEQ ID NO:73, CDRH2 comprises SEQ ID NO:74, and CDRH3 comprises SEQ ID NO:75. In another embodiment, CDRH1 comprises SEQ ID NO:76, CDRH2 comprises SEQ ID NO:77, and CDRH3 comprises SEQ ID NO:78. In another embodiment, CDRH1 comprises SEQ ID NO:79, CDRH2 comprises SEQ ID NO:80, and CDRH3 comprises SEQ ID NO:81. In another embodiment, CDRH1 comprises SEQ ID NO:82, CDRH2 comprises SEQ ID NO:83, and CDRH3 comprises SEQ ID NO:84. In another embodiment, CDRH1 comprises SEQ ID NO:85, CDRH2 comprises SEQ ID NO:86, and CDRH3 comprises SEQ ID NO:87. In another embodiment, CDRH1 comprises SEQ ID NO:88, CDRH2 comprises SEQ ID NO:89, and CDRH3 comprises SEQ ID NO:90. In another embodiment, CDRH1 comprises SEQ ID NO:76, CDRH2 comprises SEQ ID NO:91, and CDRH3 comprises SEQ ID NO:78. In another embodiment, CDRH1 comprises SEQ ID NO:92, CDRH2 comprises SEQ ID NO:93, and CDRH3 comprises SEQ ID NO:94. In another embodiment, CDRH1 comprises SEQ ID NO:76, CDRH2 comprises SEQ ID NO:95, and CDRH3 comprises SEQ ID NO:78. In another embodiment, CDRH1 comprises SEQ ID NO:73, CDRH2 comprises SEQ ID NO:74, and CDRH3 comprises SEQ ID NO:96. In another embodiment, CDRH1 comprises SEQ ID NO:97, CDRH2 comprises SEQ ID NO:98, and CDRH3 comprises SEQ ID NO:99. In another embodiment, CDRH1 comprises SEQ ID NO:100, CDRH2 comprises SEQ ID NO:101, and CDRH3 comprises SEQ ID NO:102.
[0032] In another aspect, the isolated antigen binding protein comprises a CDRL1 sequence, a CDRL2 sequence, and a CDRL3 sequence. In one embodiment, CDRL1 comprises SEQ ID NO:42, CDRL2 comprises SEQ ID NO:43, and CDRL3 comprises SEQ ID NO:44. In another embodiment, CDRL1 comprises SEQ ID NO:45, CDRL2 comprises SEQ ID NO:46, and CDRL3 comprises SEQ ID NO:47. In another embodiment, CDRL1 comprises SEQ ID NO:48, CDRL2 comprises SEQ ID NO:49, and CDRL3 comprises SEQ ID NO:50. In another embodiment, CDRL1 comprises SEQ ID NO:51, CDRL2 comprises SEQ ID NO:52, and CDRL3 comprises SEQ ID NO:53. In another embodiment, CDRL1 comprises SEQ ID NO:54, CDRL2 comprises SEQ ID NO:55, and CDRL3 comprises SEQ ID NO:56. In another embodiment, CDRL1 comprises SEQ ID NO:57, CDRL2 comprises SEQ ID NO:58, and CDRL3 comprises SEQ ID NO:59. In another embodiment, CDRL1 comprises SEQ ID NO:60, CDRL2 comprises SEQ ID NO:55, and CDRL3 comprises SEQ ID NO:56. In another embodiment, CDRL1 comprises SEQ ID NO:45, CDRL2 comprises SEQ ID NO:61, and CDRL3 comprises SEQ ID NO:47. In another embodiment, CDRL1 comprises SEQ ID NO:62, CDRL2 comprises SEQ ID NO:63, and CDRL3 comprises SEQ ID NO:64. In another embodiment, CDRL1 comprises SEQ ID NO:65, CDRL2 comprises SEQ ID NO:55, and CDRL3 comprises SEQ ID NO:56. In another embodiment, CDRL1 comprises SEQ ID NO:66, CDRL2 comprises SEQ ID NO:67, and CDRL3 comprises SEQ ID NO:68. In another embodiment, CDRL1 comprises SEQ ID NO:69, CDRL2 comprises SEQ ID NO:70, and CDRL3 comprises SEQ ID NO:71. In another embodiment, CDRL1 comprises SEQ ID NO:69, CDRL2 comprises SEQ ID NO:70, and CDRL3 comprises SEQ ID NO:72.
[0033] In another aspect, the isolated antigen binding protein comprises a CDRL1 sequence, a CDRL2 sequence, a CDRL3 sequence, a CDRH1 sequence, a CDRH2 sequence, and a CDRH3 sequence. In one embodiment, CDRL1 comprises SEQ ID NO:42, CDRL2 comprises SEQ ID NO:43, CDRL3 comprises SEQ ID NO:44, CDRH1 comprises SEQ ID NO:73, CDRH2 comprises SEQ ID NO:74, and CDRH3 comprises SEQ ID NO:75. In another embodiment, CDRL1 comprises SEQ ID NO:45, CDRL2 comprises SEQ ID NO:46, CDRL3 comprises SEQ ID NO:47, CDRH1 comprises SEQ ID NO:76, CDRH2 comprises SEQ ID NO:77, and CDRH3 comprises SEQ ID NO:78. In another embodiment, CDRL1 comprises SEQ ID NO:48, CDRL2 comprises SEQ ID NO:49, CDRL3 comprises SEQ ID NO:50, CDRH1 comprises SEQ ID NO:79, CDRH2 comprises SEQ ID NO:80, and CDRH3 comprises SEQ ID NO:81. In another embodiment, CDRL1 comprises SEQ ID NO:51, CDRL2 comprises SEQ ID NO:52, CDRL3 comprises SEQ ID NO:53, CDRH1 comprises SEQ ID NO:82, CDRH2 comprises SEQ ID NO:83, and CDRH3 comprises SEQ ID NO:84. In another embodiment, CDRL1 comprises SEQ ID NO:54, CDRL2 comprises SEQ ID NO:55, and CDRL3 comprises SEQ ID NO:56, CDRH1 comprises SEQ ID NO:85, CDRH2 comprises SEQ ID NO:86, and CDRH3 comprises SEQ ID NO:87. In another embodiment, CDRL1 comprises SEQ ID NO:57, CDRL2 comprises SEQ ID NO:58, CDRL3 comprises SEQ ID NO:59, CDRH1 comprises SEQ ID NO:88, CDRH2 comprises SEQ ID NO:89, and CDRH3 comprises SEQ ID NO:90. In another embodiment, CDRL1 comprises SEQ ID NO: 60, CDRL2 comprises SEQ ID NO: 55, CDRL3 comprises SEQ ID NO: 56, CDRH1 comprises SEQ ID NO: 85, CDRH2 comprises SEQ ID NO: 86, and CDRH3 comprises SEQ ID NO: 87. In another embodiment, CDRL1 comprises SEQ ID NO: 45, CDRL2 comprises SEQ ID NO: 61, CDRL3 comprises SEQ ID NO: 47, CDRH1 comprises SEQ ID NO: 76, CDRH2 comprises SEQ ID NO: 91, and CDRH3 comprises SEQ ID NO: 78.In another embodiment, CDRL1 comprises SEQ ID NO:62, CDRL2 comprises SEQ ID NO:63, CDRL3 comprises SEQ ID NO:64, CDRH1 comprises SEQ ID NO:92, CDRH2 comprises SEQ ID NO:93, and CDRH3 comprises SEQ ID NO:94. In another embodiment, CDRL1 comprises SEQ ID NO:45, CDRL2 comprises SEQ ID NO:61, CDRL3 comprises SEQ ID NO:47, CDRH1 comprises SEQ ID NO:76, CDRH2 comprises SEQ ID NO:95, and CDRH3 comprises SEQ ID NO:78. In another embodiment, CDRL1 comprises SEQ ID NO:65, CDRL2 comprises SEQ ID NO:55, CDRL3 comprises SEQ ID NO:56, CDRH1 comprises SEQ ID NO:85, CDRH2 comprises SEQ ID NO:86, and CDRH3 comprises SEQ ID NO:87. In another embodiment, CDRL1 comprises SEQ ID NO: 42, CDRL2 comprises SEQ ID NO: 43, CDRL3 comprises SEQ ID NO: 44, CDRH1 comprises SEQ ID NO: 73, CDRH2 comprises SEQ ID NO: 74, and CDRH3 comprises SEQ ID NO: 96. In another embodiment, CDRL1 comprises SEQ ID NO: 66, CDRL2 comprises SEQ ID NO: 67, CDRL3 comprises SEQ ID NO: 68, CDRH1 comprises SEQ ID NO: 97, CDRH2 comprises SEQ ID NO: 98, and CDRH3 comprises SEQ ID NO: 99. In another embodiment, CDRL1 comprises SEQ ID NO: 69, CDRL2 comprises SEQ ID NO: 70, CDRL3 comprises SEQ ID NO: 71, CDRH1 comprises SEQ ID NO: 100, CDRH2 comprises SEQ ID NO: 101, and CDRH3 comprises SEQ ID NO: 102. In another embodiment, CDRL1 comprises SEQ ID NO: 69, CDRL2 comprises SEQ ID NO: 70, CDRL3 comprises SEQ ID NO: 72, CDRH1 comprises SEQ ID NO: 100, CDRH2 comprises SEQ ID NO: 101, and CDRH3 comprises SEQ ID NO: 102.
[0034] In any of the above sequence definition embodiments, the isolated antigen-binding protein may be, for example, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human (e.g., fully human) antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antigen-binding fragment thereof. Furthermore, the antigen fragment of the isolated antigen-binding protein may be a Fab fragment and a Fab' fragment, a F(ab')2 fragment, an Fv fragment, a bispecific antibody, or a single-chain antibody molecule. For example, the isolated antigen-binding protein may be a human monoclonal antibody, such as an IgG1, IgG2, IgG3, or IgG4 type antibody. Furthermore, the isolated antigen-binding protein may be a neutralizing antigen-binding protein.
[0035] In any of the sequence definition embodiments described above, the isolated antigen binding protein may specifically bind to both human CRLR and human RAMP1, and does not specifically bind to AM1, AM2, or a human amylin receptor (e.g., AMY1), e.g. ... as determined using a FACS binding assay and analyzed using, e.g., the method described in Rathanaswami, et al., Biochemical and Biophysical Research Communications 334 (2005) 1004-1013, K D It may specifically bind to human CGRP-R at 1 μM or less, 100 nM or less, 10 nM or less, or 5 nM or less. In any of the sequence-defined embodiments described above, the isolated antigen binding protein may selectively inhibit human CGRP-R relative to human AM1, AM2, or AM1 receptors, e.g., with a selectivity ratio of 100 or more, 250 or more, 500 or more, 750 or more, 1,000 or more, 2,500 or more, 5,000 or more, or 10,000 or more, and the degree of selective inhibition can be determined using any suitable method, for example, using a cAMP assay as described in the Examples herein. In any of the sequence-defined embodiments described above, the isolated antigen binding protein may be isolated by radiolabeling human CGRP-R to membranes from cells expressing human CGRP-R. 125In an I-CGRP binding competition assay, such as the assay described in Example 5 herein, the K i can be 100 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less.
[0036] Another set of embodiments includes isolated antigen binding proteins that comprise one or a combination of CDRs with the consensus sequences described below, and optionally bind to human CGRP®. The consensus sequences are derived from phylogenetically related CDR sequences. In one aspect, CDRs from various groups can be mixed and matched in any particular isolated antigen binding protein that binds to human CGRP®. In another aspect, the antigen binding protein comprises heavy and light chain CDRs that are derived from the same phylogenetically related group of antibody clones. Exemplary CDR consensus sequences are as follows:
[0037] K1 Consensus CDR1 RASQGIRX1DLG (SEQ ID NO: 103), wherein X1 is selected from the group consisting of N and K. CDR2 X1ASSLQS (SEQ ID NO: 104), where X1 is selected from the group consisting of A and G. CDR3 LQYNX1X2PWT (SEQ ID NO: 105), wherein X1 is selected from the group consisting of I and S, and X2 is selected from the group consisting of Y and F. K4 Consensus CDR3 QQYGNSLX1R (SEQ ID NO: 106), wherein X1 is selected from the group consisting of S and C. K1,4 consensus CDR1 RASQX1X2X3X4GX5LX6 (SEQ ID NO: 107), wherein X1 is selected from the group consisting of S and G, X2 is selected from the group consisting of V and I, X3 is selected from the group consisting of S and R, X4 is selected from the group consisting of S, N and K, X5 is selected from the group consisting of Y and D, and X6 is selected from the group consisting of T and G. CDR2 X1ASSX2X3X4 (SEQ ID NO: 108), wherein X1 is selected from the group consisting of G and A, X2 is selected from the group consisting of R and L, X3 is selected from the group consisting of A and Q, and X4 is selected from the group consisting of T and S. CDR3 X1QYX2X3X4X5X6X7 (SEQ ID NO: 109), wherein X1 is selected from the group consisting of Q and L, X2 is selected from the group consisting of G and N, X3 is selected from the group consisting of N and T, X4 is selected from the group consisting of S, Y and F, X5 is selected from the group consisting of L and P, X6 is selected from the group consisting of C, W, and S, and X7 is selected from the group consisting of R and T. K3 Consensus CDR1 KSSQSLLHSX1GX2X3YLY (SEQ ID NO: 110), wherein X1 is selected from the group consisting of D and A, X2 is selected from the group consisting of R and K, and X3 is selected from the group consisting of N and T. K2,3 consensus CDR1 X1SSQSLLHSX2GX3X4YLX5 (SEQ ID NO: 111), wherein X1 is selected from the group consisting of R and K, X2 is selected from the group consisting of F, D, and A, X3 is selected from the group consisting of Y, R, and K, X4 is selected from the group consisting of N and T, and X5 is selected from the group consisting of D and Y. CDR2 X1X2SNRX3S (SEQ ID NO: 112), wherein X1 is selected from the group consisting of L and E, X2 is selected from the group consisting of G and V, and X3 is selected from the group consisting of A and F. CDR3 MQX1X2X3X4PX5T (SEQ ID NO: 113), wherein X1 is selected from the group consisting of A and S, X2 is selected from the group consisting of L and F, X3 is selected from the group consisting of Q and P, X4 is selected from the group consisting of T and L, and X5 is selected from the group consisting of F and L. Lm3 consensus CDR2 RX1NQRPS (SEQ ID NO: 114), wherein X1 is selected from the group consisting of N and S. Lm1,2,3 consensus CDR1 SGSSSNIGX1NX2VX3 (SEQ ID NO: 115), wherein X1 is selected from the group consisting of N and S, X2 is selected from the group consisting of Y and T, and X3 is selected from the group consisting of S, N, and Y. CDR2 X1X2NX3RPS (SEQ ID NO: 116), wherein X1 is selected from the group consisting of D, T, and R; X2 is selected from the group consisting of N and S; and X3 is selected from the group consisting of K and Q. CDR3 X1X2X3DX4X5LX6X7VV (SEQ ID NO: 117), wherein X1 is selected from the group consisting of G and A, X2 is selected from the group consisting of T and A, X3 is selected from the group consisting of W and R, X4 is selected from the group consisting of S and D, X5 is selected from the group consisting of R and S, X6 is selected from the group consisting of S and N, and X7 is selected from the group consisting of A and G. LmAll Consensus CDR1 X1GX2X3SX4X5X6X7X8X9X 10 X 11 (SEQ ID NO: 118), wherein X1 is selected from the group consisting of S and Q, X2 is present or absent and if present is S, X3 is selected from the group consisting of S and D, X4 is present or absent and if present is N, X5 is selected from the group consisting of I and L, X6 is selected from the group consisting of G and R, X7 is selected from the group consisting of N and S, X8 is selected from the group consisting of N and F, X9 is selected from the group consisting of Y and T, and X 10 is selected from the group consisting of V and A, and X 11 is selected from the group consisting of S, N, and Y. CDR2 X1X2NX3RPS (SEQ ID NO: 119), wherein X1 is selected from the group consisting of D, G, T, and R; X2 is selected from the group consisting of N, K, and S; and X3 is selected from the group consisting of K, N, and Q. CDR3 X1X2X3DX4X5X6X7X8X9V (SEQ ID NO: 120), wherein X1 is selected from the group consisting of G, N, and A, X2 is selected from the group consisting of T, S, and A, X3 is selected from the group consisting of W and R, X4 is selected from the group consisting of S and D, X5 is selected from the group consisting of R and S, X6 is selected from the group consisting of L and V, X7 is selected from the group consisting of S, Y, and N, X8 is selected from the group consisting of A, H, and G, and X9 is selected from the group consisting of V and L. HC1 consensus CDR1 X1YYMX2 (SEQ ID NO: 121), wherein X1 is selected from the group consisting of G and D; and X2 is selected from the group consisting of H and Y. CDR2 WIX1PNSGGTNYAQKFQG (SEQ ID NO: 122), wherein X1 is selected from the group consisting of N and S. CDR3 X1X2X3SX4X5X6X7X8GX9X 10 X 11 X 12 YYX 13 GMDV (SEQ ID NO: 123), wherein X1 is selected from the group consisting of D and G, X2 is selected from the group consisting of Q and G, X3 is selected from the group consisting of M and Y, X4 is selected from the group consisting of I and G, X5 is selected from the group consisting of I and Y, X6 is selected from the group consisting of M and A, X7 is present or absent and if present is L, X8 is present or absent and if present is R, X9 is selected from the group consisting of V and L; 10 is selected from the group consisting of F and Y, and X 11 is selected from the group consisting of P and S, and X 12 is selected from the group consisting of P and H, and X 13 is present or absent, and if present, is Y. HC2 Consensus CDR2 RIKSX1TDGGTTDYX2APVKG (SEQ ID NO: 124), wherein X1 is selected from the group consisting of K and T; and X2 is selected from the group consisting of T and A. HC3 Consensus CDR1 X1YX2MX3 (SEQ ID NO: 125), wherein X1 is selected from the group consisting of T and S; X2 is selected from the group consisting of S and A; and X3 is selected from the group consisting of N and S. CDR2 X1ISX2SX3X4X5X6YYADSVKG (SEQ ID NO: 126), wherein X1 is selected from the group consisting of S and A, X2 is selected from the group consisting of S and G, X3 is selected from the group consisting of S and G, X4 is selected from the group consisting of S and G, X5 is selected from the group consisting of Y and R, and X6 is selected from the group consisting of R and T. CDR3 X1X2X3X4X5X6X7PYSX8X9WYDYYYGMDV (SEQ ID NO: 127), wherein X1 is selected from the group consisting of E and D, X2 is selected from the group consisting of G and Q, X3 is selected from the group consisting of V and R, X4 is selected from the group consisting of S and E, X5 is selected from the group consisting of G and V, X6 is selected from the group consisting of S and G, X7 is present or absent and, if present, is S, X8 is selected from the group consisting of I and S, and X9 is selected from the group consisting of S and G. HC4 Consensus CDR1 SX1GMH (SEQ ID NO: 128), wherein X1 is selected from the group consisting of F and Y. CDR2 VISX1DGSX2KYX3X4DSVKG (SEQ ID NO: 129), wherein X1 is selected from the group consisting of F and Y, X2 is selected from the group consisting of I and H, X3 is selected from the group consisting of S and Y, and X4 is selected from the group consisting of V and A. CDR3 X1RX2X3X4X5X6SX7X8YYX9X 10 X 11 YYGX 12 X 13V (SEQ ID NO: 130), wherein X1 is selected from the group consisting of D and E, X2 is selected from the group consisting of L and K, X3 is selected from the group consisting of N and R, X4 is selected from the group consisting of Y and V, X5 is selected from the group consisting of Y and T, X6 is selected from the group consisting of D and M, X7 is selected from the group consisting of S and T, X8 is selected from the group consisting of G and L, and X9 is selected from the group consisting of H and Y; 10 is present or absent, and if present, it is Y, and if present, it is X 11 is selected from the group consisting of K and F, and X 12 is selected from the group consisting of M and L, and X 13 is selected from the group consisting of A and D. HCA Consensus CDR1 X1X2X3MX4 (SEQ ID NO: 131), wherein X1 is selected from the group consisting of N and S, X2 is selected from the group consisting of A, Y, and F, X3 is selected from the group consisting of W, A, and G, and X4 is selected from the group consisting of S and H. CDR2 X1IX2X3X4X5X6GX7X8X9X 10 X 11 X 12 X 13 X 14 VKG (SEQ ID NO: 132), wherein Xi is selected from the group consisting of R, A, and V; X2 is selected from the group consisting of K, S, and W; X3 is selected from the group consisting of S, G, F, and Y; X4 is present or absent and, if present, is selected from the group consisting of K and T; X5 is present or absent and, if present, is T; X6 is selected from the group consisting of D and S; X7 is selected from the group consisting of G and S; X8 is selected from the group consisting of T, R, I, N, and H; X9 is selected from the group consisting of T and K; 10 is selected from the group consisting of D and Y, and X 11 is selected from the group consisting of Y and S, and X 12 is selected from the group consisting of T, A, and V; X 13 is selected from the group consisting of A and D, and X14 is selected from the group consisting of P and S. CDR3 X1X2X3X4X5X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 GX 18 X 19 X is selected from the group consisting of D, A, and E; X is selected from the group consisting of R, Q, and G; X is selected from the group consisting of T, R, L, G, and K; X is selected from the group consisting of G, E, N, I, and R; X is selected from the group consisting of Y, V, and A; X is selected from the group consisting of S, G, Y, A, and T; X is selected from the group consisting of I, P, D, A, and M; X is present or absent and, if present, is selected from the group consisting of S and Y; X is present or absent and, if present, is selected from the group consisting of W, S, and T; 10 is selected from the group consisting of S, G, and L; X 11 is selected from the group consisting of S, G, L, and Y; X 12 is present or absent, and if present, is selected from the group consisting of W and Y; X 13 is selected from the group consisting of Y and H, and X 14 is present or absent, and if present, is selected from the group consisting of Y and D; X 15 is selected from the group consisting of Y, K and F, and X 16 is present or absent, and if present, it is Y, and if present, it is X 17 is present or absent, and if present, it is Y, and if present, it is X 18 is selected from the group consisting of M and L, and X 19 is selected from the group consisting of D and A. HCB Consensus CDR1 X1X2X3X4X5 (SEQ ID NO: 134), wherein X1 is selected from the group consisting of N, G, D, S, and A; X2 is selected from the group consisting of A, F, and Y; X3 is selected from the group consisting of W, Y, A, and G; X4 is selected from the group consisting of M and L; and X5 is selected from the group consisting of S and H. CDR2 X1IX2X3X4X5X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X is selected from the group consisting of R, W, A, V, S, and F; X is selected from the group consisting of K, N, S, W, and R; X is selected from the group consisting of S, P, G, F, and Y; X is present or absent and, if present, is selected from the group consisting of K, T, and R; X is present or absent and, if present, is selected from the group consisting of T and A; X is selected from the group consisting of D, N, H, S, and Y; X is selected from the group consisting of G and S; X is selected from the group consisting of G and S; X is selected from the group consisting of T, G, R, I, N, H, and Y; 10 is selected from the group consisting of T, K, R, and P; X 11 is selected from the group consisting of D, N, Y, and E; and X 12 is selected from the group consisting of Y and S, and X 13 is selected from the group consisting of T, A, and V; X 14 is selected from the group consisting of A, Q, and D; X 15 is selected from the group consisting of P, K, and S; X 16 is selected from the group consisting of V and F, and X 17 is selected from the group consisting of K and Q. CDR3 X1X2X3X4X5SX6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16GX 17 X 18 X is selected from the group consisting of D, G, A, and E; X is selected from the group consisting of R, G, and Q; X is selected from the group consisting of T, M, Y, R, L, G, and K; X is selected from the group consisting of G, S, E, N, I, and R; X is selected from the group consisting of Y, I, G, V, and A; X is selected from the group consisting of S, I, Y, G, A, and T; X is selected from the group consisting of I, M, A, P, and D; X is present or absent and, if present, is selected from the group consisting of S, L, and Y; X is present or absent and, if present, is selected from the group consisting of W, R, S, and T; 10 is selected from the group consisting of S, G, and L; X 11 is selected from the group consisting of S, V, L, G, and Y; X 12 is present or absent, and if present is selected from the group consisting of F, Y, and W; X 13 is selected from the group consisting of Y, P, S, and H; X 14 is present or absent, and if present, is selected from the group consisting of Y, P, D, and H; X 15 is selected from the group consisting of Y, K, and F; X 16 is present or absent, and if present, it is Y, and if present, it is X 17 is present or absent, and if present, it is Y, and if present, it is X 18 is selected from the group consisting of M and L.
[0038] In any of the above-described consensus sequence definition embodiments, the isolated antigen-binding protein can be, for example, an AVIMER polypeptide, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human (e.g., fully human) antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antigen-binding fragment thereof. Furthermore, the antibody fragment of the isolated antigen-binding protein can be a Fab fragment and a Fab' fragment, a F(ab')2 fragment, an Fv fragment, a bispecific antibody, or a single-chain antibody molecule. For example, the isolated antigen-binding protein can be a human monoclonal antibody, such as an IgG1, IgG2, IgG3, or IgG4 type antibody. Furthermore, the isolated antigen-binding protein can be a neutralizing antigen-binding protein.
[0039] In any of the above-described consensus sequence definition embodiments, the isolated antigen binding protein may specifically bind to both human CRLR and human RAMP1, and does not specifically bind to AM1, AM2, or a human amylin receptor (e.g., AMY1), e.g. ... as determined using a FACS binding assay and analyzed using, e.g., the method described in Rathanaswami, et al., Biochemical and Biophysical Research Communications 334 (2005) 1004-1013, D It may specifically bind to human CGRP-R at 1 μM or less, 100 nM or less, 10 nM or less, or 5 nM or less. In any of the consensus sequence-defined embodiments described above, the isolated antigen binding protein may selectively inhibit human CGRP-R relative to human AM1, AM2, or AM1 receptors, e.g., with a selectivity ratio of 100 or more, 250 or more, 500 or more, 750 or more, 1,000 or more, 2,500 or more, 5,000 or more, or 10,000 or more, and the degree of selective inhibition can be determined using any suitable method, for example, using a cAMP assay as described in the Examples herein. In any of the sequence-defined embodiments described above, the isolated antigen binding protein may be isolated by radiolabeling human CGRP-R to membranes from cells expressing human CGRP-R. 125In an I-CGRP binding competition assay, such as the assay described in Example 5 herein, the K i can be 100 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less.
[0040] Some of the isolated antigen binding proteins described have a heavy chain variable region (V) having at least 80%, 85%, and 90% or 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 158-170. H Some of the isolated antigen-binding proteins described include a light chain variable region (V) having at least 80%, 85%, and 90% or 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-153. L Some of the isolated antigen-binding proteins described include V having at least 80%, 85%, and 90% or 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 158-170. H and an amino acid sequence selected from the group consisting of SEQ ID NOs: 137 to 153, having at least 80%, 85%, 90% or 95% sequence identity with V. L In some embodiments, the isolated antigen binding protein comprises: (A) a heavy chain variable region (V) comprising a sequence selected from the group consisting of (i) SEQ ID NOs: 158-170, or (ii) as defined by (i) and comprising one or more (e.g., 5, 10, 15, or 20) amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H ), (B)(iii) a V comprising a sequence selected from the group consisting of SEQ ID NOs: 137-153, or (iv) a V comprising a sequence as defined by (iii) and including a sequence containing one or more (e.g., 5, 10, 15, or 20) amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L , or (C) V in (A) H and (B) V L In some embodiments, the isolated antigen binding protein comprises a heavy chain variable region (V) comprising a sequence selected from the group consisting of SEQ ID NOs: 158-170.H ) and a sequence selected from the group consisting of SEQ ID NOs: 137 to 153, L Includes.
[0041] In one embodiment, the isolated antigen binding protein comprises a heavy chain variable region (V) comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 158; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 159, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 160, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 161, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. HIn another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 162, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 163, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 164, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 165, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 166, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. HIn another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 167, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 168, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 169, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 170, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. H Includes.
[0042] In one embodiment, the isolated antigen binding protein comprises a light chain variable region (V) comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 137; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. LIn another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 138, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 139, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 140, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 141, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 142, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. LIn another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 143, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 144, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 145, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 146, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 147, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. LIn another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 148, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 149, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 150, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 151, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L In another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 152, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. LIn another embodiment, the isolated antigen binding protein comprises an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 153, (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i), and (iii) a sequence as defined by (i) that contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions. L Includes.
[0043] The above-mentioned V L and V H In any of the sequence-defined embodiments, the isolated antigen-binding protein can be, for example, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human (e.g., fully human) antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antigen-binding fragment thereof. Furthermore, the antibody fragment of the isolated antigen-binding protein can be a Fab fragment and a Fab' fragment, a F(ab')2 fragment, an Fv fragment, a bispecific antibody, or a single-chain antibody molecule. For example, the isolated antigen-binding protein can be a human monoclonal antibody, such as an IgG1, IgG2, IgG3, or IgG4 type antibody. Furthermore, the isolated antigen-binding protein can be a neutralizing antigen-binding protein.
[0044] The above-mentioned V L and V H In any of the sequence-defined embodiments, the isolated antigen binding protein may specifically bind to both human CRLR and human RAMP1, and does not specifically bind to AM1, AM2, or a human amylin receptor (e.g., AMY1), e.g. ... as determined using a FACS binding assay and analyzed using, e.g., the method described in Rathanaswami, et al., Biochemical and Biophysical Research Communications 334 (2005) 1004-1013, K D It can specifically bind to human CGRP R at 1 μM or less, 100 nM or less, 10 nM or less, or 5 nM or less. L and V HIn any of the sequence-defined embodiments, the isolated antigen binding protein may selectively inhibit human CGRP R relative to human AM1, AM2, or AM1 receptor, e.g., with a selectivity ratio of 100 or greater, 250 or greater, 500 or greater, 750 or greater, 1,000 or greater, 2,500 or greater, 5,000 or greater, or 10,000 or greater, and the degree of selective inhibition can be determined using any suitable method, for example, using a cAMP assay as described in the Examples herein. L and V H In any of the sequence-defined embodiments, the isolated antigen binding protein may be subjected to CGRP binding competition assays, e.g., radiolabeling of membranes from cells expressing human CGRP. 125 In an I-CGRP binding competition assay, such as the assay described in Example 5 herein, the K i can be 100 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less.
[0045] In one embodiment, the isolated antigen binding protein comprises a heavy chain sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 29-41. Some of the described isolated antigen binding proteins comprise a light chain sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-28. Some of the isolated antigen binding proteins comprise a heavy chain sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 29-41 and a light chain sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-28. In some embodiments, the isolated antigen binding protein comprises: (A) (i) a heavy chain comprising a sequence selected from the group consisting of SEQ ID NOs: 29-41, or (ii) as defined by (i), wherein the sequence comprises one or more (e.g., 5, 10, 15, or 20) amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; (B) (iii) a light chain comprising a sequence selected from the group consisting of SEQ ID NOs: 12-28, or (iv) as defined by (iii), wherein the sequence comprises one or more (e.g., 5, 10, 15, or 20) amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; or (C) the heavy chain of (A) and the light chain of (B). In some embodiments, the isolated antigen binding protein comprises a heavy chain comprising a sequence selected from the group consisting of SEQ ID NOs: 29-41, and a light chain comprising a sequence selected from the group consisting of SEQ ID NOs: 12-28.
[0046] In one embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 29; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 12; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0047] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 30; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 13; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0048] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 31; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 14; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0049] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 32; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 15; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0050] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 33; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 16; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0051] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 29; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 17; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0052] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 34; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 18; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0053] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 33; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 19; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0054] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 29; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 20; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0055] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 35; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 21; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0056] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 36; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 22; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0057] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 37; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 23; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0058] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 38; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 23; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0059] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 33; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 24; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0060] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 39; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 25; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0061] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 40; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 26; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0062] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 41; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 27; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by (i); and (iii) a sequence as defined by (i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0063] In another embodiment, the isolated antigen binding protein comprises: (A) a heavy chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 41; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions; and (B) a light chain comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 28; (ii) a sequence that is at least 90% or 95% identical to the sequence defined by(i); and (iii) a sequence as defined by(i), wherein the sequence contains up to 10 amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions.
[0064] In any of the above-described embodiments in which light and heavy chain sequences are defined, the isolated antigen-binding protein may comprise the specified heavy and / or light chain sequences but with a different signal peptide or no signal peptide. In any of the above-described embodiments in which light and heavy chain sequences are defined, the isolated antigen-binding protein may be, for example, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human (e.g., fully human) antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody-binding fragment thereof. Furthermore, the antibody fragment of the isolated antigen-binding protein may be a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an Fv fragment, a bispecific antibody, or a single-chain antibody molecule. For example, the isolated antigen-binding protein may be a human monoclonal antibody, such as an IgG1, IgG2, IgG3, or IgG4 type antibody. Furthermore, the isolated antigen-binding protein may be a neutralizing antigen-binding protein.
[0065] In any of the above-described embodiments in which the light and heavy chain sequences are defined, the isolated antigen-binding protein may specifically bind to both human CRLR and human RAMP1, and does not specifically bind to AM1, AM2, or human amylin receptors (e.g., AMY1). For example, the isolated antigen-binding protein may have a K of 1 μM or less, 100 nM or less, 10 nM or less, or 5 nM or less, as determined and analyzed, for example, using a FACS binding assay, using, for example, the method described in Rathanaswami, et al., Biochemical and Biophysical Research Communications 334 (2005) 1004-1013. Dand specifically binds to human CGRP®. In any of the embodiments in which the light and heavy chain sequences are defined above, the isolated antigen binding protein may selectively inhibit human CGRP® with respect to human AM1, AM2, or AMY1 receptors with a selectivity of 100 or greater, 250 or greater, 500 or greater, 750 or greater, 1,000 or greater, 2,500 or greater, 5,000 or greater, or 10,000 or greater, and the degree of selective inhibition can be determined using any suitable method, for example, using a cAMP assay as described in the Examples herein. In any of the embodiments in which the light and heavy chain sequences are defined above, the isolated antigen binding protein may be selectively inhibited with respect to human AM1, AM2, or AMY1 receptors with a selectivity of 100 or greater, 250 or greater, 500 or greater, 750 or greater, 1,000 or greater, 2,500 or greater, 5,000 or greater, or 10,000 or greater, and the degree of selective inhibition can be determined using any suitable method, for example, using a cAMP assay as described in the Examples herein. In any of the embodiments in which the light and heavy chain sequences are defined above, the isolated antigen binding protein can be selectively inhibited with respect to human AM1, AM2, or AMY1 receptors with a selectivity of 100 or greater, 250 or greater, 5,000 or greater, or 10,000 or greater, and the degree of selective inhibition can be determined using any suitable method, for example, using a cAMP assay as described in the Examples herein. 125 In a CGRP binding competition assay, such as in the I-CGRP binding competition assay, e.g., the assay described in Example 5 herein, the K may be 100 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less.
[0066] In a further aspect, an isolated nucleic acid polynucleotide encoding any of the CGRP R antigen binding proteins summarized above is also provided. In one embodiment, the isolated polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOs: 175, 176, 178, 179, 180, 181, 182, 183, 186, 187, 188, 189, 191, 192, 193, 194, 195, 196, 197, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, and 210. In another embodiment, the isolated polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOs: 224-258. In another embodiment, the isolated polynucleotide comprises a sequence capable of hybridizing to a sequence selected from the group consisting of SEQ ID NOs: 224-258 under stringent hybridization conditions. In another embodiment, the isolated polynucleotide comprises a sequence that is about 80%, 85%, 90%, or 95% or more identical to a sequence selected from the group consisting of SEQ ID NOs: 224-258. In some instances, the isolated nucleic acid molecule is operably linked to a regulatory sequence. In a related embodiment, the isolated polynucleotide is incorporated into an expression vector.
[0067] Also included are cell lines transformed with expression vectors comprising the isolated polynucleotides described above. In related embodiments, expression vectors and host cells transformed or transfected with expression vectors comprising the aforementioned isolated nucleic acid molecules encoding the above-described CGRP-R antigen binding proteins are also provided.
[0068] In another aspect, a method for preparing an antigen-binding protein is also provided, comprising preparing the antigen-binding protein from a host cell that secretes the antigen-binding protein. In some embodiments, the antigen-binding protein is produced using an immunogen comprising a soluble CGRP receptor. In some embodiments, such a soluble CGRP receptor is obtained by co-expressing and purifying the N-terminal extracellular domain (ECD) of human CRLR and the ECD of human RAMP1, for example, the ECD of human CRLR comprising SEQ ID NO:6 and the ECD of RAMP1 comprising SEQ ID NO:8, as described in Examples 1 and 2 herein.
[0069] In yet another aspect, a pharmaceutical composition is provided comprising at least one of the antigen-binding proteins summarized above and a pharmaceutically acceptable excipient. In one embodiment, the pharmaceutical composition may comprise an additional active agent selected from the group consisting of a radioisotope, a radionuclides, a toxin, or a therapeutic agent and a chemotherapeutic agent.
[0070] In one aspect, the isolated antigen binding protein, when administered to a patient, is effective in inhibiting vasodilation and / or reducing neurogenic inflammation. In one embodiment, the isolated antigen binding protein is effective in reducing the frequency and / or severity of headaches, e.g., migraines. For example, the antigen binding protein may be used as an acute treatment for migraines and / or as a prophylactic treatment to prevent or reduce the frequency and / or severity of symptoms, particularly pain symptoms associated with migraine attacks.
[0071] Another aspect further provides a method for treating or preventing a condition associated with CGRP R in a patient, comprising administering to the patient an effective amount of at least one isolated antigen binding protein as summarized above. In one embodiment, the condition is headache, e.g., migraine or cluster headache, or another type of pain, e.g., chronic pain; in another embodiment, it is diabetes (type II); in another embodiment, it is inflammation, particularly neurogenic inflammation; in another embodiment, it is cardiovascular disease; in another embodiment, it is hemodynamic abnormalities associated with endotoxemia and sepsis; and in another embodiment, it is vasodilation.
[0072] In another embodiment, methods of inhibiting binding of CGRP to human CGRP R, e.g., the extracellular portion of CGRP R, in a patient are also provided, comprising administering an effective amount of at least one antigen binding protein provided herein and / or summarized above. In preferred embodiments of the present invention, for example, the following is provided: (Item 1) An isolated antigen-binding protein that selectively inhibits the human CGRP receptor. (Item 2) 2. The isolated antigen-binding protein of item 1, wherein the isolated antigen-binding protein selectively inhibits the human CGRP receptor with a selectivity of 100 or greater. (Item 3) 3. The isolated antigen binding protein of item 2, wherein the isolated antigen binding protein selectively inhibits the human CGRP receptor with a selectivity of 500 or greater. (Item 4) The isolated antigen binding protein has a K D 2. The isolated antigen-binding protein of item 1, which specifically binds to human CGRP at (Item 5) The isolated antigen-binding protein has a K of 10 nM or less as determined using a FACS binding assay. D 5. The isolated antigen-binding protein of item 4, which specifically binds to human CGRP at (Item 6) 2. The isolated antigen-binding protein of item 1, wherein the isolated antigen-binding protein has a K of less than 10 nM in a CGRP binding competition assay. (Item 7) The isolated antigen binding protein is radiolabeled to membranes from cells expressing human CGRP. 125 7. The isolated antigen-binding protein of item 6, having a K of less than 1 nM in an I-CGRP binding competition assay. (Item 8) 2. The isolated antigen-binding protein of item 1, wherein the isolated antigen-binding protein competes with a reference antibody for binding to human CGRP-R, and the reference antibody comprises: (i) a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 161, 163, 164, 166, and 168; and (ii) a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 140, 143, 146, 148, and 150. (Item 9) 9. The isolated antigen-binding protein of item 8, wherein the reference antibody comprises (i) a heavy chain defined by a sequence selected from the group consisting of SEQ ID NOs: 32, 34, 35, 37, and 39, and (ii) a light chain defined by a sequence selected from the group consisting of SEQ ID NOs: 15, 18, 21, 23, and 25. (Item 10) 10. The isolated antigen-binding protein of item 9, wherein the reference antibody comprises a heavy chain and a light chain defined by one of the following sequence pairs: SEQ ID NO: 32 and SEQ ID NO: 15, SEQ ID NO: 34 and SEQ ID NO: 18, SEQ ID NO: 35 and SEQ ID NO: 21, SEQ ID NO: 37 and SEQ ID NO: 23, and SEQ ID NO:39 and SEQ ID NO:25. (Item 11) (A) one or more heavy chain complementarity determining regions (CDRHs) selected from the group consisting of: (i) a CDRH1 having SEQ ID NO: 134; (ii) a CDRH2 having SEQ ID NO: 135; (iii) a CDRH3 having SEQ ID NO: 136; and (iv) a CDRH of (i), (ii), or (iii) that contains one, two, three, or four amino acid substitutions, deletions, or insertions; (B) one or more light chain complementarity determining regions (CDRLs) selected from the group consisting of: (i) a CDRL1 selected from the group consisting of SEQ ID NOs: 107, 111, and 118; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 108, 112, and 119; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 109, 113, and 120; and optionally (iv) a CDRL of (i), (ii), and (iii) that contains one, two, three, or four amino acid substitutions, deletions, or insertions; or (C) one or more heavy chain CDRHs of (A) and one or more heavy chain CDRLs of (B); 1. An isolated antigen binding protein comprising: (Item 12) 12. The isolated antigen binding protein of claim 11, wherein the CDRH is further selected from the group consisting of: (i) a CDRH1 having SEQ ID NO: 131; (ii) a CDRH2 having SEQ ID NO: 132; (iii) a CDRH3 having SEQ ID NO: 133; and (iv) a CDRH of (i), (ii), and (iii) comprising one, two, or three amino acid substitutions, deletions, or insertions. (Item 13) 13. The isolated antigen binding protein of claim 12, wherein the CDRH is further selected from the group consisting of: (i) a CDRH1 selected from the group consisting of SEQ ID NOs: 76, 88, 100, 121, 125, and 128; (ii) a CDRH2 selected from the group consisting of SEQ ID NOs: 89, 101, 122, 124, 126, and 129; (iii) a CDRH3 selected from the group consisting of SEQ ID NOs: 78, 90, 102, 123, 127, and 130; and (iv) a CDRH of (i), (ii), and (iii) comprising one, two, or three amino acid substitutions, deletions, or insertions. (Item 14) 14. The isolated antigen binding protein of item 13, wherein the CDRH is further selected from the group consisting of: (i) a CDRH1 selected from the group consisting of SEQ ID NOs: 73, 76, 79, 82, 85, 88, 92, 97, and 100; (ii) a CDRH2 selected from the group consisting of SEQ ID NOs: 74, 77, 80, 83, 86, 89, 91, 93, 95, 98, 101, and 129; (iii) a CDRH3 selected from the group consisting of SEQ ID NOs: 75, 78, 81, 84, 87, 90, 96, 99, 102, and 123; and (iv) a CDRH of (i), (ii), and (iii) comprising one, two, or three amino acid substitutions, deletions, or insertions. (Item 15) 12. The isolated antigen binding protein of claim 11, wherein the CDRL is further selected from the group consisting of: (i) a CDRL1 selected from the group consisting of SEQ ID NOs: 107, 111, and 115; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 108, 112, and 116; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 109, 113, and 117; and (iv) a CDRL of (i), (ii), and (iii) that comprises one, two, three, or four amino acid substitutions, deletions, or insertions. (Item 16) 16. The isolated antigen binding protein of claim 15, wherein the CDRL is further selected from the group consisting of: (i) a CDRL1 selected from the group consisting of SEQ ID NOs: 42, 45, 51, 57, 62, 69, 103, and 110; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 43, 52, 55, 58, 63, 70, 104, 108, and 114; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 44, 47, 53, 56, 59, 64, 105, and 106; and (iv) a CDRL of (i), (ii), and (iii) that comprises one, two, or three amino acid substitutions, deletions, or insertions. (Item 17) 17. The isolated antigen binding protein of claim 16, wherein the CDRL is further selected from the group consisting of: (i) a CDRL1 selected from the group consisting of SEQ ID NOs: 42, 45, 48, 51, 54, 57, 62, 65, 66, and 69; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 43, 46, 49, 52, 55, 58, 61, 63, 67, and 70; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 44, 47, 50, 53, 56, 59, 64, 68, 71, and 72; and (iv) a CDRL of (i), (ii), and (iii) that comprises one, two, or three amino acid substitutions, deletions, or insertions. (Item 18) 18. The isolated antigen-binding protein of any of items 11 to 17, wherein the isolated antigen-binding protein comprises at least one CDRH and at least one CDRL. (Item 19) 19. The isolated antigen binding protein of item 18, wherein the isolated antigen binding protein comprises at least two CDRHs and at least two CDRLs. (Item 20) 20. The isolated antigen-binding protein of any of items 11 to 19, wherein the isolated antigen-binding protein comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3. (Item 21) A heavy chain variable region (V) having at least 90% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 158 to 170. H ) sequence. (Item 22) A light chain variable region (V) having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 137 to 153. L ) sequence. (Item 23) V having at least 90% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 158, 159, and 162-172 Hand a V having at least 90% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 137, 138, 140-145, 148-151, and 153-157. L and an isolated antigen binding protein comprising the sequence: (Item 24) 24. The isolated antigen-binding protein according to any of items 1 to 23, wherein the isolated antigen-binding protein is selected from the group consisting of a monoclonal antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an Fv fragment, a bispecific antibody, and a single-chain antibody. (Item 25) 25. The isolated antigen-binding protein of item 24, wherein the isolated antigen-binding protein is a monoclonal antibody selected from the group consisting of a fully human antibody, a humanized antibody, and a chimeric antibody. (Item 26) 26. The isolated antigen-binding protein of claim 25, wherein the monoclonal antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. (Item 27) 27. The isolated antigen-binding protein of claim 26, wherein the monoclonal antibody is an IgG1 or IgG2 antibody. (Item 28) 28. An isolated nucleic acid polynucleotide encoding the antigen-binding protein of any of items 1 to 27. (Item 29) 29. The isolated nucleic acid polynucleotide of Item 28, wherein the polynucleotide comprises a sequence that is 80% or more identical to a sequence selected from the group consisting of SEQ ID NOs: 175, 176, 178, 179, 180, 181, 182, 183, 186, 187, 188, 189, 191, 192, 193, 194, 195, 196, 197, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, and 210. (Item 30) 29. The isolated nucleic acid polynucleotide according to Item 28, wherein the polynucleotide comprises a sequence that is 80% or more identical to a sequence selected from the group consisting of SEQ ID NOs: 224 to 258. (Item 31) 29. The isolated nucleic acid polynucleotide according to Item 28, wherein the polynucleotide comprises a sequence capable of hybridizing under stringent hybridization conditions to a sequence selected from the group consisting of SEQ ID NOs: 224 to 258. (Item 32) An expression vector comprising the isolated polynucleotide according to any one of Items 28 to 31. (Item 33) A cell line transformed with the expression vector according to Item 32. (Item 34) 28. A method of making the antigen-binding protein of any of items 1 to 27, comprising preparing said antigen-binding protein from a host cell that secretes said antigen-binding protein. (Item 35) 35. The method of claim 34, wherein the antigen-binding protein is produced using an immunogen comprising a soluble CGRP receptor. (Item 36) 36. The method of claim 35, wherein the soluble CGRP receptor is obtained by co-expressing and purifying the N-terminal extracellular domain (ECD) of human CRLR and human RMAP1. (Item 37) 37. The method of claim 36, wherein the ECD of human CRLR comprises SEQ ID NO: 6 and the ECD of RAMP1 comprises SEQ ID NO: 8. (Item 38) 28. A pharmaceutical composition comprising the antigen-binding protein of any of items 1 to 27 and a pharmaceutically acceptable excipient. (Item 39) 28. A method for treating a condition associated with CGRP R in a patient, comprising administering to the patient an effective amount of the isolated antigen binding protein of any of items 1 to 27. (Item 40) 40. The method of claim 39, wherein the condition is headache. (Item 41) 41. The method of claim 40, wherein the condition is migraine. (Item 42) 42. The method according to any one of items 39 to 41, wherein the method comprises a prophylactic treatment.
[0073] These and other aspects are described in detail herein. Each of the provided aspects can encompass various embodiments provided herein. Therefore, it is anticipated that each of the embodiments comprising one element or a combination of elements can be included in each of the described aspects, and all such combinations of the above aspects and embodiments are expressly contemplated. Other features, objects, and advantages of the present invention will be apparent from the following detailed description. [Brief explanation of the drawings]
[0074] [Figure 1] Alignment of RAMP1 sequences from human, cynomolgus monkey, and rat is shown. [Figure 2] An alignment of CRLR sequences from human, cynomolgus monkey, and rat is shown. [Figure 3A] Figures 3A and 3B show phylogeny-based sequence alignments of light chain CDRs from the indicated anti-CGRP receptor antibody clones with kappa light chains, and the corresponding consensus sequences given. [Figure 3B] Figures 3A and 3B show phylogeny-based sequence alignments of light chain CDRs from the indicated anti-CGRP receptor antibody clones with kappa light chains, and the corresponding consensus sequences given. [Figure 4] Phylogeny-based sequence alignment of light chain CDRs from the indicated anti-CGRP receptor antibody clones with lambda light chains and corresponding consensus sequences given are shown. [Figure 5A] Figures 5A, 5B, 5C, 5D, and 5E show phylogenetic-based sequence alignments of heavy chain CDRs from the indicated anti-CGRP receptor antibody clones and the corresponding consensus sequences given. [Figure 5B] Figures 5A, 5B, 5C, 5D, and 5E show phylogenetic-based sequence alignments of heavy chain CDRs from the indicated anti-CGRP receptor antibody clones and the corresponding consensus sequences given. [Figure 5C] Figures 5A, 5B, 5C, 5D, and 5E show phylogenetic-based sequence alignments of heavy chain CDRs from the indicated anti-CGRP receptor antibody clones and the corresponding consensus sequences given. [Figure 5D] Figures 5A, 5B, 5C, 5D, and 5E show phylogenetic-based sequence alignments of heavy chain CDRs from the indicated anti-CGRP receptor antibody clones and the corresponding consensus sequences given. [Figure 5E] Figures 5A, 5B, 5C, 5D, and 5E show phylogenetic-based sequence alignments of heavy chain CDRs from the indicated anti-CGRP receptor antibody clones and the corresponding consensus sequences given. [Figure 5F] 1 shows the consensus sequences of exemplary anti-CGRP receptor antibody heavy chain CDRs disclosed herein. [Figure 6] Plots of data from two experiments are shown showing percent inhibition of labeled ligand binding to CGRP R by 1092 antibody CGRP R hybridoma supernatants (diamonds) and 68 negative control supernatants (squares). [Figure 7A] Figures 7A-D show representative cAMP assay IC50 data from cells expressing the hCGRP receptor (Figure 7A), hAM1 (Figure 7B), hAM2 (Figure 7C), and human amylin receptor (Figure 7D) for the three indicated anti-CGRP mAbs. [Figure 7B] Figures 7A-D show representative cAMP assay IC50 data from cells expressing the hCGRP receptor (Figure 7A), hAM1 (Figure 7B), hAM2 (Figure 7C), and human amylin receptor (Figure 7D) for the three indicated anti-CGRP mAbs. [Figure 7C] Figures 7A-D show representative cAMP assay IC50 data from cells expressing the hCGRP receptor (Figure 7A), hAM1 (Figure 7B), hAM2 (Figure 7C), and human amylin receptor (Figure 7D) for the three indicated anti-CGRP mAbs. [Figure 7D]Figures 7A-D show representative cAMP assay IC50 data from cells expressing the hCGRP receptor (Figure 7A), hAM1 (Figure 7B), hAM2 (Figure 7C), and human amylin receptor (Figure 7D) for the three indicated anti-CGRP mAbs. [Figure 8] An example of 125I-CGRP binding data is shown that can be used to determine the Ki of a mAb to the human CGRP receptor. [Figure 9A] Figures 9A-D show Biacore competition data for selected antibodies disclosed herein. [Figure 9B] Figures 9A-D show Biacore competition data for selected antibodies disclosed herein. [Figure 9C] Figures 9A-D show Biacore competition data for selected antibodies disclosed herein. [Figure 9D] Figures 9A-D show Biacore competition data for selected antibodies disclosed herein. [Figure 10] Figure 1 shows FACS Kd determination of mAb 12G8. [Figure 11] Alignment of cynomolgus, human chimera, rat, and rhesus RAMP1 sequences is shown. [Figure 12A] Figures 12A-B show alignments of human, cynomolgus, rhesus, rat, human chimeric, and consensus CRLR sequences. [Figure 12B] Figures 12A-B show alignments of human, cynomolgus, rhesus, rat, human chimeric, and consensus CRLR sequences. [Figure 13A] Figures 13A-13C show representative FACS data of different chimeric CGRP receptor binding to anti-CGRP R antibodies. [Figure 13B] Figures 13A-13C show representative FACS data of different chimeric CGRP receptor binding to anti-CGRP R antibodies. [Figure 13C] Figures 13A-13C show representative FACS data of different chimeric CGRP receptor binding to anti-CGRP R antibodies. [Figure 14] Peptide maps from AspN digestion of CGRP-R alone (chromatogram A) and digestion of a control sample containing CGRP-R monoclonal antibody 12G8 (chromatogram B) are shown. [Figure 15] 1 shows AspN digestion of CGRP-R in the presence of different concentrations of CGRP-R neutralizing antibody. [Figure 16] AspN digestion of CGRP-R in the presence of different concentrations of the CGRP-R neutralizing antibody, 4E4, is shown. [Figure 17] Immunohistochemical staining intensity of cells expressing various receptor components with antibody 32H7 is shown. DETAILED DESCRIPTION OF THE INVENTION
[0075] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0076] Unless otherwise defined herein, scientific and technical terms used in connection with this application shall have the meanings commonly understood by those skilled in the art. Further, unless otherwise required by context, singular terms include pluralities and plural terms include the singular.
[0077] Generally, the nomenclatures and techniques used in connection with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art.The methods and techniques of this application are generally carried out according to conventional methods well known in the art, as described in various general and specific references cited and discussed throughout this specification, unless otherwise specified.For example, see Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001); Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992); and Harlow and Lane Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990), which are incorporated herein by reference.Enzymatic reactions and purification techniques are carried out according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. The nomenclature used in connection with the analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry laboratory procedures and techniques described herein are those well known and commonly used in the art. Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
[0078] It is understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which is defined solely by the claims.
[0079] Except in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein are to be understood as being modified in all instances by the term "about," which, when used in reference to percentages, means ±1%.
[0080] definition The term "polynucleotide" or "nucleic acid" includes both single-stranded and double-stranded nucleotide polymers. The nucleotides comprising a polynucleotide can be ribonucleotides or deoxyribonucleotides, or modified forms of either type of nucleotide. Such modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, and phosphoramidate.
[0081] The term "oligonucleotide" refers to a polynucleotide containing 200 or fewer nucleotides. In some embodiments, oligonucleotides are 10-60 bases in length. In other embodiments, oligonucleotides are 12, 13, 14, 15, 16, 17, 18, 19, or 20-40 nucleotides in length. Oligonucleotides may be single-stranded or double-stranded, for example, when used to construct mutant genes. Oligonucleotides may be sense or antisense oligonucleotides. Oligonucleotides may contain radioactive, fluorescent, haptenic, or antigenic labels for detection assays. Oligonucleotides may be used, for example, as PCR primers, cloning primers, or hybridization probes.
[0082] An "isolated nucleic acid molecule" means DNA or RNA of genomic, mRNA, cDNA, or synthetic origin, or some combination thereof; an isolated polynucleotide is one that is not associated with all or part of a polynucleotide in which the isolated polynucleotide is found in nature or with which it is associated in nature. For purposes of this disclosure, it should be understood that a "nucleic acid molecule comprising" a particular nucleotide sequence does not encompass an entire, unprocessed chromosome. An isolated nucleic acid molecule "comprising" a particular nucleic acid sequence may, in addition to the particular sequence, include coding sequences for up to 10 or even up to 20 other proteins or portions thereof, or may include operably linked regulatory sequences that control expression of the coding region of the recited nucleic acid sequence, and / or may include vector sequences.
[0083] Unless otherwise specified, the left-hand end of any single-stranded polynucleotide sequence discussed herein is the 5'-end, and the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5'-direction. The 5' to 3' addition direction of the initial RNA transcript is referred to as the transcription direction, and the region of the sequence on the DNA strand that is 5' to 5' end of the RNA transcript and has the same sequence as the RNA transcript is referred to as the "upper sequence," and the region of the sequence on the DNA strand that is 3' to 3' end of the RNA transcript and has the same sequence as the RNA transcript is referred to as the "lower sequence."
[0084] The term "control sequence" refers to a polynucleotide that can affect the expression and processing of coding sequences to which it is ligated. The nature of such control sequences can depend on the host organism. In certain embodiments, prokaryotic control sequences can include a promoter, ribosomal binding site, and transcription termination sequence. For example, eukaryotic control sequences can include a promoter containing one or more recognition sites for transcription factors, transcription enhancer sequences, and transcription termination sequences. "Control sequences" can include leader sequences and / or fusion partner sequences.
[0085] The term "vector" refers to any molecule or entity (eg, nucleic acid, plasmid, bacteriophage, or virus) used to transfer protein-coding information into a host cell.
[0086] The term "expression vector" or "expression construct" means a vector suitable for transformation of a host cell and containing nucleic acid sequences that (in conjunction with the host cell) direct and / or control the expression of one or more heterologous coding regions operably linked thereto. Expression constructs include, but are not limited to, sequences that affect or control transcription, translation, and, if introns are present, sequences that affect RNA splicing of the coding region operably linked thereto.
[0087] As used herein, "operably linked" means that the components to which the term is applied are in a relationship which allows them to carry out their intended functions under appropriate conditions. For example, a control sequence in a vector "operably linked" to a protein-coding sequence is ligated thereto so that expression of the protein-coding sequence is achieved under conditions compatible with the transcriptional activity of the control sequences.
[0088] The term "host cell" means a cell that has been transformed or is capable of being transformed with a nucleic acid sequence and thereby expresses a gene of interest. The term includes the progeny of the parent cell, whether or not they are identical in morphology or genetic make-up to the original parent cell, so long as the gene of interest is present.
[0089] The term "transduction" refers to the transfer of genes from one bacterium to another, usually by a bacteriophage. "Transduction" can also refer to the acquisition and transfer of eukaryotic sequences by replication-defective retroviruses.
[0090] The term "transfection" refers to the uptake of foreign or exogenous DNA by a cell; a cell has been "transfected" when exogenous DNA has been introduced into the cell membrane. Numerous transfection techniques are well known in the art and are disclosed herein. See, e.g., Graham et al., 1973, Virology 52 :456, Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual above, Davis et al., 1986, Basic Methods in Molecular Biology, Elsevier, Chu et al., 1981, Gene 13 :197. Such techniques can be used to introduce one or more exogenous DNA moieties into a suitable host cell.
[0091] The term "transformation" refers to an alteration in the genetic characteristics of a cell; a cell has been transformed when it has been modified to contain new DNA or RNA. For example, a cell is transformed when it is genetically modified from its native state by the introduction of new genetic material via transfection, transduction, or other techniques. Following transfection or transduction, the transforming DNA may recombine with that of the cell by physically integrating into the cell's chromosomes, or it may be maintained transiently as an episomal element without being replicated, or it may replicate independently as a plasmid. A cell is considered to be "stably transformed" when the transforming DNA is replicated with the division of the cell.
[0092] The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. These terms also apply to amino acid polymers in which one or more amino acid residues are analogs or mimetics of corresponding naturally occurring amino acids, as well as naturally occurring amino acid polymers. These terms can also encompass amino acid polymers that have been modified, for example, by the addition of carbohydrate residues to form glycoproteins or by phosphorylation. Polypeptides and proteins can be produced naturally and non-recombinantly, or by genetically engineered or recombinant cells, and include molecules having the amino acid sequence of a native protein or molecules with deletions, additions, and / or substitutions of one or more amino acids from the native sequence. The terms "polypeptide" and "protein" specifically encompass antigen-binding proteins, such as CGRP-R antigen-binding proteins, CGRP-R binding proteins, antibodies, or sequences with deletions, additions, and / or substitutions of one or more amino acids from an antigen-binding protein. The term "polypeptide fragment" refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and / or an internal deletion compared to the full-length protein. Such fragments can also contain modified amino acids compared to the full-length protein. In certain embodiments, fragments are approximately 5 to 500 amino acids in length. For example, fragments can be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids in length. Useful polypeptide fragments include immunologically functional fragments containing the binding domain. In the case of CGRP-binding antibodies, useful fragments include, but are not limited to, CDR regions, heavy or light chain variable regions, portions of the antibody chains, or variable domains thereof containing two CDRs. "CGRP receptor" or "CGRP-R" is understood to include RAMP1 and CRLR.
[0093] The term "isolated protein" (e.g., isolated antigen-binding protein), "isolated polypeptide," or "isolated antibody" means that the subject protein, polypeptide, or antibody (1) is free from at least some other proteins with which it is normally found; (2) is essentially free from other proteins from the same source, e.g., the same species; (3) is expressed by cells from a different species; (4) is separated from at least about 50% of the polynucleotides, lipids, or other materials with which it is naturally associated; (5) is operably associated (by conjugated or non-conjugated interactions) with polypeptides with which it is not naturally associated; or (6) is not naturally occurring. Typically, an "isolated protein," "isolated polypeptide," or "isolated antibody" will constitute at least about 5%, at least about 10%, at least about 25%, or at least about 50% of a given sample. Genomic DNA, cDNA, mRNA, or other RNA, of synthetic origin, or any combination thereof, can encode such an isolated protein. Preferably, an isolated protein polypeptide or antibody is substantially free of other proteins or other polypeptides that are found in its natural environment or other contaminants that would interfere with its therapeutic, diagnostic, prophylactic, research, or other use.
[0094] A "variant" of a polypeptide (e.g., an antigen-binding protein, or an antibody) includes an amino acid sequence in which one or more amino acid residues are inserted, deleted, and / or substituted into the amino acid sequence relative to another polypeptide sequence. Variants include fusion proteins.
[0095] A "derivative" of a polypeptide is a polypeptide (e.g., an antigen-binding protein, or an antibody) that has been chemically modified in some way distinct from an insertion, deletion, or substitution variant, for example, through conjugation to another chemical moiety.
[0096] The term "naturally occurring," as used throughout this specification in reference to biological materials such as polypeptides, nucleic acids, host cells, etc., means a material that is found in nature.
[0097] As used herein, "antigen binding protein" refers to a protein that specifically binds to a particular target antigen, such as CGRP R, particularly a primate, e.g., human CGRP R. A CGRP R antigen binding protein specifically binds to the human CGRP receptor.
[0098] Antigen-binding proteins have a dissociation constant (K D ) is 10 -6 An antibody is said to "specifically bind" its target if it: D is 1x10 -8 In one embodiment, the antibody specifically binds to a target antigen with "high affinity" if it binds to CGRP-R, or human CGRP-R, with an affinity of 5x10 -7 The following K D In another embodiment, the antibody binds at 1x10 -7 The following K D In another embodiment, the antibody binds at 5x10 -8 The following K D In another embodiment, the antibody binds at 1x10 -8 The following K D In another embodiment, the antibody binds at 5x10 -9 The following K D In another embodiment, the antibody binds at 1x10 -9 The following K D In another embodiment, the antibody binds at 5x10 -10 The following K D In another embodiment, the antibody binds at 1x10 -10 The following K D Combine with.
[0099] An antibody, antigen-binding fragment thereof, or antigen-binding protein "selectively inhibits" a particular receptor relative to other receptors if the IC50 of the antibody, antibody-binding fragment thereof, or antigen-binding protein in an inhibition assay of that particular receptor is at least 50-fold lower than the IC50 in an inhibition assay of another "reference" receptor. The "selectivity" is the IC50 of the reference receptor divided by the IC50 of the particular receptor. An antibody, antigen-binding fragment thereof, or antigen-binding protein selectively inhibits the human CGRP receptor if the IC50 of the antibody, antigen-binding fragment thereof, or antigen-binding protein in a cAMP assay, for example, a cAMP inhibition assay such as that described in Example 4 herein, is at least 50-fold lower than the IC50 of the same antibody, antigen-binding fragment thereof, or antigen-binding protein in an inhibition assay of human AM1, AM2, or amylin receptors (e.g., AMY1). As a non-limiting example, a particular anti-CGRPR antibody selectively inhibits the hCGRP receptor if the IC50 of the antibody in the cAMP assay for hCGRPR is, for example, between 0.1 nM and 20 nM, and the IC50 of the same antibody in the cAMP assay for the hAM1, hAM2, or human AMY1 receptor is 1000 nM or greater. It is also understood that an antigen binding protein that selectively inhibits a particular receptor will be a neutralizing antigen binding protein with respect to that receptor.
[0100] "Antigen-binding region" refers to a protein or a portion of a protein that specifically binds to a specified antigen. For example, the portion of an antigen-binding protein that contains amino acid residues that interact with an antigen and confer its specificity and affinity to the antigen is called the "antigen-binding region." An antigen-binding region usually contains one or more "complementary binding regions" ("CDRs"). Some antigen-binding regions also contain one or more "framework" regions. "CDRs" are amino acid sequences that contribute to antigen-binding specificity and affinity. "Framework" regions can help maintain the proper configuration of CDRs to promote binding between the antigen-binding region and the antigen.
[0101] In some embodiments, recombinant antigen-binding proteins that bind to CGRP R protein or human CGRP R are provided. In this context, a "recombinant protein" is a protein formed using recombinant techniques, i.e., formed through expression of a recombinant nucleic acid as described herein. Methods and techniques for producing recombinant proteins are well known in the art.
[0102] The term "antibody" refers to an intact immunoglobulin of any isotype or an antigen-binding fragment thereof that can compete with an intact antibody for specific binding to a target antigen, including, for example, chimeric, humanized, fully human, and bispecific antibodies. Such "antibodies" are a type of antigen-binding protein. Intact antibodies generally contain at least two full-length heavy chains and two full-length light chains, although in some instances they may contain fewer chains, such as antibodies naturally occurring in camelids, which may contain only heavy chains. Antibodies may be derived from a single source or may be "chimeric," i.e., different portions of the antibody may be derived from two different antibodies, as described in further detail below. Antigen-binding proteins, antibodies, or binding fragments may be produced in hybridomas, by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Unless otherwise specified, the term "antibody" includes antibodies containing two full-length heavy chains and two full-length light chains, as well as derivatives, mutants, fragments, and variants thereof, examples of which are described below.
[0103] The term "light chain" includes full-length light chains and fragments thereof containing sufficient variable region sequence to confer binding specificity. A full-length light chain contains the variable region domain V L and constant region domain C L The variable region domain of the light chain is located at the amino terminus of the polypeptide. Light chains include kappa chains and lambda chains.
[0104] The term "heavy chain" includes full-length heavy chains and fragments thereof containing sufficient variable region sequence to confer binding specificity. A full-length heavy chain contains the variable region domain V Hand three constant region domains C H 1. C H 2, and C H Includes 3. V H The domain is located at the amino terminus of the polypeptide and is H The domain is located at the carboxyl terminus and is C H 3 is closest to the carboxy terminus of the polypeptide. The heavy chain can be of any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM, and IgE.
[0105] The terms "signal sequence," "leader sequence," or "signal peptide" refer to a short (3-60 amino acids long) peptide chain that directs the transport of a protein. Signal peptides may also be referred to as targeting signals, signal sequences, transit peptides, or localization signals. Some signal peptides are cleaved from proteins by signal peptidases after the protein is transported, and the biologically active form of the protein (e.g., an antigen-binding protein as described herein) is the cleaved, shorter form. Thus, terms such as "an antibody comprising a heavy chain ...," "an antibody comprising a light chain ...," and the like, when an antibody is characterized as having heavy and / or light chains of a particular identified sequence, are understood to include antibodies having the particular identified sequence, antibodies having the particular identified sequence except that the signal sequence is replaced by a different signal sequence, and antibodies having the identified sequence minus any signal sequence.
[0106] As used herein, the term "antigen-binding fragment" (or simply "fragment") of an antibody or immunoglobulin chain (heavy or light chain) includes a portion of an antibody (regardless of how the portion is obtained or synthesized) that lacks at least some amino acids present in the full-length chain but is still capable of specifically binding to an antigen. Such fragments are biologically active in that they specifically bind to a target antigen and can compete with other antigen-binding proteins, including intact antibodies, for specific binding to a given epitope. In one aspect, such fragments retain at least one CDR present in a full-length light or heavy chain and, in some embodiments, comprise a single heavy and / or light chain or portion thereof. These biologically active fragments can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of antigen-binding proteins, including intact antibodies. Immunologically functional immunoglobulin fragments include, but are not limited to, Fab, Fab', F(ab'), Fv, domain antibodies, and single-chain antibodies, and can be derived from any mammalian source, including, but not limited to, human, mouse, rat, camel, or rabbit. Furthermore, it is contemplated that a functional portion of the antigen binding proteins disclosed herein, e.g., one or more CDRs, can be conjugated to a second protein or small molecule to form a therapeutic agent that is directed to a specific target in the body, has bifunctional therapeutic properties, or has a long serum half-life.
[0107] A "Fab fragment" is a fragment of one light chain and one heavy chain. H 1 and variable regions. The heavy chain of a Fab molecule cannot form disulfide bonds with another heavy chain molecule.
[0108] The "Fc" region is the C H 1 and C H The two heavy chain fragments contain two or more disulfide bonds and a C H The three domains are held together by hydrophobic interactions.
[0109] A "Fab' fragment" is a fragment containing one light chain and one V H Domain and C H 1 domain, and C H 1 and C H It contains the portion of one heavy chain that contains the region between the two domains, allowing interchain disulfide bonds to form between the two heavy chains of the two Fab' fragments to form the F(ab')2 molecule.
[0110] "F(ab')2 fragment" refers to a fragment of two light chains and a C H 1 and C H It contains two heavy chains with a portion of the constant region between the two domains, allowing an interchain disulfide bond to form between the two heavy chains. The F(ab')2 fragment is therefore composed of two Fab' fragments held together by disulfide bonds between the two heavy chains.
[0111] The "Fv region" comprises the variable regions from both the heavy and light chains, but lacks the constant regions.
[0112] A "single-chain antibody" is an Fv molecule in which the heavy and light chain variable regions form a single polypeptide chain connected by a flexible linker to form an antigen-binding region. Single-chain antibodies are discussed in detail in International Patent Application Publication No. WO 88 / 01649 and U.S. Pat. Nos. 4,946,778 and 5,260,203, the disclosures of which are incorporated by reference.
[0113] A "domain antibody" is an immunologically functional immunoglobulin fragment that contains only the variable region of a heavy chain or the variable region of a light chain. In some instances, two or more V H The domains are covalently linked with a peptide linker to form a bivalent domain antibody. H The regions may target the same or different antigens.
[0114] A "bivalent antigen-binding protein" or "bivalent antibody" contains two antigen-binding sites. In some instances, the two binding sites have the same antigen specificity. Bivalent antigen-binding proteins and bivalent antibodies can be bispecific. See below.
[0115] A "multispecific antigen-binding protein" or "multispecific antibody" is one that targets multiple antigens or epitopes.
[0116] "Bispecific," "dual-specific," or "bifunctional" antigen-binding proteins or antibodies are hybrid antigen-binding proteins or antibodies, respectively, that have two different antigen-binding sites. Bispecific antigen-binding proteins and antibodies are a type of multispecific antigen-binding protein or multispecific antibody, and can be produced by a variety of methods, including, but not limited to, fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai and Lachmann, 1990, Clin. Exp. Immunol. 79 :315-321, Kostelny et al., 1992, J. Immunol. 148 :1547-1553. The two binding sites of a bispecific antigen-binding protein or antibody bind to two different epitopes, which may be present on the same or different protein targets.
[0117] The terms "neutralizing antigen-binding protein" and "neutralizing antibody" refer to an antigen-binding protein or antibody, respectively, that binds to a ligand, prevents the binding of the ligand to its binding partner, and prevents the biological response that would otherwise result from the binding of the ligand to its binding partner. When assessing the binding and specificity of an antigen-binding protein, e.g., an antibody or fragment thereof, an antibody or fragment significantly inhibits binding of a ligand to its binding partner if excess antibody reduces the amount of binding partner bound to the ligand by at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, or more (as measured in an in vitro competitive binding assay). In the case of a CGRP-binding protein, such a neutralizing molecule reduces the ability of CGRP-binding protein to bind CGRP.
[0118] The term "compete," when used in the context of antigen-binding proteins that can bind to the same region on a target antigen, means that competition between the antigen-binding proteins is determined by an assay in which the antigen-binding protein being tested (e.g., an antibody or immunologically functional antigen-binding fragment thereof) prevents or inhibits the specific binding of a reference antigen-binding protein (e.g., a ligand or reference antibody) to a common antigen (e.g., CGRP-R or its antigen-binding protein). Any of a number of competitive binding assays can be used, such as solid-phase direct or indirect radioimmunoassays (RIAs), solid-phase direct or indirect enzyme immunoassays (EIAs), sandwich competition assays (e.g., Stahl et al., 1983, Methods in Enzymology). 9 :242-253), solid-phase direct biotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol. 137:3614-3619), solid-phase direct label assay, solid-phase direct label sandwich assay (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press), solid-phase direct label RIA using I-125 label (see, e.g., Morel et al., 1988, Molec. Immunol. 25 :7-15), solid-phase direct biotin-avidin EIA (see, e.g., Cheung, et al., 1990, Virology 176 :546-552), and direct labeling RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32 :77-82). Such assays can involve the use of purified antigen bound to a solid surface or cells bearing either of these unlabeled test antigen-binding proteins and a labeled reference antigen-binding protein. Competitive inhibition can be measured by determining the amount of label bound to the solid surface in the presence of the test antigen-binding protein. Antigen-binding proteins identified by competitive assays (competing antigen-binding proteins) include antigen-binding proteins that bind to the same epitope as the reference antigen-binding protein and antigen-binding proteins that bind to an adjacent epitope sufficiently close to the epitope bound by the reference antigen-binding protein for stearic acid interference to occur. Typically, when a competing antigen-binding protein is present in excess, it inhibits specific binding of the reference antigen-binding protein to a common antigen by at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%. In some examples, binding is inhibited by at least 80%, 85%, 90%, 95%, or 97% or more. Competitive inhibition can be measured by immobilizing a reference antigen-binding protein on a substrate, e.g., a "sensor chip," capturing the antigen on the substrate by binding to the reference antibody, and assaying whether a different antigen-binding protein (a competing antigen-binding protein) can additionally bind to the antigen. An example of the latter competitive binding assay, using Biacore analysis, is described in Example 7 herein.
[0119] The term "antigen" or "immunogen" refers to a molecule or portion thereof that can be bound by a selective binding agent, such as an antigen-binding protein (including, for example, an antibody or an immunologically functional antigen-binding fragment thereof), and further used in an animal to generate antibodies capable of binding to that antigen. An antigen can have one or more epitopes that can interact with different antigen-binding proteins, e.g., antibodies.
[0120] The term "epitope" refers to the portion of a molecule that is bound by an antigen-binding protein (e.g., an antibody). This term includes any determinant capable of specifically binding to an antigen-binding protein, such as an antibody or a T-cell receptor. Epitopes can be contiguous or non-contiguous (e.g., (i) in a single-chain polypeptide, amino acid residues that are not adjacent to each other in the polypeptide sequence but are bound by the antigen-binding protein in the context of the molecule, or (ii) in a multimeric receptor, for example, RAMP1 and CRLR, amino acid residues present in two or more individual components, e.g., CGRP, that are present in two or more of the individual components but are bound by the antigen-binding protein in the context of the multimeric receptor). In some embodiments, epitopes can be mimetics, in the sense that they contain a three-dimensional structure similar to the epitope used to generate the antigen-binding protein, but do not contain, or only contain, the amino acid residues found in the epitope used to generate the antigen-binding protein. In most cases, epitopes are present on proteins, but in some instances, they can reside on other types of molecules, such as nucleic acids. Epitope determinants may include chemically active surface groupings of molecules, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three-dimensional structural characteristics, and / or specific charge characteristics. Generally, an antibody specific for a particular target antigen will selectively recognize an epitope on the target antigen in a complex mixture of proteins and / or macromolecules.
[0121] The term "identity" refers to the relationship between two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing their sequences. "Percent identity" refers to the percent of identical residues between amino acids or nucleotides in the compared molecules, and is calculated based on the size of the smallest molecule being compared. For these calculations, gaps in the sequence alignment, if any, must be addressed by a specific mathematical model or computer program (i.e., an "algorithm"). Methods that can be used to calculate the identity of aligned nucleic acids or polypeptides are described in Computational Molecular Biology, (Lesk, AM, ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, DW, ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, AM, and Griffin, HG, eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; Carillo et al., 1988, SIAM J. Applied Math. 48 :1073.
[0122] In calculating percent identity, the sequences being compared are aligned to give the largest match between the sequences. The computer program used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, WI). The computer algorithm GAP is used to align two polypeptides or polynucleotides and determine the percent sequence identity. The sequences are aligned to optimally match their respective amino acids or nucleotides (the "match span" determined by the algorithm). A gap opening penalty (calculated at 3 x average diagonal, where "average diagonal" is the average of the diagonals of the comparison matrix being used and "diagonal" is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and gap extension penalty (usually 1 / 10 of the gap opening penalty), as well as a comparison matrix such as PAM250 or BLOSUM62, are used in conjunction with the algorithm. In one embodiment, a standard comparison matrix (for the PAM250 comparison matrix, see Dayhoff et al., 1978, Atlas of Protein Sequence and Structure Linkages) is used. 5 :345-352, for the BLOSUM62 comparison matrix, Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA 89 :10915-10919) are also used by the algorithm.
[0123] Recommended parameters for determining percent identity of polypeptide or nucleotide sequences using the GAP program are as follows: Algorithm: Needleman et al., 1970, J. Mol. Biol. 48 :443-453 Comparison matrix: BLOSUM62 from Henikoff et al., 1992, supra Gap penalty: 12 (no penalty for end gaps) Gap length penalty: 4 Similarity threshold: 0
[0124] Some alignment schemes for aligning two amino acid sequences may result in matching only a short region of the two sequences, and this small aligned region may have very high sequence identity even if there is no significant relationship between the two full-length sequences. Therefore, the alignment method selected (GAP program) can be adjusted to result in an alignment over at least 50 contiguous amino acids of the target polypeptide, if desired.
[0125] As used herein, "substantially pure" means that the recited molecular species is the predominant species present, i.e., it is more abundant, on a molar basis, than any other individual species in the same mixture. In certain embodiments, a substantially pure molecule is a composition in which the species of interest constitutes at least 50% (on a molar basis) of all macromolecular species present. In other embodiments, a substantially pure composition constitutes at least 80%, 85%, 90%, 95%, or 99% of all macromolecular species present in the composition. In other embodiments, the species of interest is purified to essential homogeneity, and contaminating species cannot be detected in the composition by conventional detection methods, such that the composition is composed of a single detectable macromolecular species.
[0126] The term "treating" refers to any manifestation of success in treating or alleviating an injury, pathology, or condition, including any objective or subjective parameter, such as reduction, remission, attenuation of symptoms, or making the injury, pathology, or condition more tolerable to the patient, slowing the rate of deterioration or debilitation, reducing the debilitating end point of deterioration, or improving the patient's physical or mental health. Treating or alleviating symptoms can be based on objective or subjective parameters, including the results of a physical examination, neuropsychiatric testing, and / or psychiatric evaluation. For example, certain methods provided herein successfully treat migraines, either as a preventative or acute treatment, reducing the frequency of migraines, reducing the severity of migraines, and / or alleviating symptoms associated with migraines.
[0127] An "effective amount" is generally an amount sufficient to reduce the severity and / or frequency of symptoms, eliminate symptoms and / or their underlying causes, prevent the occurrence of symptoms and / or their underlying causes, and / or ameliorate or repair damage caused by or associated with migraine. In some embodiments, the effective amount is a therapeutically or prophylactically effective amount. A "therapeutically effective amount" is an amount sufficient to treat a disease state (e.g., migraine) or symptom, particularly a condition or symptom associated with a disease state, or otherwise prevent, hinder, delay, or reverse the progression of a disease state or other undesirable symptoms associated with the disease in any way. A "prophylactically effective amount" is an amount of a pharmaceutical composition that, when administered to a subject, has the intended prophylactic effect, for example, prevents or delays the occurrence (or recurrence) of a migraine or reduces the likelihood of the occurrence (or recurrence) of a migraine or migraine symptoms. A complete therapeutic or prophylactic effect does not necessarily occur by administration of a single dose, but may occur after administration of a series of doses. Thus, a therapeutically or prophylactically effective amount may be administered in one or more administrations.
[0128] "Amino acid" has its ordinary meaning in the art. The 20 naturally occurring amino acids and their abbreviations follow conventional practice. See Immunology - A Synthesis, 2nd Edition, (ES Golub and DR Green, eds.), Sinauer Associates: Sunderland, Mass. (1991), which is incorporated herein by reference for any purpose. Stereoisomers of the 20 conventional amino acids (e.g., D-amino acids), unnatural amino acids, such as α-, α-disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may be suitable components of polypeptides and are included in the term "amino acid." Examples of unconventional amino acids include 4-hydroxyproline, γ-carboxyproline, γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl terminal direction, in accordance with standard practices and conventions.
[0129] overview Provided herein are antigen-binding proteins that bind to CGRP R proteins, including human CGRP R (hCGRP R) proteins.An antigen-binding protein is a polypeptide in which one or more complementarity-determining regions (CDRs) are incorporated and / or combined as described herein.In some antigen-binding proteins, CDRs are incorporated into "framework" regions, which orient the CDRs and ensure that the CDRs achieve appropriate antigen-binding properties.In general, the provided antigen-binding proteins can interfere with, block, reduce, or modulate the interaction between CGRP and CGRP R.
[0130] Certain antigen-binding proteins described herein are antibodies or are derived from antibodies. In certain embodiments, the polypeptide structure of the antigen-binding protein is based on an antibody, including, but not limited to, monoclonal antibodies, bispecific antibodies, small bodies, domain antibodies, synthetic antibodies (sometimes referred to as "antibody mimetics"), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as "antibody conjugates"), and fragments thereof. The various structures are further described herein below.
[0131] The antigen binding proteins provided herein have been demonstrated to bind to CGRP-R, particularly human CGRP-R. As further described in the Examples below, certain antigen binding proteins have been tested and found to bind to epitopes distinct from those bound by numerous other antibodies directed against one or other of the components of CGRP-R. The antigen binding proteins provided herein compete with CGRP, thereby preventing CGRP from binding to its receptor. As a result, the antigen binding proteins provided herein can inhibit CGRP-R activity. In particular, antigen binding proteins that bind to these epitopes may have one or more of the following activities: particularly, inhibition of CGRP-R signal transduction pathway induction, inhibition of vasodilation, induction of vascular atrophy, reduction of inflammation, e.g., neurogenic inflammation, and other physiological effects induced by CGRP-R upon CGRP binding.
[0132] The antigen binding proteins disclosed herein have a variety of uses. Some of the antigen binding proteins are useful, for example, in specific binding assays, affinity purification of CGRP R, particularly hCGRP R, or its ligands, and screening assays to identify other antagonists of CGRP R activity. Some of the antigen binding proteins are useful for inhibiting the binding of CGRP to CGRP R.
[0133] As described herein, antigen binding proteins can be used in a variety of therapeutic applications. For example, certain CGRP®-binding proteins are useful for treating conditions associated with CGRP®-mediated signal transduction, such as reducing, alleviating, or treating the frequency and / or severity of migraines, reducing, alleviating, or treating cluster headaches, reducing, alleviating, or treating chronic pain, reducing or treating diabetes (type II), reducing, alleviating, or treating cardiovascular disease, and reducing, alleviating, or treating hemodynamic abnormalities associated with endotoxemia and sepsis in patients. Other uses for antigen binding proteins include, for example, diagnosing CGRP®-related diseases or conditions and screening assays for determining the presence or absence of CGRP®. Some of the antigen binding proteins described herein are useful in treating consequences, symptoms, and / or pathologies associated with CGRP® activity. These include, but are not limited to, various types of migraines.
[0134] CGRP receptor The antigen-binding proteins disclosed herein bind to CGRP-R, particularly human CGRP-R. CGRP-R is a multimer that includes both CRLR and RAMP1. The nucleotide sequence of human CRLR is provided herein as SEQ ID NO: 1. The amino acid sequence of human CRLR is provided herein as SEQ ID NO: 2. The nucleotide sequence of human RAMP1 is provided herein as SEQ ID NO: 3. The amino acid sequence of human RAMP1 is provided herein as SEQ ID NO: 4. The antigen-binding proteins described herein bind to the extracellular portion of CGRP-R, which includes the extracellular portions of CRLR and RAMP1. An exemplary extracellular domain ("ECD") of human CRLR is encoded by the nucleotide sequence presented as SEQ ID NO: 5 and has the amino acid sequence presented as SEQ ID NO: 6. This sequence includes the signal peptide, and an exemplary mature (minus the signal peptide) CRLR ECD has the amino acid sequence presented as SEQ ID NO: 10. An exemplary ECD of human RAMP1 is encoded by the nucleotide sequence presented as SEQ ID NO: 7 and has the amino acid sequence presented as SEQ ID NO: 8. This sequence includes the signal peptide, and a typical mature (minus the signal peptide) RAMP1 ECD has the amino acid sequence set forth as SEQ ID NO: 11. As described below, CGRP R proteins may include fragments. As used herein, the terms are used interchangeably to refer to a receptor, particularly a human receptor that specifically binds CGRP, unless otherwise specified. The term CGRP R also includes post-translational modifications of the CGRP R amino acid sequence, for example, possible N-linked glycosylation sites. Thus, antigen binding proteins may bind to or be produced from proteins that are glycosylated at one or more positions.
[0135] CGRP receptor-binding protein A variety of selective binding agents useful for modulating the activity of CGRP® are provided. These agents include, for example, antigen-binding proteins containing antigen-binding protein domains (e.g., single-chain antibodies, domain antibodies, immunoadhesions, and polypeptides having antigen-binding regions), which specifically bind to CGRP®, particularly human CGRP®. Some of these agents are useful, for example, in inhibiting the binding of CGRP to CGRP®, and can be used to inhibit, interfere with, or modulate one or more activities associated with CGRP® signal transduction.
[0136] In general, the antigen-binding proteins provided typically comprise one or more (e.g., 1, 2, 3, 4, 5, or 6) CDRs as described herein. In some examples, the antigen-binding proteins comprise (a) a polypeptide structure and (b) one or more CDRs inserted into and / or attached to the polypeptide structure. The polypeptide structure can take a variety of different forms. For example, it can be or comprise the framework of a naturally occurring antibody, or a fragment or variant thereof, or it can be entirely synthetic in nature. Examples of various polypeptide structures are further described below.
[0137] In certain embodiments, the polypeptide structure of the antigen-binding protein is an antibody or is derived from an antibody, including, but not limited to, monoclonal antibodies, bispecific antibodies, small bodies, domain antibodies, synthetic antibodies (sometimes referred to as "antibody mimetics"), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as "antibody conjugates"), and portions or fragments of each. In some instances, the antigen-binding protein is an immunological fragment of an antibody (e.g., Fab, Fab', F(ab')2, or scFv). Various structures are further described and defined herein.
[0138] Certain antigen binding proteins provided herein specifically bind to human CGRP® R. In certain embodiments, the antigen binding proteins specifically bind to human CGRP® R proteins, including human CRLR having the amino acid sequence of SEQ ID NO: 2 and human RAMP1 having the amino acid sequence of SEQ ID NO: 4.
[0139] In embodiments in which the antigen binding protein is used for therapeutic purposes, the antigen binding protein can inhibit, interfere with, or modulate one or more biological activities of CGRP R. In this example, an antigen binding protein specifically binds to and / or substantially inhibits binding of human CGRP R to CGRP if the excess antibody reduces the amount of human CGRP R bound to CGRP by at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99% or more (e.g., by measuring binding in an in vitro competitive binding assay).
[0140] Naturally occurring antibody structures Some of the antigen-binding proteins provided have a structure typically associated with naturally occurring antibodies. These antibody structural units typically comprise one or more tetramers, each composed of a couplet of two identical polypeptide chains, although certain mammalian species also produce antibodies with only a single heavy chain. In a typical antibody, each pair or couplet comprises one full-length "light" chain (in certain embodiments, approximately 25 kDa) and one full-length "heavy" chain (in certain embodiments, approximately 50-70 kDa). Each individual immunoglobulin chain is composed of several "immunoglobulin domains," each of approximately 90-110 amino acids and expressing a characteristic folding pattern. These domains are the basic units from which antibody polypeptides are constructed. The amino-terminal portion of each chain typically contains a variable domain responsible for antigen recognition. The carboxy-terminal portion is more evolutionarily conserved than the other ends of the chain and is referred to as the "constant region" or "C region." Human light chains are generally classified as kappa and lambda light chains, each of which contains one variable domain and one constant domain. Heavy chains are typically classified as μ, δ, γ, α, or ε chains, which define the antibody's isotype: IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subtypes, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM subtypes include IgM1 and IgM2. IgA subtypes include IgA1 and IgA2. In humans, IgA and IgD isotypes contain four heavy chains and four light chains, IgG and IgE isotypes contain two heavy chains and two light chains, and IgM isotypes contain five heavy chains and five light chains. The heavy chain C region typically contains one or more domains that may be involved in effector function. The number of heavy chain constant region domains depends on the isotype. IgG heavy chains, for example, contain C H 1. C H 2, and C HEach CGRP-R antibody contains three C-region domains, known as IgG1, IgG2, or IgG4 subtypes. The provided antibodies can have any of these isotypes and subtypes. In certain embodiments, the CGRP-R antibody is an IgG1, IgG2, or IgG4 subtype.
[0141] In full-length light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 or more amino acids. See, e.g., Fundamental Immunology, 2nd ed., Ch. 7 (Paul, W., ed.) 1989, New York: Raven Press (incorporated by reference in its entirety for all purposes). The variable regions of each light / heavy chain pair typically form the antigen-binding site.
[0142] An example of an IgG2 heavy constant domain of a typical CGRP R monoclonal antibody has the following amino acid sequence: ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (the last 326 residues of the sequence set forth as SEQ ID NO: 29)
[0143] An example of a kappa light constant domain of a typical CGRP R monoclonal antibody has the following amino acid sequence: RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (the last 107 residues of the sequence shown as SEQ ID NO: 14)
[0144] The variable regions of immunoglobulin chains generally exhibit the same overall structure and contain relatively conserved framework regions (FRs) connected by three hypervariable regions, more often referred to as "complementarity-determining regions" or CDRs. The CDRs from the two chains of each heavy / light chain pair are usually aligned by the framework regions to form a structure that specifically binds to a particular epitope on a target protein (e.g., CGRP R). From the N-terminus to the C-terminus, naturally occurring light and heavy chain variable regions usually follow the following order of elements: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. A numbering system has been devised to assign numbers to the amino acids that occupy positions in each of these domains. This numbering system is based on Kabat Sequences of Proteins of Immunological Interest (1987 and 1991, NIH, Bethesda, MD) or Chothia & Lesk, 1987, J. Mol. Biol. 196 :901-917, Chothia et al., 1989, Nature 342 :878-883.
[0145] The various heavy and light chain variable regions provided herein are represented in Table 3. Each of these variable regions can be attached to the heavy and light chain constant regions described above to form complete antibody heavy and light chains, respectively. Furthermore, each of the heavy and light chain sequences thus generated can be combined to form a complete antibody structure. It should be understood that the heavy and light chain variable regions provided herein can also be attached to other constant regions having sequences different from the exemplary sequences listed above.
[0146] Specific examples of some of the full-length heavy and light chains of the provided antibodies and their corresponding amino acid sequences are summarized in Tables 2A and 2B. Table 2A shows exemplary light chain sequences, and Table 2B shows exemplary heavy chain sequences.
[0147] [Table 2A-1]
[0148] [Table 2A-2]
[0149] [Table 2A-3]
[0150] [Table 2A-4]
[0151] [Table 2B-1]
[0152] [Table 2B-2]
[0153] [Table 2B-3]
[0154] [Table 2B-4]
[0155] [Table 2B-5]
[0156] The first 22 amino acids of each of the light chain sequences in Table 2A are signal sequences, except for 32H7 and 32HCS. In the case of 32H7 and 32H7CS, the signal sequence is 20 amino acids. Similarly, the first 22 amino acids of the heavy chain sequences in Table 2B are signal sequences. The signal peptide may be altered to one with a different sequence, for example, for more optimal expression in a given host cell. Thus, it should be understood that the present invention also includes antibodies with light and / or heavy chain sequences as specified in Tables 2A and 2B, but with different signal sequences.
[0157] Additionally, each of the exemplary heavy chains (H1, H2, H3, etc.) listed in Table 2B can be combined with any of the exemplary light chains shown in Table 2A to form an antibody. Examples of such combinations include H1 combined with any of L1-L17, H2 combined with any of L1-L17, H3 combined with any of L1-L17, etc. In some examples, an antibody comprises at least one heavy chain and one light chain from those listed in Tables 2A and 2B. In some examples, an antibody comprises two different heavy chains and two different light chains listed in Tables 2A and 2B. In other examples, an antibody comprises two identical light chains and two identical heavy chains. As examples, an antibody or immunologically functional fragment may contain two H1 heavy chains and two L1 light chains, or two H2 heavy chains and two L2 light chains, or two H3 heavy chains and two L3 light chains, and other similar combinations of light and heavy chain pairs as listed in Tables 2A and 2B.
[0158] Other antigen binding proteins provided are variants of antibodies formed by the combination of heavy and light chains shown in Tables 2A and 2B, and comprise a light chain and / or a heavy chain having at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% identity to the amino acid sequences of those chains. In some instances, such antibodies comprise at least one heavy chain and one light chain, while in other instances, the variant comprises two identical light chains and two identical heavy chains.
[0159] antibody variable domains As shown in Table 3 below, V H 1. V H 2. V H 3. V H 4. V H 5. V H 6. V H 7. V H 8. V H 9. V H 10. V H 11. V H 12, and V H 13, and / or V L 1. V L 2. V L 3. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. V L 12. V L 13. V L 14. V L 15, V L 16, and V L Antigen binding proteins comprising antibody light chain variable regions selected from the group consisting of 17, and immunologically functional fragments, derivatives, mutants, and variants of these light and heavy chain variable regions are also provided.
[0160] Sequence alignments of various heavy and light chain variable regions are provided in Figures 1A and 1B, respectively.
[0161] Antigen binding proteins of this type generally have the formula "V H x / V L The number of heavy chain variable regions can be specified by "x" and "y," where "x" corresponds to the number of heavy chain variable regions and "y" corresponds to the number of light chain variable regions.
[0162] [Table 3-1]
[0163] [Table 3-2]
[0164] [Table 3-3]
[0165] [Table 3-4]
[0166] [Table 3-5]
[0167] [Table 3-6]
[0168] Each of the heavy chain variable regions listed in Table 3 can be combined with any of the light chain variable regions shown in Table 3 to form an antigen binding protein. Examples of such combinations include V L 1. V L 2. V L 3. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. VL 12. V L 13. V L 14. V L 15, V L 16, or V L V combined with any of the 17 H 1. V L 1. V L 2. V L 3. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. V L 12. V L 13. V L 14. V L 15, V L 16, or V L V combined with any of the 17 H 2. V L 1. V L 2. V L 3. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. V L 12. V L 13. V L 14. V L 15, V L 16, or V L V combined with any of the 17 H 3, etc.
[0169] In some examples, the antigen binding protein comprises at least one heavy chain variable region and / or one light chain variable region that differs from those listed in Table 3. In some examples, the antigen binding protein comprises at least two heavy chain variable regions and / or one light chain variable region that differs from those listed in Table 3. Examples of such antigen binding proteins include: (a) one V H 1, and (b) VH 2. V H 3. V H 4. V H 5. V H 6. V H 7. V H 8. V H 9. V H 10. V H 11. V H 12, or V H 13. Another example is (a) one V H 2 and (b) V H 1. V H 3. V H 4. V H 5. V H 6. V H 7. V H 8. V H 9. V H 10. V H 11. V H 12, or V H 13. Yet another example is (a) one V H 3 and (b) V H 1. V H 2. V H 4. V H 5. V H 6. V H 7. V H 8. V H 9. V H 10. V H 11. V H 12, or V H 13. Yet another example of such an antigen-binding protein is one having (a) one V L 1 and (b) V L 2. V L 3. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. V L 12. V L 13. V L 14. V L 15, V L 16, V L17, V L 18, V L 19. V L 20, or V L 21. Yet another example of such an antigen-binding protein is one comprising (a) one V L 2 and (b) V L 1. V L 3. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. V L 12. V L 13. V L 14. V L 15, V L 16, V L 17, V L 18, V L 19. V L 20, or V L 21. Yet another example of such an antigen-binding protein is one comprising (a) one V L 3 and (b) V L 1. V L 2. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. V L 12. V L 13. V L 14. V L 15, V L 16, V L 17, V L 18, V L 19. V L 20, or V L Contains one of 21, etc.
[0170] Various combinations of heavy chain variable regions may be combined with any of various combinations of light chain variable regions, as will be apparent to one of skill in the art.
[0171] In other examples, the antigen binding protein comprises two identical light chain variable regions and / or two identical heavy chain variable regions. As an example, the antigen binding protein may be an antibody or immunologically functional fragment that comprises two light chain variable regions and two heavy chain variable regions listed in Table 3, together with a pair of light chain variable regions and a pair of heavy chain variable regions.
[0172] Some antigen binding proteins provided have V and V sequences in as few as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid residues. H 1. V H 2. V H 3. V H 4. V H 5. V H 6. V H 7. V H 8. V H 9. V H 10. V H 11. V H 12, and V H 13, wherein each such sequence difference is independently either a deletion, insertion, or substitution of one amino acid, and the deletion, insertion, and / or substitution does not result in more than 15 amino acid changes relative to the aforementioned variable domain sequence. H 1. V H 2. V H 3. V H 4. V H 5. V H 6. V H 7. V H 8. V H 9. V H 10. V H 11. V H 12, and V H It comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% sequence identity to the amino acid sequences of 13 heavy chain variable regions.
[0173] A given antigen-binding protein may have V sequences at no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid residues. L 1. V L 2. V L 3. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. V L 12. V L 13. V L 14. V L 15, V L 16, or V L 17, wherein each such sequence difference is independently either a deletion, insertion, or substitution of one amino acid, and the deletion, insertion, and / or substitution does not result in more than 15 amino acid changes relative to the aforementioned variable domain sequence. L 1. V L 2. V L 3. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. V L 12. V L 13. V L 14. V L 15, V L 16, or V L It comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% sequence identity to the amino acid sequences of 17 light chain variable regions.
[0174] In additional examples, the antigen binding proteins comprise the following pairs of light and heavy chain variable domains: VL1 and VH1, VL2 and VH2, VL3 and VH3, VL4 and VH4, VL5 and VH5, VL6 and VH1, VL7 and VH6, VL8 and VH5, VL9 and VH1, VL10 and VH7, VL11 and VH8, VL12 and VH9, VL12 and VH10, VL13 and VH5, VL14 and VH11, VL15 and VH12, VL16 and VH13, and VL17 and VH13. In some examples, the antigen binding proteins in the above pairs may comprise amino acid sequences having 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the particular variable domains.
[0175] Still other antigen binding proteins, such as antibodies or immunologically functional fragments, include variants of the variant variable heavy chains and variant variable light chains described above.
[0176] CDR The antigen-binding proteins disclosed herein are polypeptides into which one or more CDRs are grafted, inserted, and / or attached. Antigen-binding proteins may have 1, 2, 3, 4, 5, or 6 CDRs. An antigen-binding protein thus comprises, for example, one heavy chain CDR1 ("CDRH1"), and / or one heavy chain CDR2 ("CDRH2"), and / or one heavy chain CDR3 ("CDRH3"), and / or one light chain CDR1 ("CDRL1"), and / or one light chain CDR2 ("CDRL2"), and / or one light chain CDR3 ("CDRL3"). Some antigen-binding proteins comprise both a CDRH3 and a CDRL3. Specific heavy and light chain CDRs are identified in Tables 4A and 4B, respectively.
[0177] The complementarity-determining regions (CDRs) and framework regions (FRs) of a given antibody can be identified using the system described by Kabat et al. in Sequences of Proteins of Immunological Interest, 5th Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242, 1991. Certain antibodies disclosed herein contain one or more amino acid sequences that are identical to or have high sequence identity to the amino acid sequences of one or more of the CDRs presented in Table 4A (CDRH) and Table 4B (CDRL).
[0178] [Table 4A-1]
[0179] [Table 4A-2]
[0180] [Table 4A-3]
[0181] [Table 4B-1]
[0182] [Table 4B-2]
[0183] [Table 4B-3]
[0184] The structure and properties of CDRs in naturally occurring antibodies have been described above. Briefly, in traditional antibodies, CDRs are incorporated into frameworks in the heavy and light chain variable regions, which constitute the regions involved in antigen binding and recognition. The variable regions are described above (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Public Health Service NIH, Bethesda, MD; Chothia and Lesk, 1987, J. Mol. Biol. 196 :901-917, Chothia et al., 1989, Nature 342 :877-883), and comprise at least three heavy or light chain CDRs in framework regions (designated framework regions 1-4, FR1, FR2, FR3, and FR4; see also Kabat et al., 1991, supra; Chothia and Lesk, 1987, supra). The CDRs provided herein, however, are not only used to define the antigen-binding domain of traditional antibody structures, but can also be incorporated into a variety of other polypeptide structures, as described herein.
[0185] In one embodiment, the CDRs provided comprise: (a) a CDRH1 selected from the group consisting of (i) SEQ ID NOs: 73, 76, 79, 82, 85, 88, 92, 97, and 100; (ii) a CDRH2 selected from the group consisting of SEQ ID NOs: 74, 77, 80, 83, 86, 89, 91, 93, 95, 98, 101, and 129; (iii) a CDRH3 selected from the group consisting of SEQ ID NOs: 75, 78, 81, 84, 87, 90, 96, 99, 102, and 123; and (iv) a CDRH selected from the group consisting of (i), (ii), and (iii) that contains one or more amino substitutions (e.g., conservative amino acid substitutions), deletions, or insertions of not more than 5, 4, 3, 2, or 1 amino acid. (B) (i) a CDRL1 selected from the group consisting of SEQ ID NOs: 42, 45, 48, 51, 54, 57, 62, 65, 66, and 69; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 43, 46, 49, 52, 55, 58, 61, 63, 67, and 70; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 44, 47, 50, 53, 56, 59, 64, 68, 71, and 72; and (iv) a CDRL selected from the group consisting of the CDRHs of (i), (ii), and (iii) that contain one or more amino substitutions (e.g., conservative amino acid substitutions), deletions, or insertions of not more than 5, 4, 3, 2, or 1 amino acid.
[0186] In another embodiment, the antigen binding protein comprises one, two, three, four, five, or six variants of the CDRs listed in Tables 4A and 4B, which have at least 80%, 85%, 90%, or 95% sequence identity to the CDR sequences listed in Tables 4A and 4B, respectively. Some antigen binding proteins comprise one, two, three, four, five, or six variants of the CDRs listed in Tables 4A and 4B, which differ by no more than one, two, three, four, or five amino acids from the CDRs listed in these tables, respectively.
[0187] In yet another embodiment, the CDRs disclosed herein comprise consensus sequences derived from a group of related monoclonal antibodies. As used herein, "consensus sequence" refers to an amino acid sequence that has conserved amino acids common to several sequences and variable amino acids that vary within a given amino acid sequence. The provided CDR consensus sequences include the CDRs corresponding to each of CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3.
[0188] In yet another embodiment, the antigen binding protein comprises the following associations of CDRL1, CDRL2, and CDRL3: SEQ ID NOs: 42, 43, and 44, SEQ ID NOs: 45, 46, and 47, SEQ ID NOs: 48, 49, and 50, SEQ ID NOs: 51, 52, and 53, SEQ ID NOs: 54, 55, and 56, SEQ ID NOs: 57, 58, and 59, SEQ ID NOs: 60, 55, and 56, SEQ ID NOs: 45, 61, and 47, SEQ ID NOs: 62, 63, and 64, SEQ ID NOs: 65, 55, and 56, SEQ ID NOs: 66, 67, and 68, SEQ ID NOs: 69, 70, and 71, and SEQ ID NOs: 69, 70, and 72.
[0189] In additional embodiments, the antigen binding protein comprises the following associations of CDRH1, CDRH2, and CDRH3: SEQ ID NOs: 73, 74, and 75, SEQ ID NOs: 76, 77, and 78, SEQ ID NOs: 79, 80, and 81, SEQ ID NOs: 82, 83, and 84, SEQ ID NOs: 85, 86, and 87, SEQ ID NOs: 88, 89, and 90, SEQ ID NOs: 76, 91, and 78, SEQ ID NOs: 92, 93, and 94, SEQ ID NOs: 76, 95, and 78, SEQ ID NOs: 73, 74, and 96, SEQ ID NOs: 97, 98, and 99, SEQ ID NOs: 100, 101, and 102.
[0190] In another embodiment, the antigen binding protein comprises the following associations of CDRL1, CDRL2, and CDRL3 with CDRH1, CDRH2, and CDRH3: SEQ ID NOs: 42, 43, and 44 with SEQ ID NOs: 73, 74, and 75; SEQ ID NOs: 45, 46, and 47 with SEQ ID NOs: 76, 77, and 78; SEQ ID NOs: 48, 49, and 50 with SEQ ID NOs: 79, 80, and 81; SEQ ID NOs: 51, 52, and 53 with SEQ ID NOs: 82, 83, and 84; SEQ ID NOs: 54, 55, and 56 with SEQ ID NOs: 85, 86, and 87; SEQ ID NOs: 57, 58, and 59 with SEQ ID NOs: 88, 89, and 90; SEQ ID NOs: 60, 55, and 56 SEQ ID NOs: 6 and SEQ ID NOs: 85, 86, and 87; SEQ ID NOs: 45, 61, and 47 and SEQ ID NOs: 76, 91, and 78; SEQ ID NOs: 62, 63, and 64 and SEQ ID NOs: 92, 93, and 94; SEQ ID NOs: 45, 61, and 47 and SEQ ID NOs: 76, 95, and 78; SEQ ID NOs: 65, 55, and 56 and SEQ ID NOs: 85, 86, and 87; SEQ ID NOs: 42, 43, and 44 and SEQ ID NOs: 73, 74, and 96; SEQ ID NOs: 66, 67, and 68 and SEQ ID NOs: 97, 98, and 99; SEQ ID NOs: 69, 70, and 71 and SEQ ID NOs: 100, 101, and 102; SEQ ID NOs: 69, 70, and 72 and SEQ ID NOs: 100, 101, and 102.
[0191] The consensus sequence is V for anti-CGRP R antibodies. H and V L The consensus sequence was determined using standard phylogenetic analysis of the CDRs corresponding to V. H or V L The CDRs were determined by keeping them adjacent within the same sequence corresponding to:
[0192] As shown in Figures 3A, 3B, 4, 5A, 5B, 5C, 5D, and 5E, phylogenetic analysis of the various antigen-binding proteins provided herein has resulted in groups of related sequences, designated light chain CDR groups K1, K2, K3, and K4 (Figures 3A and 3B), light chain CDR groups L1, L2, L3, and L4 (Figure 4), and heavy chain CDR groups HC1 (Figure 5A), HC2 (Figure 5B), HC3 (Figure 5C), HC4 (Figure 5C), HC5 (Figure 5D), and HC6 (Figure 5E). Some of the above groups were used to generate additional consensus sequences, shown in Figures 3A, 3B, 4, and 5F, resulting in light chain CDR groups K1,4 (Figure 3A), K2,3 (Figure 3B), L1,2,3 (Figure 4), and L11 (Figure 4), and heavy chain CDR groups HCA and HCB (Figure 5F).
[0193] Consensus sequences for the various CDR regions are provided below. K1 Consensus CDR1 RASQGIRX1DLG (SEQ ID NO: 103), wherein X1 is selected from the group consisting of N and K. CDR2 X1ASSLQS (SEQ ID NO: 104), where X1 is selected from the group consisting of A and G. CDR3 LQYNX1X2PWT (SEQ ID NO: 105), wherein X1 is selected from the group consisting of I and S, and X2 is selected from the group consisting of Y and F. K4 Consensus CDR3 QQYGNSLX1R (SEQ ID NO: 106), wherein X1 is selected from the group consisting of S and C. K1,4 consensus CDR1 RASQX1X2X3X4GX5LX6 (SEQ ID NO: 107), wherein X1 is selected from the group consisting of S and G, X2 is selected from the group consisting of V and I, X3 is selected from the group consisting of S and R, X4 is selected from the group consisting of S, N and K, X5 is selected from the group consisting of Y and D, and X6 is selected from the group consisting of T and G. CDR2 X1ASSX2X3X4 (SEQ ID NO: 108), wherein X1 is selected from the group consisting of G and A, X2 is selected from the group consisting of R and L, X3 is selected from the group consisting of A and Q, and X4 is selected from the group consisting of T and S. CDR3 X1QYX2X3X4X5X6X7 (SEQ ID NO: 109), wherein X1 is selected from the group consisting of Q and L, X2 is selected from the group consisting of G and N, X3 is selected from the group consisting of N and T, X4 is selected from the group consisting of S, Y and F, X5 is selected from the group consisting of L and P, X6 is selected from the group consisting of C, W and S, and X7 is selected from the group consisting of R and T. K3 Consensus CDR1 KSSQSLLHSX1GX2X3YLY (SEQ ID NO: 110), wherein X1 is selected from the group consisting of D and A, X2 is selected from the group consisting of R and K, and X3 is selected from the group consisting of N and T. K2,3 consensus CDR1 X1SSQSLLHSX2GX3X4YLX5 (SEQ ID NO: 111), wherein X1 is selected from the group consisting of R and K, X2 is selected from the group consisting of F, D and A, X3 is selected from the group consisting of Y, R and K, X4 is selected from the group consisting of N and T, and X5 is selected from the group consisting of D and Y. CDR2 X1X2SNRX3S (SEQ ID NO: 112), wherein X1 is selected from the group consisting of L and E, X2 is selected from the group consisting of G and V, and X3 is selected from the group consisting of A and F. CDR3 MQX1X2X3X4PX5T (SEQ ID NO: 113), wherein X1 is selected from the group consisting of A and S, X2 is selected from the group consisting of L and F, X3 is selected from the group consisting of Q and P, X4 is selected from the group consisting of T and L, and X5 is selected from the group consisting of F and L. Lm3 consensus CDR2 RX1NQRPS (SEQ ID NO: 114), wherein X1 is selected from the group consisting of N and S. Lm1,2,3 consensus CDR1 SGSSSNIGX1NX2VX3 (SEQ ID NO: 115), wherein X1 is selected from the group consisting of N and S, X2 is selected from the group consisting of Y and T, and X3 is selected from the group consisting of S, N, and Y. CDR2 X1X2NX3RPS (SEQ ID NO: 116), wherein X1 is selected from the group consisting of D, T and R; X2 is selected from the group consisting of N and S; and X3 is selected from the group consisting of K and Q. CDR3 X1X2X3DX4X5LX6X7VV (SEQ ID NO: 117), wherein X1 is selected from the group consisting of G and A, X2 is selected from the group consisting of T and A, X3 is selected from the group consisting of W and R, X4 is selected from the group consisting of S and D, X5 is selected from the group consisting of R and S, X6 is selected from the group consisting of S and N, and X7 is selected from the group consisting of A and G. LAll Consensus CDR1 X1GX2X3SX4X5X6X7X8X9X 10 X 11 (SEQ ID NO: 118), wherein X1 is selected from the group consisting of S and Q, X2 is present or absent and if present is S, X3 is selected from the group consisting of S and D, X4 is present or absent and if present is N, X5 is selected from the group consisting of I and L, X6 is selected from the group consisting of G and R, X7 is selected from the group consisting of N and S, X8 is selected from the group consisting of N and F, X9 is selected from the group consisting of Y and T, and X 10 is selected from the group consisting of V and A, and X 11 is selected from the group consisting of S, N and Y. CDR2 X1X2NX3RPS (SEQ ID NO: 119), wherein X1 is selected from the group consisting of D, G, T and R, X2 is selected from the group consisting of N, K and S, and X3 is selected from the group consisting of K, N and Q. CDR3 X1X2X3DX4X5X6X7X8X9V (SEQ ID NO: 120), wherein X1 is selected from the group consisting of G, N and A, X2 is selected from the group consisting of T, S and A, X3 is selected from the group consisting of W and R, X4 is selected from the group consisting of S and D, X5 is selected from the group consisting of R and S, X6 is selected from the group consisting of L and V, X7 is selected from the group consisting of S, Y and N, X8 is selected from the group consisting of A, H and G, and X9 is selected from the group consisting of V and L. HC1 consensus CDR1 X1YYMX2 (SEQ ID NO: 121), wherein X1 is selected from the group consisting of G and D; and X2 is selected from the group consisting of H and Y. CDR2 WIX1PNSGGTNYAQKFQG (SEQ ID NO: 122), wherein X1 is selected from the group consisting of N and S. CDR3 X1X2X3SX4X5X6X7X8GX9X 10 X 11 X 12 YYX 13 GMDV (SEQ ID NO: 123), wherein X1 is selected from the group consisting of D and G, X2 is selected from the group consisting of Q and G, X3 is selected from the group consisting of M and Y, X4 is selected from the group consisting of I and G, X5 is selected from the group consisting of I and Y, X6 is selected from the group consisting of M and A, X7 is present or absent and if present is L, X8 is present or absent and if present is R, X9 is selected from the group consisting of V and L; 10 is selected from the group consisting of F and Y, and X 11 is selected from the group consisting of P and S, and X 12 is selected from the group consisting of P and H, and X 13 is present or absent, and if present, is Y. HC2 Consensus CDR2 RIKSX1TDGGTTDYX2APVKG (SEQ ID NO: 124), wherein X1 is selected from the group consisting of K and T; and X2 is selected from the group consisting of T and A. HC3 Consensus CDR1 X1YX2MX3 (SEQ ID NO: 125), wherein X1 is selected from the group consisting of T and S; X2 is selected from the group consisting of S and A; and X3 is selected from the group consisting of N and S. CDR2 X1ISX2SX3X4X5X6YYADSVKG (SEQ ID NO: 126), wherein X1 is selected from the group consisting of S and A, X2 is selected from the group consisting of S and G, X3 is selected from the group consisting of S and G, X4 is selected from the group consisting of S and G, X5 is selected from the group consisting of Y and R, and X6 is selected from the group consisting of R and T. CDR3 X1X2X3X4X5X6X7PYSX8X9WYDYYYGMDV (SEQ ID NO: 127), wherein X1 is selected from the group consisting of E and D, X2 is selected from the group consisting of G and Q, X3 is selected from the group consisting of V and R, X4 is selected from the group consisting of S and E, X5 is selected from the group consisting of G and V, X6 is selected from the group consisting of S and G, X7 is present or absent and, if present, is S, X8 is selected from the group consisting of I and S, and X9 is selected from the group consisting of S and G. HC4 Consensus CDR1 SX1GMH (SEQ ID NO: 128), wherein X1 is selected from the group consisting of F and Y. CDR2 VISX1DGSX2KYX3X4DSVKG (SEQ ID NO: 129), wherein X1 is selected from the group consisting of F and Y, X2 is selected from the group consisting of I and H, X3 is selected from the group consisting of S and Y, and X4 is selected from the group consisting of V and A. CDR3 X1RX2X3X4X5X6SX7X8YYX9X 10 X 11 YYGX 12 X 13V (SEQ ID NO: 130), wherein X1 is selected from the group consisting of D and E, X2 is selected from the group consisting of L and K, X3 is selected from the group consisting of N and R, X4 is selected from the group consisting of Y and V, X5 is selected from the group consisting of Y and T, X6 is selected from the group consisting of D and M, X7 is selected from the group consisting of S and T, X8 is selected from the group consisting of G and L, and X9 is selected from the group consisting of H and Y; 10 is present or absent, and if present, it is Y, and if present, it is X 11 is selected from the group consisting of K and F, and X 12 is selected from the group consisting of M and L, and X 13 is selected from the group consisting of A and D. HCA Consensus CDR1 X1X2X3MX4 (SEQ ID NO: 131), wherein X1 is selected from the group consisting of N and S, X2 is selected from the group consisting of A, Y, and F, X3 is selected from the group consisting of W, A, and G, and X4 is selected from the group consisting of S and H. CDR2 X1IX2X3X4X5X6GX7X8X9X 10 X 11 X 12 X 13 X 14 VKG (SEQ ID NO: 132), wherein X1 is selected from the group consisting of R, A, and V; X2 is selected from the group consisting of K, S, and W; X3 is selected from the group consisting of S, G, F, and Y; X4 is present or absent and, if present, is selected from the group consisting of K and T; X5 is present or absent and, if present, is T; X6 is selected from the group consisting of D and S; X7 is selected from the group consisting of G and S; X8 is selected from the group consisting of T, R, I, N, and H; X9 is selected from the group consisting of T and K; 10 is selected from the group consisting of D and Y, and X 11 is selected from the group consisting of Y and S, and X 12 is selected from the group consisting of T, A, and V; X 13 is selected from the group consisting of A and D, and X14 is selected from the group consisting of P and S. CDR3 X1X2X3X4X5X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 GX 18 X 19 X is selected from the group consisting of D, A, and E; X is selected from the group consisting of R, Q, and G; X is selected from the group consisting of T, R, L, G, and K; X is selected from the group consisting of G, E, N, I, and R; X is selected from the group consisting of Y, V, and A; X is selected from the group consisting of S, G, Y, A, and T; X is selected from the group consisting of I, P, D, A, and M; X is present or absent and, if present, is selected from the group consisting of S and Y; X is present or absent and, if present, is selected from the group consisting of W, S, and T; 10 is selected from the group consisting of S, G and L, and X 11 is selected from the group consisting of S, G, L and Y; X 12 is present or absent, and if present, is selected from the group consisting of W and Y; X 13 is selected from the group consisting of Y and H, and X 14 is present or absent, and if present, is selected from the group consisting of Y and D; X 15 is selected from the group consisting of Y, K and F, and X 16 is present or absent, and if present, it is Y, and if present, it is X 17 is present or absent, and if present, it is Y, and if present, it is X 18 is selected from the group consisting of M and L, and X 19 is selected from the group consisting of D and A. HCB Consensus CDR1 X1X2X3X4X5 (SEQ ID NO: 134), wherein X1 is selected from the group consisting of N, G, D, S and A; X2 is selected from the group consisting of A, F and Y; X3 is selected from the group consisting of W, Y, A and G; X4 is selected from the group consisting of M and L; and X5 is selected from the group consisting of S and H. CDR2 X1IX2X3X4X5X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X (SEQ ID NO: 135), wherein X1 is selected from the group consisting of R, W, A, V, S and F; X2 is selected from the group consisting of K, N, S, W and R; X3 is selected from the group consisting of S, P, G, F and Y; X4 is present or absent and, if present, is selected from the group consisting of K, T and R; X5 is present or absent and, if present, is selected from the group consisting of T and A; X6 is selected from the group consisting of D, N, H, S and Y; X7 is selected from the group consisting of G and S; X8 is selected from the group consisting of G and S; X9 is selected from the group consisting of T, G, R, I, N, H and Y; 10 is selected from the group consisting of T, K, R and P; X 11 is selected from the group consisting of D, N, Y and E, and X 12 is selected from the group consisting of Y and S, and X 13 is selected from the group consisting of T, A and V, and X 14 is selected from the group consisting of A, Q and D, and X 15 is selected from the group consisting of P, K and S, and X 16 is selected from the group consisting of V and F, and X 17 is selected from the group consisting of K and Q. CDR3 X1X2X3X4X5SX6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16 GX17 X 18 X is selected from the group consisting of D, G, A, and E; X is selected from the group consisting of R, G, and Q; X is selected from the group consisting of T, M, Y, R, L, G, and K; X is selected from the group consisting of G, S, E, N, I, and R; X is selected from the group consisting of Y, I, G, V, and A; X is selected from the group consisting of S, I, Y, G, A, and T; X is selected from the group consisting of I, M, A, P, and D; X is present or absent and, if present, is selected from the group consisting of S, L, and Y; X is present or absent and, if present, is selected from the group consisting of W, R, S, and T; 10 is selected from the group consisting of S, G and L, and X 11 is selected from the group consisting of S, V, L, G and Y; X 12 is present or absent, and if present is selected from the group consisting of F, Y and W; X 13 is selected from the group consisting of Y, P, S and H, and X 14 is present or absent, and if present is selected from the group consisting of Y, P, D and H; X 15 is selected from the group consisting of Y, K and F, and X 16 is present or absent, and if present, it is Y, and if present, it is X 17 is present or absent, and if present, it is Y, and if present, it is X 18 is selected from the group consisting of M and L.
[0194] In some examples, the antigen binding protein comprises at least one heavy chain CDR1, CDR2, or CDR3 having one of the above consensus sequences. In some examples, the antigen binding protein comprises at least one light chain CDR1, CDR2, or CDR3 having one of the above consensus sequences. In other examples, the antigen binding protein comprises at least two heavy chain CDRs according to the above consensus sequence and / or at least two light chain CDRs according to the above consensus sequence. In yet other examples, the antigen binding protein comprises at least three heavy chain CDRs according to the above consensus sequence and / or at least three light chain CDRs according to the above consensus sequence.
[0195] Typical antigen-binding proteins According to one embodiment, (A) one or more heavy chain complementarity determining regions (CDRHs) selected from the group consisting of: (i) a CDRH1 selected from the group consisting of SEQ ID NOs: 73, 76, 79, 82, 85, 88, 92, 97, and 100; (ii) a CDRH2 selected from the group consisting of SEQ ID NOs: 74, 77, 80, 83, 86, 89, 91, 93, 95, 98, 101, and 129; (iii) a CDRH3 selected from the group consisting of SEQ ID NOs: 75, 78, 81, 84, 87, 90, 96, 99, 102, and 123; and (iv) a CDRH of (i), (ii), and (iii) that contains one or more, e.g., one, two, three, four or more, amino acid substitutions, deletions, or insertions of not more than five, four, three, two, or one amino acid; (B) (i) SEQ ID NOs: 42, 45, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 80, 83, 86, 89, 91, 93, 95, 98, 101, and 129; (i) a CDRL1 selected from the group consisting of SEQ ID NOs: 43, 46, 49, 52, 55, 58, 61, 63, 67, and 70; (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 44, 47, 50, 53, 56, 59, 64, 68, 71, and 72; and (iv) one or more light chain complementarity determining regions (CDRLs) selected from the group consisting of the CDRLs of (i), (ii), and (iii) that contain one or more, e.g., two, three, four or more amino acid substitutions, deletions, or insertions of not more than five, four, three, two, or one amino acid; or (C) one or more heavy chain CDRHs of (A) and one or more light chain CDRLs of (B).
[0196] In yet another embodiment, the isolated antigen binding protein comprises: (A) a CDRH selected from the group consisting of: (i) a CDRH1 selected from the group consisting of SEQ ID NOs: 73, 76, 79, 82, 85, 88, 92, 97, and 100; (ii) a CDRH2 selected from the group consisting of SEQ ID NOs: 74, 77, 80, 83, 86, 89, 91, 93, 95, 98, 101, and 129; and (iii) a CDRH3 selected from the group consisting of SEQ ID NOs: 75, 78, 81, 84, 87, 90, 96, 99, 102, and 123; (ii) a CDRL1 selected from the group consisting of SEQ ID NOs: 42, 45, 48, 51, 54, 57, 62, 65, 66, and 69; (ii) a CDRL2 selected from the group consisting of SEQ ID NOs: 43, 46, 49, 52, 55, 58, 61, 63, 67, and 70; and (iii) a CDRL3 selected from the group consisting of SEQ ID NOs: 44, 47, 50, 53, 56, 59, 64, 68, 71, and 72; or (C) one or more heavy chain CDRHs of (A) and one or more light chain CDRLs of (B). In one embodiment, the isolated antigen binding protein may comprise (A) a CDRH1 of SEQ ID NO: 73, 76, 79, 82, 85, 88, 92, 97, and 100, a CDRH2 of SEQ ID NO: 74, 77, 80, 83, 86, 89, 91, 93, 95, 98, 101, and 129, and a CDRH3 of SEQ ID NO: 75, 78, 81, 84, 87, 90, 96, 99, 102, and 123; and (B) a CDRL1 of SEQ ID NO: 42, 45, 48, 51, 54, 57, 62, 65, 66, and 69, a CDRL2 of SEQ ID NO: 43, 46, 49, 52, 55, 58, 61, 63, 67, and 70, and a CDRL3 of SEQ ID NO: 44, 47, 50, 53, 56, 59, 64, 68, 71, and 72.
[0197] In another embodiment, the heavy chain variable region (V H ) has at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 158-170, and / or V Lhas at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-153. H is selected from the group consisting of SEQ ID NOs: 158 to 170, and / or V L is selected from the group consisting of SEQ ID NOs: 137-153.
[0198] In another embodiment, an isolated antigenic protein is provided that specifically binds to an epitope formed by amino acid residues from both the CRLR and RAMP1 components of CGRP R.
[0199] In yet another embodiment, the isolated antigen binding protein described above comprises a first amino acid sequence comprising at least one of the CDRH consensus sequences disclosed herein and a second amino acid sequence comprising at least one of the CDRL consensus sequences disclosed herein. In one aspect, the first amino acid sequence comprises at least two of the CDRH consensus sequences and / or the second amino acid sequence comprises at least two of the CDRL consensus sequences.
[0200] In certain embodiments, the first and second amino acid sequences are covalently linked to one another.
[0201] In a further embodiment, the first amino acid sequence of the isolated antigen binding protein comprises a CDRH3 of SEQ ID NOs: 75, 78, 81, 84, 87, 90, 96, 99, 102, and 123, a CDRH2 of SEQ ID NOs: 74, 77, 80, 83, 86, 89, 91, 93, 95, 98, 101, and 129, and a CDRH3 of SEQ ID NOs: 73, 76, 79, 82, 85, 88, 92, 97, and 100. and / or the first amino acid sequence of the isolated antigen binding protein comprises a CDRH3 of SEQ ID NOs: 44, 47, 50, 53, 56, 59, 64, 68, 71, and 72, a CDRH2 of SEQ ID NOs: 43, 46, 49, 52, 55, 58, 61, 63, 67, and 70, and a CDRH1 of SEQ ID NOs: 42, 45, 48, 51, 54, 57, 62, 65, 66, and 69.
[0202] In a further embodiment, the isolated antigen binding protein comprises at least two CDRH sequences of heavy chain sequence H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, or H13, as shown in Table 5 A. In yet a further embodiment, the antigen binding protein comprises at least two CDRL sequences of light chain sequence L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, or L17, as shown in Table 5B. Moreover, in a further embodiment, the antigen binding protein comprises at least two CDRH sequences of heavy chain sequence H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, or H13 as shown in Table 5A, and at least two CDRL sequences of light chain sequence L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, or L17 as shown in Table 5B.
[0203] Moreover, in another embodiment, the antigen binding protein comprises the CDRH1, CDRH2, and CDRH3 sequences of heavy chain sequence H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, or H13, as shown in Table 5 A. In yet another embodiment, the antigen binding protein comprises the CDRL1, CDRL2, and CDRL3 sequences of light chain sequence L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, or L17, as shown in Table 5B.
[0204] In yet another embodiment, the antigen binding protein comprises all six CDRs of L1 and H1, or L2 and H2, or L3 and H3, or L4 and H4, or L5 and H5, or L6 and H1, or L7 and H6, or L8 and H5, or L9 and H1, or L10 and H7, or L11 and H8, or L12 and H9, or L12 and H10, or L13 and H5, or L14 and H11, or L15 and H12, or L16 and H13, or L17 and H13, as shown in Table 5A and Table 5B.
[0205] [Table 5A-1]
[0206] [Table 5A-2]
[0207] [Table 5B-1]
[0208] [Table 5B-2]
[0209] In one aspect, the isolated antigen-binding proteins provided herein can be monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, chimeric antibodies, multispecific antibodies, or antibody antigen-binding fragments thereof.
[0210] In another embodiment, the antibody fragment of the isolated antigen binding protein provided herein can be a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an Fv fragment, a diabody, or a single-chain antibody molecule.
[0211] In a further embodiment, the isolated antigen binding proteins provided herein are human antibodies and may be of the IgG1, IgG2, IgG3, or IgG4 type.
[0212] In another embodiment, the antigen binding protein is composed solely of a light or heavy chain polypeptide as set forth in Tables 5A-5B. In some embodiments, the antigen binding protein is composed solely of a light chain variable or heavy chain variable domain as listed in Tables 5A-5B. Such antigen binding proteins may be PEGylated with one or more PEG molecules.
[0213] In yet another aspect, the isolated antigen binding proteins provided herein can be conjugated to a labeling group and compete with one of the isolated antigen binding proteins provided herein for binding to the extracellular portion of human CGRP R. In one embodiment, the isolated antigen binding proteins provided herein, when administered to a patient, can reduce monocyte chemotaxis, inhibit monocyte migration to tumors, or inhibit the accumulation and function of tumor-associated macrophages in tumors.
[0214] As will be appreciated by those skilled in the art, for any antigen binding protein having multiple CDRs from the depicted sequences, combinations of CDRs independently selected from the depicted sequences are useful. Thus, antigen binding proteins can be generated having 1, 2, 3, 4, 5, or 6 independently selected CDRs. However, as will be appreciated by those skilled in the art, certain embodiments will generally utilize non-repetitive CDR combinations, e.g., antigen binding proteins generally not formed by two CDRH2 regions.
[0215] Some of the antigen binding proteins that are provided are discussed in detail below.
[0216] Antigen-binding proteins, binding epitopes, and binding domains When an antigen-binding protein is said to bind to an epitope, e.g., one or both components of CGRP-R or the extracellular domain of CGRP-R, this means that the antigen-binding protein specifically binds to a particular portion of CGRP-R, which may be CRLR, RAMP1, or a portion spanning both CRLR and RAMP1. In cases where an antigen-binding protein binds only to CRLR (and not RAMP1), the antigen-binding protein is not expected to selectively bind CGRP-R, since CRLR is particularly shared with AM1 and the AM1 receptor. Similarly, in cases where an antigen-binding protein binds only to RAMP1 (and not CRLR), the antigen-binding protein is not expected to selectively bind CGRP-R, since RAMAP1 is particularly shared with the AMY1 receptor. In cases where an antigen-binding protein interacts with both CRLR and RAMP1, the antigen-binding protein is expected to bind to a residue or sequence of residues or a region in both CRLR and RAMP1. In any of the foregoing embodiments, the antigen-binding protein is not expected to contact every residue in CRLR or RAMP1. Similarly, not all amino acid substitutions or deletions within CRLR, RAMP1, or their extracellular domains are expected to significantly affect binding affinity.
[0217] For example, the methods detailed in Example 10 can be used to assess which regions of a multimeric receptor, such as CGRP R, may be involved in binding to a selected antigen binding protein.
[0218] Competitive antigen-binding proteins In another embodiment, antigen binding proteins are provided that compete with one of the exemplary or "reference" antibodies or functional fragments that bind to the above-mentioned epitopes for specific binding to CGRP-R. Such antigen binding proteins may bind to the same epitope as one of the antigen binding proteins exemplified herein, or an overlapping epitope. Antigen binding proteins and fragments that compete with or bind to the same epitope as an exemplary or reference antigen binding protein are expected to exhibit similar functional properties. Exemplary antigen binding proteins and fragments include heavy and light chains, variable region domains V, ... L 1-V L 17 and V H 1-V H 13, and those having CDRs included in Tables 2A, 2B, 3, 4A, 4B, 5A, and 5B. Thus, as a specific example, provided antigen binding proteins include those having (a) all six CDRs listed for antibodies listed in Tables 5A and 5B, (b) V L 1-V L 17 and V H 1-V H 13 and V listed for the antibodies listed in Tables 5A and 5B H and V L or (c) competes with an antibody having two light chains and two heavy chains specified for an antibody listed in Tables 5A and 5B. An example of a suitable reference antibody includes one having a heavy chain variable region having a sequence corresponding to any of the sequences identified as SEQ ID NOs: 158-170 and a light chain variable region having a sequence corresponding to any of the sequences identified as SEQ ID NOs: 137-153.
[0219] Binding competition can be evaluated using a binning assay, such as the Biacore assay described in Example 7 below. In this example, the 19 antibodies described herein were tested against six "reference" antibodies, including five neutralizing antibodies (11D11, 3B6, 4H6, 12G8, and 9F5) and one non-neutralizing antibody (34E3). As shown in Table 13, the assay results showed that all tested neutralizing antibodies (1E11, 1H7, 2E7, 3B6, 3C8, 4E4, 4H6, 5F5, 9D4, 9F5, 10E4, 11D11, 11H9, 12E8, 12G8, 13H2, and 32H7) essentially bind to the same region of CGRP R, which is different from the region of CGRP R bound by the tested non-neutralizing antibodies (32H8, 33B5, 33E4, and 34E3). Based on these data, any of the neutralizing antibodies, particularly any of the neutralizing antibodies immortalized in the assays described in Examples 7-11D11, 3B6, 4H6, 12G8, and 9F5, would be exemplary reference antigen-binding proteins in a competitive assay.
[0220] Monoclonal antibodies The antigen-binding proteins provided include monoclonal antibodies that bind to CGRP-R. Monoclonal antibodies can be produced using any technique known in the art, for example, by immortalizing pancreatic cells harvested from transgenic animals after the completion of the immunization schedule. Pancreatic cells can be immortalized using any technique known in the art, for example, by fusing them with myeloma cells to produce hybridomas. The myeloma cells used in the hybridoma production fusion procedure are preferably non-antibody-producing, have high fusion efficiency, and enzyme deficiencies, so that they cannot grow in a predetermined selective medium that supports the growth of only the desired fused cells (hybridomas). Examples of cell lines suitable for use in mouse fusions include Sp-20, P3-X63 / Ag8, P3-X63-Ag8.653, NS1 / 1.Ag41, Sp210-Ag14, FO, NSO / U, MPC-11, MPC11-X45-GTG1.7, and S194 / 5XXO Bul; examples of cells used in rat fusions include R210.RCY3, Y3-Ag1.2.3, IR983F, and 4B210. Other cell lines useful for cell fusions are U-266, GM1500-GRG2, LICR-LON-HMy2, and UC729-6. A typical method for preparing monoclonal antibodies is described in Example 2 below.
[0221] In some examples, a hybridoma cell line is produced by immunizing an animal (e.g., a transgenic animal having human immunoglobulin sequences) with a CGRP R immunogen, harvesting pancreatic cells from the immunized animal, fusing the harvested pancreatic cells with a myeloma cell line, thereby producing hybridoma cells, establishing a hybridoma cell line from the hybridoma cells, and identifying a hybridoma cell line that produces an antibody that binds to CGRP R (e.g., as described in Examples 1-3 below). Such hybridoma cell lines, and the anti-CGRP R monoclonal antibodies produced by them, are embodiments of the present application.
[0222] Monoclonal antibodies secreted by hybridoma cell lines can be produced using any technique known in the art. Hybridomas or mAbs can be further screened for specific properties, such as the ability to bind to cells expressing CGRP, a CGRP ligand, or a CGRP. 8-37 mAbs are identified that have the ability to block or interfere with peptide binding or functionally block the receptor, for example, using a cAMP assay as described below.
[0223] Chimeric and Humanized Antibodies Chimeric and humanized antibodies based on the foregoing sequences are also provided. Monoclonal antibodies for use as therapeutic agents can be modified in various ways before use. One example is a chimeric antibody, which is an antibody composed of protein segments from different antibodies that are conjugated to produce a functional immunoglobulin light or heavy chain, or immunologically functional portion thereof. Generally, portions of the heavy and / or light chains are identical to or homologous to corresponding sequences in antibodies from a particular species or belong to a particular antibody class or subclass, while the remainder of the chains are identical to or homologous to corresponding sequences in antibodies from another species or belong to another antibody class or subclass. For methods related to chimeric antibodies, see, for example, U.S. Pat. No. 4,816,567 and Morrison et al., 1985, Proc. Natl. Acad. Sci. USA, incorporated herein by reference. 81 :6851-6855. CDR grafting is described, for example, in U.S. Patent Nos. 6,180,370, 5,693,762, 5,693,761, 5,585,089, and 5,530,101.
[0224] Generally, the goal in creating chimeric antibodies is to create chimeras that maximize the number of amino acids from the intended patient's species. One example is a "CDR-grafted" antibody, in which the antibody contains one or more complementarity-determining regions (CDRs) from a particular species or belonging to a particular antibody class or subclass, while the remainder of the antibody chain is identical or homologous to corresponding sequences from another species or from another antibody class or subclass. For use in humans, variable regions or selected CDRs from a rodent antibody are often grafted into a human antibody, replacing the naturally occurring variable regions or CDRs of the human antibody.
[0225] One useful type of chimeric antibody is a "humanized" antibody. Generally, humanized antibodies are generated from monoclonal antibodies that are first produced in non-human animals. Certain amino acid residues in the monoclonal antibody, usually from the non-antigen-recognizing portion of the antibody, are modified to become homologous to corresponding residues in a human antibody of the corresponding isotype. Humanization can be performed using various methods, for example, by replacing at least a portion of a rodent variable region with the corresponding region of a human antibody (see, for example, U.S. Pat. Nos. 5,585,089 and 5,693,762; Jones et al., 1986, Nature 321 :522-525, Riechmann et al., 1988, Nature 332 :323-27, Verhoeyen et al., 1988, Science 239 :1534-1536).
[0226] In one embodiment, the CDRs of the light and heavy chain variable regions of the antibodies provided herein (see Table 4) are grafted onto framework regions (FRs) from antibodies of the same or different lineages. For example, the heavy and light chain variable regions V H 1. V H 2. V H 3. V H 4. V H 5. V H 6. V H 7. V H 8. V H9. V H 10. V H 11. V H 12, and V H 13 and / or V L 1. V L 2. V L 3. V L 4. V L 5. V L 6. V L 7. V L 8. V L 9. V L 10. V L 11. V L 12. V L 13. V L 14. V L 15, V L 16, and V L The 17 CDRs can be grafted onto consensus human FRs. To form consensus human FRs, FRs from several human heavy or light chain amino acid sequences are aligned to identify a consensus amino acid sequence. In other embodiments, the FRs of the heavy or light chains disclosed herein are replaced with FRs from a different heavy or light chain. In one aspect, rare amino acids in the FRs of the heavy and light chains of an anti-CGRP R antibody are not replaced, but the remaining FR amino acids are replaced. A "rare amino acid" is a specific amino acid located at a position where this specific amino acid is not normally found in the FR. Alternatively, the variable region grafted from a heavy or light chain may be combined with a constant region different from the constant region of the specific heavy or light chain disclosed herein. In other embodiments, the grafted variable region is part of a single-chain Fv antibody.
[0227] In certain embodiments, constant regions from species other than human can be used in conjunction with human variable regions to generate hybrid antibodies.
[0228] Fully human antibodies Fully human antibodies are also provided. Methods are available for generating fully human antibodies specific to a given antigen without exposing a human to the antigen ("fully human antibodies"). One specific means provided for implementing the generation of fully human antibodies is the "humanization" of the mouse humoral immune system. The introduction of human immunoglobulin (Ig) loci into mice in which the endogenous Ig genes have been inactivated is one means of generating fully human monoclonal antibodies (mAbs) in mice, animals that can be immunized with any desired antigen. The use of fully human antibodies can minimize immunogenic and allergic reactions that may result from administering mice or mouse-derived mAbs to humans as therapeutic agents.
[0229] Fully human antibodies can be produced by immunizing transgenic animals (usually mice) that are capable of producing a range of human antibodies in the absence of endogenous immunoglobulin production. Antigens for this purpose typically have six or more contiguous amino acids and are optionally conjugated to a carrier such as a hapten. See, e.g., Jakobovits et al., 1993, Proc. Natl. Acad. Sci. USA 90 :2551-2555, Jakobovits et al., 1993, Nature 362 :255-258, and Bruggermann et al., 1993, Year in Immunol. 7See, e.g., PCT Publication Nos. WO 96 / 33735 and WO 94 / 02602. In one example of such a method, transgenic animals are generated by rendering the endogenous mouse immunoglobulin loci encoding mouse heavy and light immunoglobulin chains nonfunctional and inserting large fragments of human genomic DNA loci encoding human heavy and light chain proteins into the mouse genome. The partially modified animals, which have fewer than the total number of human immunoglobulin loci, are then bred to obtain animals with all of the desired immune system modifications. Upon administration of an immunogen, these transgenic animals produce antibodies immunospecific to the immunogen but with human amino acid sequences, including the variable regions, rather than mouse amino acid sequences. For further details of such methods, see, e.g., PCT Publication Nos. WO 96 / 33735 and WO 94 / 02602. Additional methods involving transgenic mice for generating human antibodies are described in U.S. Pat. Nos. 5,545,807, 6,713,610, 6,673,986, 6,162,963, 5,545,807, 6,300,129, 6,255,458, 5,877,397, 5,874,299, and 5,545,806, PCT Publication Nos. WO 91 / 10741, WO 90 / 04036, and European Patent Nos. EP 546073 B1 and EP 546073 A1.
[0230] The above-described transgenic mice, referred to herein as "HuMab" mice, contain human immunoglobulin genes with minilocuses encoding unrearranged human heavy ([μ] and [γ]) and [κ] light chain immunoglobulin sequences, along with targeted mutations that inactivate the endogenous [μ] and [κ] chain loci (Lonberg et al., 1994, Nature 368:856-859). Thus, in response to immunization, mice exhibit low expression of mouse IgM or [κ], and the introduced human heavy chain transgene undergoes class switching and somatic mutation to generate high-affinity human IgG [κ] monoclonal antibodies (Lonberg et al., supra; Lonberg and Huszar, 1995, Intern. Rev. Immunol. 13 :65-93, Harding nd Lonberg, 1995, Ann.NY Acad.Sci. 764 :536-546). Preparation of HuMab mice was carried out according to Taylor et al., 1992, Nucleic Acids Research 20 :6287-6295, Chen et al., 1993, International Immunology 5 :647-656, Tuaillon et al., 1994, J. Immunol. 152 :2912-2920, Lonberg et al., 1994, Nature 368 :856-859, Lonberg, 1994, Handbook of Exp. Pharmacology 113 :49-101, Taylor et al., 1994, International Immunology 6 :579-591, Lonberg and Huszar, 1995, Intern. Rev. Immunol. 13 :65-93, Harding and Lonberg, 1995, Ann.NY Acad.Sci. 764 :536-546, Fishwild et al., 1996, Nature Biotechnology 14:845-851, the foregoing references being incorporated herein by reference in their entireties for all purposes. Further reference is made to U.S. Patent Nos. 5,545,806, 5,569,825, 5,625,126, 5,633,425, 5,789,650, 5,877,397, 5,661,016, 5,814,318, 5,874,299, and 5,770,429, as well as U.S. Patent No. 5,545,807, International Publication Nos. WO 93 / 1227, WO 92 / 22646, and WO 92 / 03918, the disclosures of all of which are incorporated herein by reference in their entireties for all purposes. The techniques utilized to generate human antibodies in these transgenic mice are described in International Publication No. WO 98 / 24893 and Mendez et al., 1997, Nature Genetics 15 :146-156, which is incorporated herein by reference. For example, HCo7 and HCo12 transgenic mouse strains can be used to generate anti-CGRP antibodies. Further details regarding the generation of human antibodies using transgenic mice are provided in the Examples below.
[0231] Hybridoma technology can be used to generate antigen-specific human mAbs with desired specificity and selected from transgenic mice such as those described above. Such antibodies can be cloned and expressed using appropriate vectors and host cells, or the antibodies can be harvested from cultured hybridoma cells.
[0232] Fully human antibodies can also be obtained from phage display libraries (Hoogenboom et al., 1991, J. Mol. Biol. 227 :381, and Marks et al., 1991, J. Mol. Biol. 222(As disclosed in [Publication ID No. 1002 / 00249] pp. 581-581). Phage display techniques mimic immune selection by displaying antibody repertoires on the surface of filamentous bacteriophage and subsequent selection of phage by binding to an antigen of choice. One such technique is described in PCT Publication No. WO 99 / 10494 (incorporated herein by reference), which describes the isolation of high affinity and functional agonist antibodies of the MPL and msk receptors using such an approach.
[0233] Bispecific or bifunctional antigen-binding proteins The provided antigen-binding proteins also include bispecific and bifunctional antibodies, which contain one or more CDRs or one or more variable regions, as described above. Bispecific or bifunctional antibodies, in some instances, are artificial hybrid antibodies having two different heavy / light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods, including, but not limited to, fusion of hybridomas or linking of Fab' fragments. See, for example, Songsivilai and Lachmann, 1990, Clin. Exp. Immunol. 79 :315-321, Kostelny et al., 1992, J. Immunol. 148 :1547-1553.
[0234] Various other forms Some of the antigen binding proteins provided are variants of the antigen binding proteins disclosed above (e.g., those having the sequences listed in Tables 2-5). For example, some of the antigen binding proteins have one or more conservative amino acid substitutions in one or more of the heavy or light chains, variable regions, or CDRs listed in Tables 2-5.
[0235] Naturally occurring amino acids can be divided into the following classes based on common side chain properties: 1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile 2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln 3) Acidic: Asp, Glu 4) Basic: His, Lys, Arg 5) Residues that influence chain orientation: Gly, Pro and 6) Aromatic: Trp, Tyr, Phe
[0236] Conservative amino acid substitutions may involve replacing a member of one of these classes with another member of the same class. Conservative amino acid substitutions may involve non-naturally occurring amino acid residues and are usually incorporated by chemical peptide synthesis rather than synthesis in biological systems. These include peptidomimetics and other inverted or reversed forms of amino acid moieties.
[0237] Non-conservative substitutions may involve exchanging a member of one of the above classes for a member from another class. Such substituted residues may be introduced into regions of the antibody that are homologous to human antibodies, or into the non-homologous regions of the molecule.
[0238] In making such changes, according to certain embodiments, the hydropathic index of amino acids can be taken into consideration. The hydropathic profile of a protein is calculated by assigning a numerical value to each amino acid (a "hydropathy index") and then averaging these values repeatedly along the peptide chain. Each amino acid is assigned a hydropathic index based on its hydrophobicity and charge characteristics. They are isoleucine (+4.5), valine (+4.2), leucine (+3.8), phenylalanine (+2.8), cysteine / cystine (+2.5), methionine (+1.9), alanine (+1.8), glycine (-0.4), threonine (-0.7), serine (-0.8), tryptophan (-0.9), tyrosine (-1.3), proline (-1.6), histidine (-3.2), glutamate (-3.5), glutamine (-3.5), aspartate (-3.5), asparagine (-3.5), lysine (-3.9), and arginine (-4.5).
[0239] The importance of hydropathy profiles in conferring interactive biological function to proteins is understood in the art (see, e.g., Kyte et al., 1982, J. Mol. Biol. 157 :105-131). It is known that certain amino acids may be substituted with other amino acids having a similar hydropathic index or score and still maintain similar biological activity. When making changes based on hydropathic index, in certain embodiments, substitutions of amino acids whose hydropathic index is within ±2 are included. In some embodiments, within ±1 is included, and in other embodiments, within ±0.5 is included.
[0240] It is also understood in the art that substitutions of like amino acids can be made effectively on the basis of hydrophilicity, particularly when, as in the present example, a biologically functional protein, or peptide formed thereby, is intended for use in immunological embodiments. In certain embodiments, the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigen binding or immunogenicity, i.e., a biological property of the protein.
[0241] The following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0), lysine (+3.0), aspartate (+3.0 ± 1), glutamate (+3.0 ± 1), serine (+0.3), asparagine (+0.2), glutamine (+0.2), glycine (0), threonine (-0.4), proline (-0.5 ± 1), alanine (-0.5), histidine (-0.5), cysteine (-1.0), methionine (-1.3), valine (-1.5), leucine (-1.8), isoleucine (-1.8), tyrosine (-2.3), phenylalanine (-2.5), and tryptophan (-3.4). When making changes based on similar hydrophilicity values, in some embodiments, substitutions of amino acids with hydrophilicity values within ±2 are included, in other embodiments, those within ±1 are included, and in still other embodiments, those within ±0.5 are included. In some instances, epitopes may be identified from the primary amino acid sequence based on hydrophilicity. These regions are also referred to as "epitope core regions."
[0242] Exemplary conservative amino acid substitutions are listed in Table 6. [Table 6]
[0243] A skilled artisan will be able to determine suitable variants of the polypeptides described herein using well-known techniques. By targeting regions not believed to be important for activity, those skilled in the art will be able to identify suitable regions of the molecule that can be altered without destroying activity. Those skilled in the art will also be able to identify residues and portions of the molecule that are conserved among similar polypeptides. In further embodiments, even regions that may be important for biological activity or structure can be subjected to conservative amino acid substitutions without destroying biological activity or adversely affecting the polypeptide structure.
[0244] Additionally, one skilled in the art can review structure-function studies that identify residues in similar polypeptides that are important for activity or structure. Such comparisons can be used to predict the importance of amino acid residues in a protein that correspond to amino acid residues in the similar protein that are important for activity or structure. One skilled in the art can select chemically similar amino acid substitutions for such predicted important amino acid residues.
[0245] Those skilled in the art can also analyze the three-dimensional structure and the amino acid sequence associated with the structure in similar polypeptides. Taking such information into account, those skilled in the art can predict the sequence of amino acid residues of an antibody relative to its three-dimensional structure. Those skilled in the art may choose not to make radical changes to amino acid residues predicted to be on the surface of the protein, because such residues may be involved in important interactions with other molecules. Furthermore, those skilled in the art can generate test variants containing single amino acid substitutions at each desired amino acid residue. These variants can then be screened using a test for CGRP neutralizing activity (see Examples below), providing information on which amino acids can be changed and which should not be changed. In other words, based on the information collected from such routine experiments, those skilled in the art can easily determine the amino acid positions that need to be avoided, alone or in combination with other mutations, for further substitution.
[0246] Numerous scientific publications have been devoted to the prediction of secondary structure. Moult, 1996, Curr. Op. in Biotech. 7 :422-427, Chou et al., 1974, Biochem. 13 :222-245, Chou et al., 1974, Biochemistry 113 :211-222, Chou et al.,1978,Adv.Enzymol.Relat.Areas Mol.Biol. 47 :45-148, Chou et al.,1979,Ann.Rev.Biochem.47 :251-276, and Chou et al., 1979, Biophys. J. 26 :367-384. Additionally, computer programs are now available that assist in the prediction of secondary structure. One method for predicting secondary structure is based on homology modeling. For example, two polypeptides or proteins with greater than 30% sequence identity or greater than 40% similarity may have similar structural topologies. The recent growth of the protein structural database (PDB) has increased the predictability of secondary structure, including the potential number of folds within a polypeptide or protein structure. Holm et al., 1999, Nucl. Acid. Res. 27 :244-247. It has been suggested that for a given polypeptide or protein, there are a limited number of folds, and once a critical number of structures have been solved, structure prediction becomes dramatically more accurate (Brenner et al., 1997, Curr. Op. Struct. Biol. 7 :369-376).
[0247] Additional methods for predicting secondary structure include "threading" (Jones, 1997, Curr. Opin. Struct. Biol. 7 :377-387, Sippl et al., 1996, Structure 4 :15-19), "Profile Analysis" (Bowie et al., 1991, Science 253 :164-170, Gribskov et al., 1990, Meth.Enzym. 183 :146-159, Gribskov et al.,1987,Proc.Nat.Acad.Sci. 84 :4355-4358), and "evolutionary coupling" (see Holm, 1999, supra, and Brenner, 1997, supra).
[0248] In some embodiments, amino acid substitutions are made that (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) modify ligand or antigen binding affinity, and / or (5) confer or modify other physicochemical or functional properties of such polypeptides. For example, single or multiple amino acid substitutions (in certain embodiments, conservative amino acid substitutions) may be made in a naturally occurring sequence. Substitutions can be made in portions of antibodies outside of the domains that form intermolecular contacts. In such embodiments, conservative amino acid substitutions that do not significantly alter the structural features of the parent sequence can be used (e.g., one or more substituted amino acids that do not disrupt the secondary structure that characterizes the parent or native antigen-binding protein). Examples of art-recognized polypeptide secondary and tertiary structures are found in Proteins, Structures and Molecular Principles (Creighton, Ed.), 1984, W.H. New York: Freeman and Company; Introduction to Protein Structure (Branden and Tooze, eds.), 1991, New York: Garland Publishing; and Thornton et al., 1991, Nature 354 :105, each of which is incorporated herein by reference.
[0249] Additional suitable antibody variants include cysteine variants, in which one or more cysteine residues in the parent or native amino acid sequence have been deleted or substituted with another amino acid (e.g., serine). Cysteine variants are particularly useful when the antibody must be refolded into a biologically active conformation. Cysteine variants may have fewer cysteine residues than the native antibody, and typically have an even number to minimize interactions resulting from unpaired cysteines.
[0250] The disclosed heavy and light chains, variable region domains, and CDRs can be used to prepare polypeptides comprising antigen-binding regions that can specifically bind to CGRP-R. For example, one or more of the CDRs listed in Tables 4 and 5 can be incorporated into a molecule (e.g., a polypeptide) either conjugated or non-conjugated to form an immunoadhesin. The immunoadhesin can incorporate the CDR as part of a larger polypeptide chain, or the CDR can be conjugated to another polypeptide chain, or the CDR can be incorporated non-conjugated. The CDR enables the immunoadhesin to specifically bind to a particular antigen of interest (e.g., CGRP-R or an epitope thereof).
[0251] Also provided are mimetics (e.g., "peptide mimetics" or "peptidomimetics") based on the variable region domains and CDRs described herein. These analogs can be peptide, non-peptide, or a combination of peptide and non-peptide regions. Fauchere, 1986, Adv. Drug Res. 15 :29, Veber and Freidinger, 1985, TINS p.392, and Evans et al., 1987, J.Med.Chem. 30:1229 is incorporated herein by reference for any purpose. Peptide mimetics structurally similar to therapeutically effective peptides can be used to achieve similar therapeutic or prophylactic effects. Such compounds are often developed with the aid of computerized molecular modeling. Generally, a peptidomimetic is a protein structurally similar to an antibody that exhibits a desired biological activity, e.g., the ability to specifically bind to CGRP R, but with one or more peptide bonds optionally replaced by bonds selected from -CHNH-, -CHS-, -CH-CH-, -CH-CH- (cis and trans), -COCH-, -CH(OH)CH-, and -CHSO, by methods known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine for L-lysine) can be used in some embodiments to generate more stable proteins. Additionally, restricted peptides containing the consensus sequence or substantially identical variants of the consensus sequence can be generated by methods known in the art, for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges that cyclize the peptide (Rizo and Gierasch, 1992, Ann. Rev. Biochem. , incorporated herein by reference). 61 :387).
[0252] Derivatives of the antigen-binding proteins described herein are also provided. Derivatized antigen-binding proteins can include any molecule or substance that confers desirable properties, such as a long half-life in a particular application, to an antibody or fragment. Derivatized antigen-binding proteins can include, for example, a detectable (or labeled) moiety (e.g., a radioactive, colorimetric, antigen, or enzymatic molecule, a detectable bead (e.g., a magnetic or electron-dense (e.g., gold) bead), or a molecule that binds to another molecule (e.g., biotin or streptavidin)), a therapeutic or diagnostic moiety (e.g., a radioactive, cytotoxic, or pharmaceutically active moiety), or a molecule that enhances the suitability of the antigen-binding protein for a particular application (e.g., administration to a subject, such as a human subject, in vivo, or in vitro applications, etc.). Examples of molecules that can be used to derivatize antigen-binding proteins include albumin (e.g., human serum albumin) and polyethylene glycol (PEG). Albumin-binding and PEGylated derivatives of antigen-binding proteins can be prepared using techniques well known in the art. The antigen-binding protein of interest comprises a PEGylated single-chain polypeptide described herein. In one embodiment, the antigen-binding protein is conjugated or otherwise linked to transthyretin (TTR) or a TTR variant. The TTR or TTR variant can be chemically modified, for example, with a chemical selected from the group consisting of dextran, poly(n-vinylpyrrolidone), polyethylene glycol, propylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyol, and polyvinyl alcohol.
[0253] Other derivatives include conjugation or aggregation of CGRP R binding proteins with other proteins or polypeptides, for example, by expression of a recombinant fusion protein containing a heterologous polypeptide fused to the N- or C-terminus of the CGRP R binding protein. For example, the conjugated peptide can be a heterologous signal (or leader) polypeptide, such as the yeast α-factor leader, or a peptide such as an epitope tag. CGRP antigen binding protein-containing fusion proteins can include an additional peptide to facilitate purification or identification of the CGRP R binding protein (e.g., poly-His). CGRP R binding proteins can be prepared using the methods described by Hopp et al., 1988, Bio / Technology 6 :1204, and U.S. Patent No. 5,011,912. The FLAG peptide is highly antigenic and provides an epitope that is inversely bound by a specific monoclonal antibody (mAb), allowing for rapid detection and easy purification of expressed recombinant proteins. Reagents useful for preparing fusion proteins in which the FLAG peptide is fused to a given polypeptide are commercially available (Sigma, St. Louis, MO).
[0254] Oligomers containing one or more CGRP R binding proteins can be used as CGRP R antagonists. The oligomers may be in the form of covalently or non-covalently linked dimers, trimers, or higher-order oligomers. Oligomers containing two or more CGRP R binding proteins are contemplated for use in combination, with one embodiment being a homodimer. Other oligomers include heterodimers, homotrimers, heterotrimers, homotetramers, heterotetramers, etc.
[0255] One embodiment is directed to oligomers comprising multiple CGRP®-binding polypeptides linked via covalent or non-covalent interactions between peptide moieties fused to the CGRP®-binding protein. Such peptides may be peptide linkers (spacers) or peptides with oligomerization-promoting properties. Antibody-derived leucine zippers and certain polypeptides, as described in more detail below, are peptides that can promote oligomerization of CGRP®-binding proteins attached thereto.
[0256] In certain embodiments, the oligomer comprises two to four CGRP® binding proteins. The CGRP® binding protein portion of the oligomer can be in any of the forms described above, e.g., mutants or fragments. Preferably, the oligomer comprises a CGRP® binding protein that has CGRP® binding activity.
[0257] In one embodiment, oligomers are prepared using polypeptides derived from immunoglobulins. The preparation of fusion proteins comprising certain heterologous polypeptides fused to various portions of antibody-derived polypeptides (including Fc domains) is described, for example, in Ashkenazi et al., 1991, Proc. Natl. Acad. Sci. USA 88 :10535, Byrn et al., 1990, Nature 344 :677, and Hollenbaugh et al., 1992 "Construction of Immunoglobulin Fusion Proteins", in Current Protocols in Immunology, Suppl. 4, pages 10.19.1-10.19.11.
[0258] One embodiment is directed to a dimer comprising two fusion proteins formed by fusing a CGRP-binding protein to the Fc region of an antibody. The dimer can be formed, for example, by inserting a gene fusion encoding the fusion protein into an appropriate expression vector, expressing the gene fusion in a host cell transformed with the recombinant expression vector, and allowing the expressed fusion proteins to assemble like antibody molecules, in which interchain disulfide bonds form between the Fc portions to produce a dimer.
[0259] As used herein, the term "Fc polypeptide" includes native and mutant polypeptides derived from the Fc region of an antibody. Also included are truncated forms of such polypeptides containing the hinge region that promotes dimerization. Fusion proteins containing Fc portions (and oligomers formed therefrom) offer the advantage of easy purification by affinity chromatography over Protein A and Protein G columns.
[0260] One suitable Fc polypeptide, described in PCT International Application No. WO 93 / 10151 and U.S. Patent Nos. 5,426,048 and 5,262,522, is a single-chain polypeptide extending from the N-terminal hinge region to the native C-terminus of the Fc region of a human IgG1 antibody. Another useful Fc polypeptide is described in U.S. Patent No. 5,457,035 and Baum et al., 1994, EMBO J. 13 :3992-4001. The amino acid sequence of this mutein is identical to that of the native Fc sequence presented in International Publication No. WO 93 / 10151, except that amino acid 19 is changed from Leu to Ala, amino acid 20 is changed from Leu to Glu, and amino acid 22 is changed from Gly to Ala. The mutein exhibits low affinity for Fc receptors.
[0261] In other embodiments, the variable regions of the heavy and / or light chains of a CGRP R binding protein as disclosed herein may be substituted for the variable portions of an antibody heavy and / or light chain.
[0262] Alternatively, the oligomer is a fusion protein comprising multiple CGRP R binding proteins, with or without a peptide linker (spacer peptide). Suitable peptide linkers are those described in U.S. Patent Nos. 4,751,180 and 4,935,233.
[0263] Another method for preparing oligomeric CGRP-binding protein derivatives involves the use of leucine zippers. Leucine zipper domains are peptides that promote oligomerization of the proteins in which they are found. Leucine zippers were first identified in several DNA-binding proteins (Landschulz et al., 1988 Science 240 Leucine zippers have since been found in a variety of different proteins. Particularly known leucine zippers are naturally occurring peptides and their derivatives that dimerize or trimerize. Examples of leucine zipper domains suitable for generating soluble oligomeric proteins are described in PCT Application No. WO 94 / 10308, and the leucine zipper derived from pulmonary surfactant protein D (SPD) is described in Hoppe et al., 1994, FEBS Letters 344 :191, incorporated herein by reference. The use of a modified leucine zipper that allows for stable trimerization of a heterologous protein fused thereto is described by Fanslow et al., 1994, Semin. Immunol. 6 In one approach, a recombinant fusion protein comprising a CGRP® binding protein fragment or derivative fused to a leucine zipper peptide is expressed in a suitable host cell, and the resulting soluble oligomeric CGRP® binding protein fragment or derivative is recovered from the culture supernatant.
[0264] In certain embodiments, the antigen binding protein has a K of less than 1 pM, 10 pM, 100 pM, 1 nM, 2 nM, 5 nM, 10 nM, 25 nM, or 50 nM. D (equilibrium binding affinity).
[0265] Another aspect provides antigen binding proteins that have a half-life in vitro or in vivo (e.g., when administered to a human subject) of at least one day. In one embodiment, the antigen binding protein has a half-life of at least three days. In another embodiment, the antibody or portion thereof has a half-life of four days or more. In another embodiment, the antibody or portion thereof has a half-life of eight days or more. In another embodiment, the antibody or antigen-binding portion thereof is derivatized or modified to have a longer half-life compared to the underivatized or unmodified antibody. In another embodiment, the antigen binding protein contains point mutations to increase serum half-life, e.g., as described in International Publication No. WO 00 / 09560, published February 24, 2000, which is incorporated by reference.
[0266] Glycosylation Antigen-binding proteins may have glycosylation patterns that are different or altered from those found in native species. As is known in the art, glycosylation patterns can depend on both the sequence of the protein (e.g., the presence or absence of particular glycosylated amino acid residues, discussed below) and the host cell or organism in which the protein is produced. Specific expression systems are discussed below.
[0267] Glycosylation of polypeptides is usually either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine (where X is any amino acid except proline) are recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
[0268] Addition of glycosylation sites to an antigen-binding protein is conveniently accomplished by altering the amino acid sequence to include one or more of the above-mentioned tripeptide sequences (for N-linked glycosylation sites). Alterations may also be made by the addition or substitution of one or more serine or threonine residues to the starting sequence (for O-linked glycosylation sites). To facilitate this, the antigen-binding protein amino acid sequence may be altered at the DNA level by mutating the DNA encoding the target polypeptide at preselected bases to generate codons that translate into the desired amino acids.
[0269] Another means of increasing the number of carbohydrate moieties on antigen-binding proteins is by chemical or enzymatic conjugation of glycosides to the protein. These methods have the advantage of not requiring the production of glycosylation-competent proteins in host cells for N-linked and O-linked glycosylation. Depending on the conjugation mode used, sugars can be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as cysteine, (d) free hydroxyl groups such as serine, threonine, or hydroxyproline, (e) aromatic residues such as phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine. These methods are described in International Publication No. WO 87 / 05330, published September 11, 1987, and in Aplin and Wriston, 1981, CRC Crit. Rev. Biochem., pp. 259-306.
[0270] Removal of carbohydrate moieties present on the starting antigen-binding protein can be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the protein to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin et al., 1987, Arch. Biochem. Biophys. 259 :52 and Edge et al., 1981, Anal. Biochem. 118 :131. Enzymatic cleavage of carbohydrate moieties on polypeptides is described by Thotakura et al., 1987, Meth. Enzymol. 138 Glycosylation at potential glycosylation sites can be achieved by using a variety of endogenous and exogenous glycosidases, as described by Duskin et al., 1982, J. Biol. Chem. 257This can be circumvented by the use of the compound tunicamycin, as described by :3105. Tunicamycin blocks the formation of protein-N-glycosidic bonds.
[0271] Thus, embodiments include glycosylation variants of antigen-binding proteins, in which the number and / or type of glycosylation is altered compared to the amino acid sequence of the parent polypeptide. In certain embodiments, antibody protein variants contain more or fewer N-linked glycosylation sites than native antibodies. N-linked glycosylation sites are characterized by the sequence Asn-X-Ser or Asn-X-Thr, where the amino acid residue designated as X can be any amino acid residue except proline. Substitution of amino acid residues to form this sequence provides a potential new site for the addition of an N-linked carbohydrate chain. Alternatively, substitutions that eliminate or alter this sequence avoid the addition of an N-linked carbohydrate chain present in the native polypeptide. For example, glycosylation can be reduced by deleting Asn or substituting Asn with a different amino acid. In other embodiments, one or more new N-linked sites are formed. Typically, antibodies have N-linked glycosylation sites in the Fc region.
[0272] Labels and Effector Groups In some embodiments, the antigen binding comprises one or more labels. The term "labeling group" or "label" refers to any detectable label. Examples of suitable labeling groups include the following radioisotopes or radionuclides (e.g., 3 H, 14 C. 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131Examples of secondary reporters include, but are not limited to, fluorescent groups (e.g., FITC, rhodamine, lanthanide fluorophores), enzymatic groups (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent groups, biotinyl groups, or predetermined polypeptide epitopes recognized by secondary reporters (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, the labeling group is attached to the antigen-binding protein via a spacer arm of various lengths to reduce potential steric hindrance. Various methods for labeling proteins are known in the art and can be used as deemed suitable.
[0273] The term "effector group" refers to any group attached to an antigen-binding protein that acts as a cytotoxic agent. Examples of suitable effector groups are radioisotopes or radionuclides (e.g., 3 H, 14 C. 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I). Other suitable groups include toxins, therapeutic drug groups, or chemotherapeutic drug groups. Examples of suitable groups include calicheamicin, auristatin, geldanamycin, and maytansine. In some embodiments, the effector group is attached to the antigen binding protein via a spacer arm of various lengths to reduce potential steric hindrance.
[0274] Generally, labels are classified into various groups depending on the assay in which they are detected: a) isotopic labels, which can be radioactive or heavy isotopes; b) magnetic labels (e.g., magnetic particles; c) redox-active moieties; d) optical dyes; enzyme groups (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase); e) biotinylation groups; and f) predetermined polypeptide epitopes recognized by secondary reporters (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags, etc.). In some embodiments, the labeling group is attached to the antigen-binding protein via spacer arms of various lengths to reduce potential steric hindrance. Various methods for labeling proteins are known in the art.
[0275] Specific labels include optical dyes, including, but not limited to, chromophores, phosphores, and fluorophores, the latter being specific in many instances. Fluorophores can be either "small molecule" fluores, or proteinaceous fluores.
[0276] By "fluorescent label" is meant any molecule that can be detected via its inherent fluorescent properties. Suitable fluorescent labels include fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methylcoumarin, pyrene, Malacite green, stilbene, Lucifer Yellow, Cascade BlueJ, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red640, Cy5, Cy5.5, LC Red705, Oregon green, Alexa-Fluor stains (Alexa Fluor350, Alexa Fluor430, Alexa Fluor488, Alexa Fluor546, Alexa Fluor568, Alexa Fluor594, Alexa Fluor633, Alexa Fluor647, Alexa Fluor660, Alexa Fluor680), Cascade Blue, Cascade Yellow, and R-phycoerythrin (PE) (Molecular Probes, Eugene, OR), FITC, rhodamine, and Texas Red. Suitable optical dyes, including fluorophores, include, but are not limited to, Red (Pierce, Rockford, IL), Cy5, Cy5.5, Cy7 (Amersham Life Science, Pittsburgh, PA). Suitable optical dyes, including fluorophores, are described in MOLECULAR PROBES HANDBOOK by Richard P. Haugland, expressly incorporated herein by reference.
[0277] Suitable proteinaceous fluorescent labels include GFP from Renilla, Ptilosarcus, or Aequorea species (Chalfie et al., 1994, Science 263 :802-805), EGFP (Clontech Labs., Inc., Genbank Accession Number U55762), blue fluorescent protein (BFP, Quantum Biotechnologies, Inc., Quebec, Canada, Stauber, 1998, Biotechniques 24:462-471, Heim et al.,1996,Curr.Biol. 6 :178-182), enhanced yellow fluorescent protein (EYFP, Clontech Labs., Inc.), luciferase (Ichiki et al., 1993, J. Immunol. 150 :5408-5417), β-galactosidase (Nolan et al., 1988, Proc. Natl. Acad. Sci. USA 85 :2603-2607) and Renilla (International Publication Nos. WO92 / 15673, WO95 / 07463, WO98 / 14605, WO98 / 26277, WO99 / 49019, U.S. Pat. Nos. 5,292,658, 5,418,155, 5,683,888, 5,741,668, 5,777,079, 5,804,387, 5,874,304, 5,876,995, 5,925,558).
[0278] Nucleic acid sequences encoding CGRP antigen-binding proteins Nucleic acids encoding the antigen-binding proteins described herein, or portions thereof, are also provided, including nucleic acids encoding one or both chains of an antibody, or fragments, derivatives, mutants, or variants thereof; polynucleotides encoding only the heavy chain variable region or CDRs; polynucleotides sufficient for use as hybridization probes; PCR or sequencing primers for identifying, analyzing, mutating, or amplifying polynucleotides encoding the polypeptides; antisense nucleic acids for inhibiting expression of polynucleotides; and complementary sequences to the foregoing. Nucleic acids can be of any length. They can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1,000, 1,500, or more nucleotides in length, and / or can include one or more additional sequences, e.g., regulatory sequences, and / or can be part of a larger nucleic acid, e.g., a vector. Nucleic acids can be single-stranded or double-stranded and can comprise RNA and / or DNA nucleotides, and artificial variants thereof (eg, peptide nucleic acids).
[0279] Table 7 shows exemplary nucleic acid sequences encoding the IgG2 heavy chain constant region, the κ light chain constant region, and the λhCL-1 light chain constant region. Any variable region provided herein can be attached to these constant regions to form complete heavy and light chain sequences. However, it should be understood that these constant region sequences are provided merely as specific examples, and one skilled in the art can also use other constant regions, including the IgG1 heavy chain constant region, the IgG3 or IgG4 heavy chain constant region, any of the seven λ light chain constant regions, including hCL-1, hCL-2, hCL-3, and hCL-7, as well as constant regions modified to improve stability, expression, manufacturability, or other desired properties. In some embodiments, the variable region sequences are linked to other constant region sequences known in the art. Exemplary nucleic acid sequences encoding heavy and light chain variable regions are provided in Table 8.
[0280] [Table 7]
[0281] Table 8 shows exemplary nucleic acid sequences encoding heavy and light chain variable regions, incorporating various CDRL1, CDRL2 and CDRL3, or CDRH1, CDRH2 and CDRH3 sequences.
[0282] [Table 8-1]
[0283] [Table 8-2]
[0284] [Table 8-3]
[0285] [Table 8-4]
[0286] [Table 8-5]
[0287] [Table 8-6]
[0288] [Table 8-7]
[0289] [Table 8-8]
[0290] Table 9 provides the SEQ ID NOs for exemplary nucleic acid sequences encoding the complete heavy and light chains and heavy and light chain variable regions of exemplary isolated antigen binding proteins, particularly the hCGRP R binding proteins disclosed herein.
[0291] [Table 9-1]
[0292] [Table 9-2]
[0293] Nucleic acids encoding an antigen-binding protein, or portions thereof (e.g., full-length antibodies, heavy or light chains, variable domains, or CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL3), can be isolated from, for example, full-length CGRP-R (including both CRLR and RAMP1), the extracellular domain of CGRP-R (including both CRLR and RAMP1), the extracellular domain of CGRP-R (including the extracellular domains of CRLR and RAMP1), whole cells expressing CGRP-R, membranes prepared from cells expressing CGRP-R, fusion proteins, e.g., CRLR fused to Fc, Fc fusions containing RAMP1 (or its extracellular domain), and B cells of mice immunized with CGRP-R, or immunogenic components thereof, by immunization using other methods known in the art, such as those described in Examples 1-3 herein. Nucleic acids can be isolated by conventional procedures, such as polymerase chain reaction (PCR). Phage display is another example of a well-known technique by which derivatives of antibodies and other antigen-binding proteins can be prepared. In one approach, polypeptides that are components of an antigen binding protein of interest can be expressed in any suitable recombinant expression system, and the expressed polypeptides can be combined to form an antigen binding protein molecule.
[0294] The nucleic acids provided in Tables 7-9 are merely exemplary. Due to the degeneracy of the genetic code, each of the polypeptide sequences listed in Tables 2-5 or otherwise represented herein is also encoded by numerous other nucleic acid sequences in addition to those provided. Those skilled in the art will appreciate that the present application therefore provides appropriate descriptions and enablement of degenerate nucleotide sequences encoding each antigen-binding protein.
[0295] One embodiment further provides a nucleic acid that hybridizes to other nucleic acids (e.g., nucleic acids comprising the nucleotide sequences listed in Table 7, Table 8, Table 9, and / or SEQ ID NOs: 224-258) under specific hybridization conditions. Methods for hybridizing nucleic acids are well known in the art. See, for example, Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6. As defined herein, moderately stringent hybridization conditions use a pre-wash solution containing a hybridization buffer of 5x sodium chloride / sodium citrate (SSC), 0.5% SDS, 1.0 mM EDTA (pH 8.0), about 50% formamide, 6x SSC, and a hybridization temperature of 55°C (or other similar hybridization solutions, e.g., containing about 50% formamide, a hybridization temperature of 42°C), and wash conditions of 0.5x SSC, 0.1% SDS at 60°C. Stringent hybridization conditions are hybridization in 6x SSC at 45°C, followed by one or more washes in 0.1x SSC, 0.2% SDS at 68°C. Moreover, one skilled in the art can manipulate hybridization and / or wash conditions to increase or decrease the stringency of hybridization such that nucleic acids containing nucleotide sequences at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to each other will typically remain hybridized to each other.
[0296] The basic parameters affecting the selection of hybridization conditions and guidance for setting appropriate conditions are described, for example, by Sambrook, Fritsch, and Maniatis (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, supra, and Current Protocols in Molecular Biology, 1995, Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4) and can be readily determined by one of skill in the art based, for example, on the length and / or base composition of the nucleic acid.
[0297] Changes can be introduced by mutation into a nucleic acid, thereby resulting in a change in the amino acid sequence of the polypeptide (e.g., an antibody or antibody derivative) it encodes. Mutations can be introduced using any technique known in the art. In one embodiment, one or more specific amino acid residues are altered, for example, using a site-directed mutagenesis protocol. In another embodiment, one or more randomly selected residues are altered, for example, using a random mutagenesis protocol. However generated, the mutant polypeptides can be expressed and screened for desired properties.
[0298] Mutations can be introduced into a nucleic acid without significantly altering the biological activity of the polypeptide it encodes. For example, nucleotide substitutions can be made to result in amino acid substitutions at non-essential amino acid residues. Alternatively, one or more mutations can be introduced into a nucleic acid that selectively alters the biological activity of the polypeptide it encodes. For example, mutations can quantitatively or qualitatively alter biological activity. Examples of quantitative changes include increasing, reducing, or eliminating activity. Examples of qualitative changes include changing the antigen specificity of an antibody. In one embodiment, a nucleic acid encoding any of the antigen-binding proteins described herein can be mutated to change the amino acid sequence using molecular biology techniques well established in the art.
[0299] Another embodiment provides nucleic acid molecules suitable for use as primers or hybridization probes for the detection of nucleic acid sequences. The nucleic acid molecule can contain only a portion of a nucleic acid sequence encoding a full-length polypeptide, e.g., a fragment that can be used as a probe or primer, or a fragment that encodes an active portion of the polypeptide (e.g., a CGRP-binding portion).
[0300] Probes based on the sequence of a nucleic acid can be used to detect a nucleic acid or a similar nucleic acid, for example, a transcript encoding a polypeptide. The probe can contain a labeling group, for example, a radioisotope, a fluorescent compound, an enzyme, or an enzyme cofactor. Such probes can be used to identify cells expressing the polypeptide.
[0301] Another aspect provides a vector comprising a nucleic acid encoding a polypeptide or portion thereof (e.g., a fragment containing one or more CDRs, or one or more variable region domains). Examples of vectors include, but are not limited to, plasmids, vial vectors, non-episomal mammalian vectors, and expression vectors, e.g., recombinant expression vectors. A recombinant expression vector can comprise a nucleic acid in a form suitable for expression of the nucleic acid in a host cell. The recombinant expression vector comprises one or more regulatory sequences, selected based on the host cell to be used for expression, operably linked to the nucleic acid sequence to be expressed. Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells (e.g., the SV40 early gene enhancer, the Rous sarcoma virus promoter, and the cytomegalovirus promoter), and those that direct expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences, see Voss et al., 1986, Trends Biochem. Sci., which are incorporated herein by reference in their entireties). 11 :287,Maniatis et al.,1987,Science 236 :1237), and those that direct inducible expression of nucleotide sequences in response to a particular treatment or condition (e.g., the metallothionine promoter in mammalian cells, and tet- and / or streptomycin-responsive promoters in both prokaryotic and eukaryotic systems (see ibid.)). It will be understood by those skilled in the art that the design of the expression vector can depend on such factors as the host cell to be transformed, the expression level of protein desired, and the like. The expression vector can be introduced into a host cell to thereby produce a protein or peptide, including a fusion protein or peptide, encoded by a nucleic acid as described herein.
[0302] Another embodiment provides a host cell into which a recombinant expression vector has been introduced. The host cell can be any prokaryotic cell (e.g., E. coli) or eukaryotic cell (e.g., yeast, insect, or mammalian cell (e.g., CHO cell)). Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. For stable transfection of mammalian cells, it is known that only a small fraction of cells can integrate the foreign DNA into their genome, depending on the expression vector and transfection technique used. To identify and select these integrants, a gene encoding a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Suitable selectable markers include those that confer resistance to drugs such as G418, hygromycin, and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection, among other methods (e.g., cells that have incorporated the selectable marker gene will survive, while other cells die).
[0303] Preparation of antigen-binding proteins The provided non-human antibodies can be derived, for example, from any antibody-producing animal, such as mouse, rat, rabbit, goat, donkey, or non-human primate (e.g., monkey (e.g., cynomolgus monkey or rhesus monkey) or ape (e.g., chimpanzee). Non-human antibodies can be used, for example, in in vitro cell culture and cell culture-based applications, or any other application in which an immune response to the antibody is not generated or is insignificant, can be avoided, is of no concern, or is desired. In certain embodiments, antibodies can be generated by immunizing animals using methods known in the art, as described above and / or in Examples 1-3 below. These examples include anti-CGRP R antibodies using three different immunogen preparations: (i) whole cells expressing full-length versions of the two major components, CGRP R-RAMP1 and CRLR; (ii) membrane extracts from such cells; and (iii) soluble CGRP R obtained by co-expressing and purifying the N-terminal extracellular domains of CRLR and RAMP1. The generation of R antibodies is described. Antibodies can be polyclonal, monoclonal, or synthesized in host cells by expressing recombinant DNA. Fully human antibodies can be prepared as described above by immunizing transgenic animals containing human immunoglobulin loci or by selecting phage display libraries expressing a set of human antibodies.
[0304] Monoclonal antibodies (mAbs) can be produced using conventional monoclonal antibody methods, e.g., Kohler and Milstein, 1975, Nature 256Hybridomas can be produced by a variety of techniques, including standard somatic cell hybridization techniques such as those described in 495. Alternatively, other techniques for producing monoclonal antibodies can be used, such as viral or oncogenic transformation of B lymphocytes. One suitable animal system for preparing hybridomas is the murine system, a well-established procedure. Immunization protocols and techniques for isolating immunized splenocytes for fusion are known in the art, and exemplary approaches are described in the Examples below. In such procedures, B cells from immunized mice are typically fused with a suitable immortalized fusion partner, such as a murine myeloma cell line. If desired, rats or other mammals can be immunized instead of mice, and B cells from such animals can be fused with a murine myeloma cell line to form hybridomas. Alternatively, myeloma cell lines from sources other than murine may be used. Fusion procedures for forming hybridomas are also well known.
[0305] The provided single-chain antibodies may be formed by linking heavy and light chain variable region (Fv region) fragments via an amino acid bridge (short peptide linker), resulting in a single polypeptide chain. Such single-chain Fvs (scFvs) comprise two variable domain polypeptides (V L and V H ) may be prepared by fusing DNA encoding a peptide linker between DNA encoding the two variable domains. The resulting polypeptide can either fold back to form an antigen-binding monomer or, depending on the length of the flexible linker between the two variable domains, can form multimers (e.g., dimers, trimers, or tetramers) (Kortt et al., 1997, Prot. Eng. 10 :423, Kortt et al.,2001,Biomol.Eng. 18 :95-108). Different V containing polypeptides L and V HBy combining these, it is possible to form multimeric scFvs that bind to different epitopes (Kriangkum et al., 2001, Biomol. Eng. 18 :31-40). Techniques developed for the production of single chain antibodies are described in U.S. Pat. No. 4,946,778, Bird, 1988, Science 242 :423, Huston et al.,1988,Proc.Natl.Acad.Sci.USA 85 :5879, Ward et al., 1989, Nature 334 :544,de Graaf et al.,2002,Methods Mol Biol. 178 :379-387. Single chain antibodies derived from the antibodies provided herein include, but are not limited to, scFvs comprising a combination of heavy and light chain variable regions represented in Table 3, or a combination of light and heavy chain variable region domains comprising the CDRs represented in Tables 4A and 4B.
[0306] The antibodies provided herein that are of one subclass can be converted to antibodies from a different subclass using subclass exchange methods. Thus, for example, an IgG antibody can be obtained from an IgM antibody, and vice versa. Such techniques allow for the preparation of new antibodies that have the antigen-binding properties of a given antibody (parent antibody), but also exhibit biological properties associated with an antibody isotype or subclass different from that of the parent antibody. Recombinant DNA technology may also be used. Cloned DNA encoding a specific antibody polypeptide, for example, DNA encoding the constant domain of an antibody of a desired isotype, may be used in such procedures. See, for example, Lantto et al., 2002, Methods Mol. Biol. 178 :303-316.
[0307] Thus, the antibodies provided include, for example, those containing a combination of the above-mentioned variable domains and containing the desired isotype (e.g., IgA, IgG1, IgG2, IgG3, IgG4, IgE, and IgD) and Fab or F(ab')2 fragments thereof. Furthermore, if IgG4 is desired, the antibody may be selected from the group consisting of Fab and F(ab')2 fragments of the desired isotype (e.g., IgA, IgG1, IgG2, IgG3, IgG4, IgE, and IgD). 6 It may also be desirable to introduce a point mutation (CPSCP→CPPCP) in the hinge region to reduce the tendency to form intra-H chain disulfide bonds, which can lead to heterogeneity in IgG4 antibodies, as described in J. Immunol. 1999, 14:407, incorporated herein by reference.
[0308] Furthermore, techniques are known for obtaining antibodies with different properties (i.e., altering the affinity for the antigen to which they bind). One such technique, called chain shuffling, involves displaying immunoglobulin variable domain gene repertoires on the surface of filamentous bacteriophage, often referred to as phage display. Chain shuffling is described in Marks et al., 1992, Bio Technology 10 :779 has been used to prepare high affinity antibodies against the hapten 2-phenyloxazol-5-one.
[0309] Conservative modifications can be made to the heavy and light chain variable regions set forth in Table 3, or the CDRs set forth in Tables 4A and 4B (and corresponding modifications to the encoding nucleic acids) to generate CGRP R binding proteins with predetermined desired functional and biochemical characteristics. Methods for achieving such modifications are described above.
[0310] CGRP antigen-binding proteins can be further modified in various ways. For example, when used for therapeutic purposes, they may be conjugated with polyethylene glycol (pegylated) to extend serum half-life or enhance protein delivery. Alternatively, the V region of a target antibody or fragment thereof may be fused to the Fc region of a different antibody molecule. The Fc region used for this purpose may be modified so that it does not bind complement, thus reducing the likelihood of inducing cytolysis in patients when the fusion protein is used as a therapeutic agent. Furthermore, a target antibody or functional fragment thereof may be conjugated with human serum albumin to enhance the antibody or its antigen-binding fragment. Another useful fusion partner for antigen-binding proteins or fragments thereof is transthyretin (TTR). TTR has the ability to form tetramers, and therefore, antibody-TTR fusion proteins can form multivalent antibodies, which can increase their binding affinity.
[0311] Alternatively, significant modifications in the functional and / or biochemical characteristics of the antigen-binding proteins described herein can be achieved by making substitutions in the amino acid sequences of the heavy and light chains that differ significantly in their effect on (a) the structure of the molecular backbone, e.g., sheet or helix structure, in the region of the substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) maintaining side-chain bulk. A "conservative amino acid substitution" can include the substitution of a native amino acid residue with a non-native residue that has little or no effect on the polarity or charge of the amino acid residue at that position. See Table 4 above. Additionally, any native residue in the polypeptide can be substituted with alanine, as described above for alanine-scanning mutagenesis.
[0312] Amino acid substitutions (whether conservative or non-conservative) of the subject antibodies can be achieved by those skilled in the art by applying routine techniques. Amino acid substitutions can be used to identify key residues in the antibodies provided herein, or to increase or decrease the affinity of these antibodies for human CGRP-R, or to alter the binding affinity of other antigen-binding proteins described herein.
[0313] Methods for expressing antigen-binding proteins Also provided herein are expression systems and constructs in the form of plasmids, expression vectors, transcription or expression cassettes, which comprise at least one polynucleotide as described above, as well as host cells containing such expression systems and constructs.
[0314] The antigen binding protein provided herein can be prepared by any of a number of conventional techniques.For example, CGRP R antigen binding protein can be produced by recombinant expression system using any technique known in the art.For example, see Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet et al. (eds.) Plenum Press, New York (1980), and Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1988).
[0315] Antigen-binding proteins can be expressed in hybridoma cell lines (e.g., antibodies, in particular, can be expressed in hybridomas) or cell lines other than hybridomas. Expression constructs encoding the antibodies can be used to transform mammalian, insect, or microbial host cells. Transformation can be carried out using any known method for introducing polynucleotides into host cells, including, for example, packaging the polynucleotide in a virus or bacteriophage and transducing the host cell with the construct by transfection procedures known in the art, as exemplified by U.S. Pat. Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455. The optimal transformation procedure used will depend on the type of host cell being transformed. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art and include, but are not limited to, dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, encapsulation of polynucleotides in liposomes, mixing nucleic acids with positively charged lipids, and direct microinjection of DNA into the nucleus.
[0316] The recombinant expression constructs typically contain one or more CDRs provided herein, a light chain constant region, a light chain variable region, a heavy chain constant region (e.g., C H 1. C H 2 and / or C H3), and / or another scaffold portion of a CGRP-R antigen binding protein. These nucleic acid sequences are inserted into an appropriate expression vector using standard ligation techniques. In one embodiment, a heavy or light chain constant region is added to the C-terminus of the anti-CGRP-R-specific heavy or light chain variable region and conjugated to the expression vector. Vectors are typically selected to be functional in the particular host cell to be used (i.e., the vector is compatible with the host cell machinery and allows gene amplification and / or expression to occur). In some embodiments, vectors are used that use protein fragment complementation assays using protein reporters such as dihydrofolate reductase (see, e.g., U.S. Pat. No. 6,270,964, incorporated herein by reference). Suitable expression vectors can be purchased, for example, from Invitrogen Life Technologies or BD Biosciences (formerly "Clontech"). Other useful vectors for cloning and expressing antibodies and fragments are described in Bianchi and McGrew, 2003, Biotech. Biotechnol. Bioeng., incorporated herein by reference. 84 :439-44. Additional suitable expression vectors are discussed, for example, in Methods Enzymol., vol. 185 (DV Goeddel, ed.), 1990, New York: Academic Press.
[0317] Expression vectors used in any of the host cells typically contain sequences for plasmid maintenance and cloning and expression of exogenous nucleotide sequences. In certain embodiments, such sequences, collectively referred to as "flanking sequences," typically include one or more nucleotide sequences of a promoter, one or more enhancers, an origin of replication, a transcription termination sequence, a complete intron sequence including donor and acceptor splice sites, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting a nucleic acid encoding an expressed polypeptide, and a selectable marker element. Each of these sequences is discussed below.
[0318] Optionally, the vector may contain a "tag"-encoding sequence, i.e., an oligonucleotide molecule located at the 5' or 3' end of the CGRP-R binding protein-encoding sequence, encoding poly-His (e.g., hexa-His) or another "tag," such as FLAG®, HA (influenza virus hemagglutinin), or myc, for which commercially available antibodies exist. This tag is typically fused to the polypeptide upon expression and can serve as a means for affinity purification or detection of the CGRP-R binding protein from host cells. Affinity purification can be achieved, for example, by column chromatography using an antibody against the tag as an affinity matrix. Optionally, the tag can be subsequently removed from the purified CGRP-R binding protein by various means, such as using a specific peptidase for cleavage.
[0319] Flanking sequences can be homologous (i.e., from the same species and / or strain as the host cell), heterologous (i.e., from a species other than the host cell species or strain), hybrid (i.e., a combination of flanking sequences from multiple sources), synthetic, or natural. Thus, the source of the flanking sequences can be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, so long as the flanking sequences are functional in and can be activated by the host cell machinery.
[0320] The flanking sequence useful in vectors can be obtained by any of several methods well known in the art.Usually, the flanking sequence useful herein has already been identified by mapping and / or restriction endonuclease digestion, and can be isolated from a suitable tissue source using appropriate restriction endonuclease.In some cases, the complete nucleotide sequence of the flanking sequence may be known.In this case, the flanking sequence can be synthesized using the method described herein for nucleic acid synthesis or cloning.
[0321] If all or only part of the flanking sequence is known, it can be obtained using polymerase chain reaction (PCR) and / or by screening a genomic library with appropriate probes, such as oligonucleotides and / or flanking sequence fragments from the same or another species. If the flanking sequence is unknown, a fragment of DNA containing the flanking sequence can be isolated from a larger fragment of DNA that may also contain, for example, the coding sequence or another gene or genes. Isolation can be achieved by generating the appropriate DNA fragment by restriction endonuclease digestion, followed by isolation using agarose gel purification, Qiagen® column chromatography (Chatsworth, CA), or other methods known to the skilled artisan. The selection of appropriate enzymes to achieve this purpose will be readily apparent to one of ordinary skill in the art.
[0322] Origins of replication are usually part of commercially purchased prokaryotic expression vectors; the origin aids in the amplification of the vector in host cells. If the vector of choice does not contain an origin of replication site, one may be chemically synthesized based on a known sequence and conjugated to the vector. For example, the origin of replication from the plasmid pBR322 (New England Biolabs, MA) is suitable for most Gram-negative bacteria, and various viral origins (e.g., SV40, polyoma, adenovirus, vesicular stomatitis virus (VSV), or papillomaviruses such as HPV or BPV) are useful for cloning vectors in mammalian cells. Generally, origin of replication components are not required for mammalian expression vectors (e.g., the SV40 origin is often used simply because it also contains the viral early promoter).
[0323] Transcription termination sequences are typically located 3' to the end of a polypeptide coding region and terminate transcription. In prokaryotic cells, transcription termination sequences are typically GC-rich fragments followed by a poly-T sequence. Sequences can be easily cloned from libraries or purchased commercially as part of a vector, or can be easily synthesized using nucleic acid synthesis methods such as those described herein.
[0324] A selectable marker gene encodes a protein essential for the survival and growth of host cells grown in selective media. Typical selectable marker genes encode proteins that (a) confer resistance to antibiotics or other toxins, such as ampicillin, tetracycline, or kanamycin, to prokaryotic host cells; (b) complement auxotrophic defects in the cells; or (c) supply critical nutrients not available from complex or defined media. Specific selectable markers are the kanamycin resistance gene, the ampicillin resistance gene, and the tetracycline resistance gene. Advantageously, the neomycin resistance gene can be used for selection in both prokaryotic and eukaryotic host cells.
[0325] Other selectable genes can be used to amplify the expressed gene. Amplification is a process in which genes required for the production of proteins essential for growth or cell survival are repeated side by side in the chromosomes of successive generations of recombinant cells. Examples of selectable markers suitable for mammalian cells include dihydrofolate reductase (DHFR) and promoterless thymidine kinase genes. Transformed mammalian cells are placed under selection pressure; only the transformed cells are uniquely adapted to survive due to the selectable gene present in the vector. Selection pressure is applied by culturing the transformed cells under conditions in which the concentration of a selection agent in the medium is gradually increased, thereby resulting in the amplification of both the selectable gene and DNA encoding another gene, e.g., an antigen-binding protein that binds to CGRP. As a result, increased amounts of a polypeptide, e.g., an antigen-binding protein, are synthesized from the amplified DNA.
[0326] A ribosome binding site is usually necessary for translation initiation of mRNA and is characterized by a Shine-Dalgarno (prokaryotic) or Kozak sequence (eukaryotic). The element is usually located 3' to the promoter and 5' to the coding sequence of the polypeptide to be expressed.
[0327] In some instances, such as when glycosylation is desired in a eukaryotic host cell expression system, various pre- or pro-sequences can be manipulated to improve glycosylation or yield. For example, the peptidase cleavage site of a particular signal peptide can be altered or a pro-sequence added, which can also affect glycosylation. The final proteinaceous product may have one or more additional amino acids at position -1 (relative to the first amino acid of the mature protein) resulting from expression and may not be completely removed. For example, the final protein product may have one or two amino acid residues found at the peptidase cleavage site, attached to the amino terminus. Alternatively, the use of some enzyme cleavage sites may result in a slightly truncated form of the desired polypeptide if the enzyme cleaves at such a region within the mature polypeptide.
[0328] Expression and cloning typically involve a promoter that is recognized by the host organism and operably linked to the molecule encoding the CGRP-binding protein. A promoter is an untranscribed sequence located upstream (i.e., 5') to the start codon of a structural gene (generally about 100-1000 bp) that controls transcription of the structural gene. Promoters are conventionally classified into one of two groups: inducible promoters and constitutive promoters. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as the presence or absence of a nutrient or a change in temperature. Constitutive promoters, on the other hand, unidirectionally transcribe the gene to which they are operably linked, i.e., they exert little or no control over gene expression. Numerous promoters recognized by a variety of potential host cells are well known. A suitable promoter is operably linked to DNA encoding a heavy or light chain containing the CGRP-binding protein by removing the promoter from the source DNA by restriction enzyme digestion and inserting the desired promoter sequence into a vector.
[0329] Suitable promoters for use with yeast host cells are also well known in the art. Yeast enhancers are advantageously used with yeast promoters. Suitable promoters for use with mammalian host cells are well known and include, but are not limited to, those obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (e.g., adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retrovirus, hepatitis B virus, and simian virus 40 (SV40). Other suitable mammalian promoters include, for example, heterologous mammalian promoters such as heat shock promoters and actin promoters.
[0330] Additional promoters that may be of interest include the SV40 early promoter (Benoist and Chambon, 1981, Nature 290:304-310), CMV promoter (Thornsen et al., 1984, Proc. Natl. Acad. USA 81 :659-663), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22 :787-797), herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. USA 78 :1444-1445), promoter and regulatory sequences from the metallothionine gene (Prinster et al., 1982, Nature 296 :39-42), and prokaryotic promoters such as the β-lactamase promoter (Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. USA 75 :3727-3731), or the tac promoter (DeBoer et al., 1983, Proc. Natl. Acad. Sci. USA 80 :21-25). The following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals, may also be of interest: the elastase I gene control region, which is active in pancreatic cells (Swift et al., 1984, Cell 1:111-112). 38 :639-646, Ornitz et al.,1986,Cold Spring Harbor Symp.Quant.Biol. 50 :399-409, MacDonald, 1987, Hepatology 7 :425-515), the insulin gene regulatory region active in pancreatic β cells (Hanahan, 1985, Nature 315 :115-122), immunoglobulin gene control regions active in lymphoid cells (Grosschedl et al., 1984, Cell 38 :647-658, Adams et al., 1985, Nature 318 :533-538, Alexander et al., 1987, Mol. Cell. Biol.7 :1436-1444), the mouse mammary tumor virus control region, which is active in testicular, breast, lymphoid, and mast cells (Leder et al., 1986, Cell 45 :485-495), the albumin gene control region, which is active in the liver (Pinkert et al., 1987, Genes and Devel. 1 :268-276), the α-fetoprotein gene regulatory region which is active in the liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5 :1639-1648, Hammer et al., 1987, Science 253 :53-58), the α1-antitrypsin gene regulatory region, which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1 :161-171), the β-globin gene regulatory region active in myeloid cells (Mogram et al., 1985, Nature 315 :338-340, Kollias et al., 1986, Cell 46 :89-94), the myelin basic protein gene regulatory region, which is active in oligodendritic cells of the brain (Readhead et al., 1987, Cell 48 :703-712), the myosin light chain-2 gene control region active in skeletal muscle (Sani, 1985, Nature 314 :283-286), and the gonadotropin-releasing gene regulatory region active in the parathyroid gland (Mason et al., 1986, Science 234 :1372-1378).
[0331] Enhancer sequences may be inserted into vectors to increase transcription of DNA encoding light or heavy chains, including human CGRP-binding proteins, by higher eukaryotes. Enhancers are cis-acting elements of DNA, typically about 10 to 300 bp in length, that act on promoters to increase transcription. Enhancers are relatively independent of orientation and position and have been found at both 5' and 3' positions relative to the transcription unit. Several enhancer sequences are known from mammalian genes (e.g., globin, elastase, albumin, α-fetoprotein, and insulin). However, enhancers from viruses are typically used. The SV40 enhancer, cytomegalovirus early promoter enhancer, polyoma enhancer, and adenovirus enhancer, known in the art, are typical enhancing elements for eukaryotic promoter activity. Enhancers can be located 5' or 3' to the coding sequence in vectors, but are usually located at a site 5' from the promoter. A sequence encoding an appropriate native or heterologous signal sequence (leader sequence or signal peptide) can be incorporated into the expression vector to promote extracellular secretion of the antibody. The choice of signal peptide or leader depends on the type of host cell in which the antibody is to be produced, and a heterologous signal sequence can replace the native signal sequence. Examples of signal peptides functional in mammalian host cells include the signal sequence of interleukin-7 (IL-7), described in U.S. Pat. No. 4,965,195; Cosman et al., 1984, Nature 106:107-108; 312 :768, the interleukin-4 receptor signal peptide described in European Patent No. 0367566, the type I interleukin-1 receptor signal peptide described in U.S. Patent No. 4,968,607, and the type II interleukin-1 receptor signal peptide described in European Patent No. 0460846.
[0332] The provided expression vectors may be constructed from a starting vector, such as a commercially available vector. Such vectors may or may not contain all of the desired flanking sequences. If one or more of the flanking sequences described herein are not already present in the vector, they may be obtained individually and ligated into the vector. The methods used to obtain each of the flanking sequences are well known to those skilled in the art.
[0333] After the vector is constructed and the nucleic acid molecule encoding the light chain, heavy chain, or light and heavy chain containing the CGRP-R antigen-binding sequence is inserted into a specific site in the vector, the complete vector can be inserted into an appropriate host cell for amplification and / or polypeptide expression. Transformation of the antigen-binding protein expression vector into the selected host cell can be achieved by well-known methods, including transfection, infection, calcium phosphate co-precipitation, electroporation, microinjection, lipofection, DEAE-dextran-mediated transfection, or other known techniques. The method selected can be a function, in part, of the type of host cell used. These and other suitable methods are well known to those skilled in the art and are described, for example, in Sambrook et al., 2001, supra.
[0334] When cultured under appropriate conditions, the host cells will synthesize the antigen binding protein, which can then be collected from the culture medium (if the host cells secrete it into the medium) or directly from the host cells that produce it (if they do not secrete it). The selection of an appropriate host cell will depend on a variety of factors, including the desired expression level, polypeptide modifications (e.g., glycosylation or phosphorylation) that are desirable or necessary for activity and that facilitate folding into a biologically active molecule.
[0335] Mammalian cell lines that can be used as host cells for expression are well known in the art and include, but are not limited to, immortal cell lines available from the American Type Culture Collection, including, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and many other cell lines. In one embodiment, a cell line can be selected by determining which cell line has a high expression level and constitutively produces an antigen-binding protein with CGRP-binding properties. In another embodiment, a cell line from a B cell line can be selected that does not form its own antibody but has t...
Claims
1. A recombinant antibody that specifically binds to a human calcitonin gene-related peptide (CGRP) receptor comprising a heavy chain and a light chain, said antibody being isolated from a host cell expressing the heavy chain nucleic acid and the light chain nucleic acid; (a) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:244 and the light chain nucleic acid comprises the sequence of SEQ ID NO:226; (b) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:257 and the light chain nucleic acid comprises the sequence of SEQ ID NO:239; (c) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:248 and the light chain nucleic acid comprises the sequence of SEQ ID NO:230; (d) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:246 and the light chain nucleic acid comprises the sequence of SEQ ID NO:228; (e) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:249 and the light chain nucleic acid comprises the sequence of SEQ ID NO:231; (f) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:255 and the light chain nucleic acid comprises the sequence of SEQ ID NO:237; (g) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:242 and the light chain nucleic acid comprises the sequence of SEQ ID NO:224; (h) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:247 and the light chain nucleic acid comprises the sequence of SEQ ID NO:229; (i) the heavy chain nucleic acid comprises the sequence of SEQ ID NO: 250 and the light chain nucleic acid comprises the sequence of SEQ ID NO: 232; (j) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:256 and the light chain nucleic acid comprises the sequence of SEQ ID NO:238; (k) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:252 and the light chain nucleic acid comprises the sequence of SEQ ID NO:234; (l) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:253 and the light chain nucleic acid comprises the sequence of SEQ ID NO:235; (m) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:254 and the light chain nucleic acid comprises the sequence of SEQ ID NO:236; (n) the heavy chain nucleic acid comprises the sequence of SEQ ID NO: 243 and the light chain nucleic acid comprises the sequence of SEQ ID NO: 225; (o) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:251 and the light chain nucleic acid comprises the sequence of SEQ ID NO:233; (p) the heavy chain nucleic acid comprises the sequence of SEQ ID NO:245 and the light chain nucleic acid comprises the sequence of SEQ ID NO:227; (q) the heavy chain nucleic acid comprises the sequence of SEQ ID NO: 258 and the light chain nucleic acid comprises the sequence of SEQ ID NO: 240; or (r) A recombinant antibody, wherein the heavy chain nucleic acid comprises the sequence of SEQ ID NO:258 and the light chain nucleic acid comprises the sequence of SEQ ID NO:
241.
2. The recombinant antibody of claim 1 , wherein the host cell secretes the antibody and the antibody is isolated from the host cell medium.
3. The recombinant antibody of claim 1 or 2, wherein the heavy chain nucleic acid comprises the sequence of SEQ ID NO: 247 and the light chain nucleic acid comprises the sequence of SEQ ID NO:
229.
4. The recombinant antibody of claim 1 or 2, wherein the heavy chain nucleic acid comprises the sequence of SEQ ID NO: 251 and the light chain nucleic acid comprises the sequence of SEQ ID NO:
233.
5. A pharmaceutical composition comprising the antibody of any one of claims 1 to 4 and a pharma- ceutically acceptable excipient.
6. A pharmaceutical composition for treating a condition associated with CGRP receptor-mediated vasodilation or neurogenic inflammation in a patient in need of such treatment, comprising an antibody according to any one of claims 1 to 4.
7. The pharmaceutical composition of claim 6, wherein the symptom is a headache.
8. The pharmaceutical composition of claim 6, wherein the condition is a migraine headache.
9. 9. The pharmaceutical composition of claim 8, wherein the antibody is administered periodically to the patient to reduce the frequency of migraine attacks.
10. A method for producing an antibody according to any one of claims 1 to 4, comprising the steps of: Isolating the antibody from a host cell expressing the heavy and light chain nucleic acids of the antibody according to any one of claims 1 to 4. A method comprising:
11. The method of claim 10, wherein the host cell secretes the antibody and the antibody is isolated from the host cell culture medium.
Citation Information
Patent Citations
Isolated DNA Molecules Encoding Humanized Calcitonin Gene-Related Peptide Receptors, Related Non-Human Transgenic Animals and Assay Methods
JP2005503809A
Human CGRP receptor binding protein
JP2012513214A
